RELATED APPLICATIONS

This application claims priority to U.S. Serial No. 62/491,633 filed April 28, 2017, the contents of which are incorporated herein by reference in their entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on April 26, 2018, is named E2070-7006WO_SL.txt and is 308,533 bytes in size.

BACKGROUND

Multispecific molecules that include a non-immunoglobulin heterodimerization domain (e.g., a T cell receptor (TCR) constant domain), methods of making said molecules (e.g., in a single cell), and methods of using the same, are disclosed.

SUMMARY OF THE INVENTION

The disclosure relates, inter alia, to novel multispecific molecules that include a non- immunoglobulin heterodimerization domain (e.g., a naturally occurring heterodimerization domain (e.g., a T cell receptor (TCR) constant domain)). Without being bound by theory, the multispecific molecules disclosed herein are expected to provide correctly assembled

multispecific molecules (e.g., bispecific antibodies) retaining a natural immunoglobulin like structure, comprising a non-immunoglobulin heterodimerization domain (e.g., a T cell receptor (TCR) constant domain). Accordingly, provided herein are, inter alia, multispecific molecules (e.g., multispecific (e.g., bispecific) antibody molecules) that include the aforementioned non- immunoglobulin heterodimerization domain, nucleic acids encoding the same, methods of producing the aforementioned molecules (e.g., in a single cell), and methods of treating a cancer using the aforementioned molecules. In one aspect, disclosed herein is a multispecific (e.g., bispecific) molecule (e.g., an isolated multispecific molecule), comprising:

(i) a first antigen binding moiety (ABM) (e.g., a first antibody molecule);

(ii) a second ABM (e.g., a second antibody molecule), wherein the first and second ABMs do not bind the same epitope, and

(iii) a heterodimerization domain comprising a first and a second polypeptide chain, wherein the first polypeptide chain comprises a TCRa constant domain (or a functional fragment thereof, e.g., a fragment capable of forming stable association with a TCRP constant domain), and the second polypeptide chain comprises a TCRP constant domain (or a functional fragment thereof, e.g., a fragment capable of forming stable association with a TCRa constant domain). In some embodiments, the first polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to the TCRa constant domain, optionally via a linker, and/or the second polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to the TCRP constant domain, optionally via a linker.

In some embodiments, (i) the first ABM is connected to the first polypeptide chain, optionally via a linker; and (ii) the second ABM is connected to the second polypeptide chain, optionally via a linker. In some embodiments, (i) the first ABM is connected to the N-terminus of the first polypeptide chain, optionally via a linker; and/or (ii) the second ABM is connected to the N-terminus of the second polypeptide chain, optionally via a linker. In some embodiments, (i) the first ABM is connected to the C-terminus of the first polypeptide chain, optionally via a linker; and/or (ii) the second ABM is connected to the C-terminus of the second polypeptide chain, optionally via a linker. In some embodiments, (i) the first polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to the TCRa constant domain, optionally via a linker, and/or (ii) the second polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to the TCRP constant domain, optionally via a linker. In some embodiments, (i) the first polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to the N-terminus of the TCRa constant domain, optionally via a linker, and/or (ii) the second polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to the N-terminus of the TCRP constant domain, optionally via a linker. In some embodiments, (i) the first polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to the C- terminus of the TCRa constant domain, optionally via a linker, and/or (ii) the second polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to the C-terminus of the TCRP constant domain, optionally via a linker. In some embodiments, the linker comprises or consists of the amino acid sequence of any of SEQ ID NOs: 101-110. In some embodiments, (i) the first polypeptide chain of the heterodimerization domain does not comprise an immunoglobulin CH3 domain (e.g., any portion of a CH3 domain), (ii) the second polypeptide chain of the heterodimerization domain does not comprise an immunoglobulin CH3 domain (e.g., any portion of a CH3 domain), or (iii) neither the first nor the second polypeptide chain of the heterodimerization domain contains an immunoglobulin CH3 domain (e.g., any portion of a CH3 domain). In some embodiments, neither the first nor the second polypeptide chain of the heterodimerization domain contains any portion of an immunoglobulin CH3 domain capable of stable self-association (i.e., the first polypeptide chain does not contain any portion of a CH3 domain capable of stable association with the CH3 domain of the second polypeptide chain).

In some embodiments, the TCRa constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 158 (or a sequence having at least 75, 80, 85, 90, or 99% identity thereof) and/or the TCRP constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 159 (or a sequence having at least 75, 80, 85, 90, or 99% identity thereof), optionally wherein the TCRa constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 158 and/or the TCRP constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 159. In some embodiments, the TCRa domain has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 158; and/or the TCRP domain has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 159. In some embodiments, the TCRa domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 158; and/or the TCRp domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 159. In some embodiments, the TCRa constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 1 (or a sequence having at least 75, 80, 85, 90, or 99% identity thereof) and/or the TCRP constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 2 (or a sequence having at least 75, 80, 85, 90, or 99% identity thereof), optionally wherein the TCRa constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 1 and/or the TCRP constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 2. In some embodiments, the TCRa domain has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 1; and/or the TCRP domain has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 2. In some embodiments, the TCRa domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 1; and/or the TCRP domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 2. In some embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 158. In some embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, or 80 contiguous amino acids of SEQ ID NO: 1. In some embodiments, the TCRa domain has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 1. In some embodiments, the TCRa domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 1. In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, or 170 contiguous amino acids of SEQ ID NO: 159. In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, or 130 contiguous amino acids of SEQ ID NO: 2. In some embodiments, the TCRP has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 2. In some embodiments, the TCRP domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid modifications (e.g., substitutions, additions, or deletions) from SEQ ID NO: 2. In some embodiments, the TCRa constant domain comprises a functional fragment of the amino acid sequence of SEQ ID NO: 158 (e.g., a fragment capable of forming a stable association with a TCRP constant domain, e.g., the TCRa constant domain comprises amino acids 1-140, 1-130, 1-120, 1-110, 1-100, 1-93, 1-90, 1-85, 1-80, 1-70, 10-100, 10-90, or 10-70 of SEQ ID NO: 158 (or a sequence with no more than 5 (e.g., 5, 4, 3, 2, or 1) amino acid modifications from amino acids 1-140, 1-130, 1-120, 1-110, 1-100, 1-93, 1-90, 1-85, 1-80, 1-70, 10-100, 10-90, or 10-70 of SEQ ID NO: 158)); and/or the TCRP constant domain comprises a functional fragment of the amino acid sequence of SEQ ID NO: 159 (e.g., a fragment capable of forming a stable association with a TCRP constant domain, e.g., the TCRP constant domain comprises amino acids 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 10-150, 10-140, 10-130, or 10-120 of SEQ ID NO: 159 (or a sequence with no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid modifications from amino acids 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 10-150, 10-140, 10-130, or 10-120 of SEQ ID NO: 159)). In some embodiments, the TCRa constant domain comprises amino acids 1-85 or 1-93 of SEQ ID NO: 158 (or a sequence with no more than 5 (e.g., 5, 4, 3, 2, or 1) amino acid modifications from amino acids 1-85 or 1-93 of SEQ ID NO: 158); and/or the TCRP constant domain comprises amino acids 1-130 of SEQ ID NO: 159 (or a sequence with no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid modifications from amino acids 1-130 of SEQ ID NO: 159). In some embodiments, the TCRa constant domain comprises a cysteine amino acid substitution relative to a naturally-existing TCRa constant domain (e.g., SEQ ID NO: 158) (e.g., the TCRa constant domain comprises a T49C substitution, numbered according to SEQ ID NO: 158) and/or the TCRP constant domain comprises a cysteine amino acid substitution relative to a naturally-existing TCRP constant domain (e.g., SEQ ID NO: 159) (e.g., the TCRP constant domain comprises a S57C, numbered according to SEQ ID NO: 159). In some embodiments, the multispecific molecule comprises at least two non-contiguous polypeptide chains. In some embodiments, the first ABM comprises a first antibody molecule (e.g., a first antibody molecule comprising a first heavy and first light chain), and the second ABM comprises a second antibody molecule (e.g., a second antibody molecule comprising a second heavy and second light chain). In some embodiments, the heterodimerization domain promotes correct pairing of the first and second heavy chains, e.g., as measured by a method described herein (e.g., as measure by mass spectrometry), e.g., as measured by a method described in Example 3, e.g., the first heavy chain is more likely (e.g., 10, 20, 30, or 40-fold more likely) to form a heterodimer with the second heavy chain in the presence of the heterodimerization domain, than in the absence of the heterodimerization. In some embodiments, the first antibody molecule and the second antibody molecule are, independently, a full antibody (e.g., an antibody that includes at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains), or an antigen-binding fragment (e.g., a Fab, F(ab')2, Fv, a scFv, a single domain antibody, or a diabody (dAb)). In some embodiments, the first antibody molecule comprises a kappa light chain constant region, or a fragment thereof, and the second antibody molecule comprises a lambda light chain constant region, or a fragment thereof. In some embodiments, the first antibody molecule comprises a lambda light chain constant region, or a fragment thereof, and the second antibody molecule comprises a kappa light chain constant region, or a fragment thereof. In some embodiments, the first antibody molecule and the second antibody molecule have a common light chain variable region.

In some embodiments, the first or second ABM comprises a tumor-targeting moiety. In some embodiments, the first or second ABM comprises an immune cell engager, or a binding moiety to a cytokine. In some embodiments, the first ABM comprises a first tumor-targeting moiety, and the second ABM comprises a second tumor-targeting moiety. In some

embodiments, the first ABM comprises a first immune cell engager, and the second ABM comprises a second immune cell engager. In some embodiments, the first ABM comprises a tumor-targeting moiety, and the second ABM comprises an immune cell engager. In some embodiments, the first ABM comprises an immune cell engager, and the second ABM comprises a tumor- targeting moiety.

In one aspect, provided herein is a multispecific molecule comprising:

(a) a first polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a first antigen binding moiety (ABM) (e.g., wherein the first ABM comprises a VH-CH1 of a first Fab molecule, that binds to an antigen, e.g., a cancer antigen, connected, optionally via a linker to, a first subunit of a heterodimerization domain (e.g., an immunoglobulin CH2 connected, optionally via a linker to, a TCRa constant domain);

(b) a second polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a second ABM (e.g., wherein the second ABM comprises a VH-CH1 of a second Fab molecule, that binds to an antigen, e.g., a cancer antigen, connected, optionally via a linker to, a second subunit of a heterodimerization domain (e.g., an immunoglobulin CH2 connected, optionally via a linker to, a TCRP constant domain); (c) a third polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the first ABM (e.g., a VL-CL of the first Fab, where the VL is of kappa subtype and binds to an antigen, e.g., a cancer antigen (e.g., the same cancer antigen bound by the VH-CH1 of the first Fab molecule); and

(d) a fourth polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the second antigen domain (e.g. a VL-CL of the second Fab, where the VL is of lambda subtype and binds to an antigen, e.g., a cancer antigen, (e.g., the same cancer antigen bound by the VH-CH1 of the second Fab molecule). In one aspect, provided herein is a multispecific molecule comprising:

(a) a first polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a first antigen binding moiety (ABM) (e.g., wherein the first ABM comprises a VH-CH1 of a first Fab molecule, that binds to an antigen, e.g., a cancer antigen, connected, optionally via a linker to, a first subunit of a heterodimerization domain (e.g., an immunoglobulin CH2 connected, optionally via a linker to, a TCRa constant domain);

(b) a second polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a second ABM (e.g., wherein the second ABM comprises a VH-CH1 of a second Fab molecule, that binds to an antigen, e.g., a cancer antigen, connected, optionally via a linker to, a second subunit of a heterodimerization domain (e.g., an immunoglobulin CH2 connected, optionally via a linker to, a TCRP constant domain);

(c) a third polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the first ABM (e.g., a VL-CL of the first Fab, where the VL is of lambda subtype and binds to an antigen, e.g., a cancer antigen (e.g., the same cancer antigen bound by the VH-CH1 of the first Fab molecule); and

(d) a fourth polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the second antigen domain (e.g. a VL-CL of the second Fab, where the VL is of kappa subtype and binds to an antigen, e.g., a cancer antigen, (e.g., the same cancer antigen bound by the VH-CH1 of the second Fab molecule). In one aspect, provided herein is a multispecific molecule comprising: (a) a first polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a first antigen binding moiety (ABM) (e.g., wherein the first ABM comprises a VH-CH1 of a first Fab molecule, that binds to an antigen, e.g., a cancer antigen, connected, optionally via a linker to, a first subunit of a heterodimerization domain (e.g., a TCRa variable domain connected a TCRa constant domain);

(b) a second polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a second ABM (e.g., wherein the second ABM comprises a VH-CH1 of a second Fab molecule, that binds to an antigen, e.g., a cancer antigen, connected, optionally via a linker to, a second subunit of a heterodimerization domain (e.g., TCRP variable domain connected to a TCRP constant domain);

(c) a third polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the first ABM (e.g., a VL-CL of the first Fab, where the VL is of kappa subtype and binds to an antigen, e.g., a cancer antigen (e.g., the same cancer antigen bound by the VH-CH1 of the first Fab molecule); and

(d) a fourth polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the second antigen domain (e.g. a VL-CL of the second Fab, where the VL is of lambda subtype and binds to an antigen, e.g., a cancer antigen, (e.g., the same cancer antigen bound by the VH-CH1 of the second Fab molecule). In one aspect, provided herein is a multispecific molecule comprising:

(a) a first polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a first antigen binding moiety (ABM) (e.g., wherein the first ABM comprises a VH-CH1 of a first Fab molecule, that binds to an antigen, e.g., a cancer antigen, connected, optionally via a linker to, a first subunit of a heterodimerization domain (e.g., a TCRa variable domain connected a TCRa constant domain);

(b) a second polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a second ABM (e.g., wherein the second ABM comprises a VH-CH1 of a second Fab molecule, that binds to an antigen, e.g., a cancer antigen, connected, optionally via a linker to, a second subunit of a heterodimerization domain (e.g., TCRP variable domain connected to a TCRP constant domain); (c) a third polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the first ABM (e.g., a VL-CL of the first Fab, where the VL is of lambda subtype and binds to an antigen, e.g., a cancer antigen (e.g., the same cancer antigen bound by the VH-CH1 of the first Fab molecule); and

(d) a fourth polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the second antigen domain (e.g. a VL-CL of the second Fab, where the VL is of kappa subtype and binds to an antigen, e.g., a cancer antigen, (e.g., the same cancer antigen bound by the VH-CH1 of the second Fab molecule). In one aspect, provided herein is a multispecific molecule comprising:

(a) a first polypeptide comprising, from N-terminus to C-terminus, a first VH, a first CHI, a first CH2, and a TCRa constant domain,

(b) a second polypeptide comprising, from N-terminus to C-terminus, a second VH, a second CHI, a second CH2, and a TCRP constant domain,

(c) a third polypeptide comprising, from N-terminus to C-terminus, a first VL (e.g., a VL of kappa subtype), and a kappa CL, and

(d) a fourth polypeptide comprising, from N-terminus to C-terminus, a second VL (e.g., a VL of lambda subtype), and a lambda CL, wherein:

(i) the first and the third polypeptides form a first antigen binding moiety (ABM) that binds a first antigen,

(ii) the second and the fourth polypeptides form a second ABM that binds a second antigen, and

(iii) the first and the second polypeptides form a heterodimer, optionally wherein:

the TCRa constant domain comprises the amino acid sequence of SEQ ID NO: 1 (or a sequence having at least 75, 80, 85, 90, or 99% identity thereof), and/or the TCRP constant domain comprises the amino acid sequence of SEQ ID NO: 2 (or a sequence having at least 75, 80, 85, 90, or 99% identity thereof).

In one aspect, provided herein is a multispecific molecule comprising:

(a) a first polypeptide comprising, from N-terminus to C-terminus, a first VH, a first

CHI, a first CH2, and a TCRa constant domain, (b) a second polypeptide comprising, from N-terminus to C-terminus, a second VH, a second CHI, a second CH2, and a TCRP constant domain,

(c) a third polypeptide comprising, from N-terminus to C-terminus, a first VL (e.g., a VL of lambda subtype), and a lambda CL, and

(d) a fourth polypeptide comprising, from N-terminus to C-terminus, a second VL (e.g., a

VL of kappa subtype), and a kappa CL, wherein:

(i) the first and the third polypeptides form a first antigen binding moiety (ABM) that binds a first antigen,

(ii) the second and the fourth polypeptides form a second ABM that binds a second antigen, and

(iii) the first and the second polypeptides form a heterodimer, optionally wherein:

the TCRa constant domain comprises the amino acid sequence of SEQ ID NO: 1 (or a sequence having at least 75, 80, 85, 90, or 99% identity thereof), and/or the TCRP constant domain comprises the amino acid sequence of SEQ ID NO: 2 (or a sequence having at least 75, 80, 85, 90, or 99% identity thereof).

In some embodiments of the aforementioned aspects and embodiments, the multispecific molecule comprises a multispecific molecule disclosed in WO2018/057955, incorporated herein by reference in its entirety.

In some embodiments of the aforementioned aspects and embodiments, the multispecific molecule comprises a multispecific molecule disclosed in the subsection titled "Lambda/Kappa Formats" provided herein.

In some embodiments, the multispecific molecule comprises:

(i) an antigen binding moiety (ABM) comprising:

a first heavy chain comprising a first heavy chain variable region and a first heavy chain constant region, and

a lambda light chain comprising a lambda variable region and a lambda constant region, and

(ii) an ABM comprising:

a second heavy chain comprising a second heavy chain variable region and a second heavy chain constant region, and a kappa light chain comprising a kappa variable region and a kappa constant region, optionally wherein:

the first heavy chain is different from the second heavy chain.

In some embodiments, (i) the first heavy chain variable region has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a first heavy chain germline sequence selected from column 2 of Table 9, (ii) the lambda variable region has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a lambda light chain germline sequence selected from column 3 of Table 9, (iii) the second heavy chain variable region has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a second heavy chain germline sequence selected from column 4 of Table 9, and/or (iv) the kappa variable region has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a kappa light chain germline sequence selected from column 5 of Table 9. In some embodiments, the first heavy chain germline sequence, the lambda light chain germline sequence, the second heavy chain germline sequence, and the kappa light chain germline sequence are selected from a single row of Table 9.

In some embodiments, (i) the first heavy chain constant region does not comprise a mutation that promotes the preferential pairing of the first heavy chain and the lambda light chain (e.g., the first heavy chain constant region is a naturally existing heavy chain constant region), or the lambda constant region does not comprise a mutation that promotes the preferential pairing of the first heavy chain and the lambda light chain (e.g., the lambda constant region is a naturally existing lambda constant region), and (ii) the second heavy chain constant region does not comprise a mutation that promotes the preferential pairing of the second heavy chain and the kappa light chain (e.g., the second heavy chain constant region is a naturally existing heavy chain constant region), or the kappa constant region does not comprise a mutation that promotes the preferential pairing of the second heavy chain and the kappa light chain (e.g., the kappa constant region is a naturally existing kappa constant region).

In some embodiments, (i) the first heavy chain preferentially binds to the lambda light chain over the kappa light chain, (ii) the lambda light chain preferentially binds to the first heavy chain over the second heavy chain, (iii) the second heavy chain preferentially binds to the kappa light chain over the lambda light chain, and/or (iv) the kappa light chain preferentially binds to the second heavy chain over the first heavy chain. In one aspect, disclosed herein are multispecific molecule (e.g., an isolated multispecific molecule), comprising (i) a first antigen binding moiety (ABM) (e.g., an antibody molecule); (ii) a second ABM, wherein the first ABM and the second ABM do not bind the same antigen; and (iii) a constant region (e.g., a heavy chain constant region of IgGl, IgG2, and IgG4) comprising a first and a second polypeptide chain, wherein (a) the first polypeptide chain comprises a first non-immunoglobulin domain, and (b) the second polypeptide chain comprises a second non- immunoglobulin domain, wherein the first and the second non-immunoglobulin domains are capable of forming a stable association, and wherein neither the first nor second polypeptide chain contains a CH3 domain (e.g., any portion of a CH3 domain, any portion of a CH3 domain capable of stable self-association).

In one aspect, the disclosure provides, multispecific molecules (e.g., an isolated multispecific molecule), comprising (i) a first antigen binding moiety (ABM) (e.g., an antibody molecule); (ii) a second ABM, wherein the first and second ABMs do not bind the same antigen, and (iii) a heterodimerization domain comprising a first and a second polypeptide chain, wherein the first polypeptide chain comprises a TCRa constant domain (or a functional fragment thereof, e.g., a fragment capable of forming stable association with a TCRP constant domain), and the first polypeptide chain comprises a TCRP constant domain (or a functional fragment thereof, e.g., a fragment capable of forming stable association with a TCRa constant domain).

In some embodiments, the first polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to (optionally via a linker) the TCRa constant domain, and the second polypeptide chain comprises an immunoglobulin CH2 domain (e.g., an IgGl, IgG2, or IgG4 CH2 domain) connected to (optionally via a linker) the TCRP constant domain. In some embodiments, neither the first nor the second polypeptide chain of the heterodimerization domain contains an immunoglobulin CH3 domain (e.g., any portion of a CH3 domain). In some embodiments, neither the first nor the second polypeptide chain of the heterodimerization domain contains any portion of an immunoglobulin CH3 domain capable of stable self-association (i.e., the first polypeptide chain does not contain an any portion of a CH3 domain capable of stable association with the CH3 domain of the second polypeptide).

In some embodiments, the first polypeptide chain comprises a TCRa variable domain connected to the TCRa constant domain, and the second polypeptide chain comprises a TCRP variable domain connected to the TCRP constant domain. In some embodiments, neither the first nor the second polypeptide chain of the heterodimerization domain contains more than 50, 25, 10, or 5 amino acids of an immunoglobulin CH2 and/or more than 50, 25, 10, or 5 amino acids of an immunoglobulin CH3. In some embodiments, neither the first nor the second polypeptide chain of the heterodimerization domain contains an immunoglobulin CH2 and/or CH3 domain (e.g., any portion of a CH2 and/or CH3 domain).

In some embodiments, the TCRa constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 158 and/or the TCRP constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 159. In some embodiments, the TCRa domain has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid substitutions; and/or the TCRP domain has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid substitutions. In some embodiments, the TCRa domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid substitutions; and/or the TCRP domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid substitutions.

In some embodiments, the TCRa constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 1 and/or the TCRP constant domain comprises or consists of the amino acid sequence of SEQ ID NO: 2. In some embodiments, the TCRa domain has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid substitutions; and/or the TCRP domain has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid substitutions. In some embodiments, the TCRa domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid substitutions; and/or the TCRP domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid substitutions.

In some embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 158. In some

embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, or 80 contiguous amino acids of SEQ ID NO: 1. In some embodiments, the TCRa has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid substitutions. In some embodiments, the TCRa domain has no more than 10 (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) amino acid substitutions.

In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, or 170 contiguous amino acids of SEQ ID NO: 159. In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, or 130 contiguous amino acids of SEQ ID NO: 2. In some embodiments, the TCRP has 1 or more (e.g., 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more) amino acid substitutions.

In some embodiments, the TCRa constant domain comprises a functional fragment of the amino acid sequence of SEQ ID NO: 158 (e.g., a fragment capable of forming a stable association with a TCRP constant domain, (e.g., the TCRa constant domain comprises amino acids 1-140 (e.g., 1-130, 1-120, 1-110, 1-100, 1-90, 1-80 (e.g., 1-85), 1-70, 10-100, 10-90, 10- 70) of SEQ ID NO: 158); and/or the TCRP constant domain comprises a functional fragment of the amino acid sequence of SEQ ID NO: 159 (e.g., a fragment capable of forming a stable association with a TCRP constant domain (e.g., the TCRP constant domain comprises amino acids 1-170 (e.g., 1-170, 1-160, 1-150, 1-140, 1-130, 1-120, 1-110, 10-150, 10-40, 10-130, 10- 120) of SEQ ID NO: 159)).

In some embodiments, the TCRa constant domain comprises amino acids l-85of SEQ ID NO: 158; and/or the TCRP constant domain comprises amino acids 1-130 of SEQ ID NO: 159.

In some embodiments, the TCRa constant domain comprises a cysteine amino acid substitution relative to SEQ ID NO: 1 or SEQ ID NO: 158 and and/or the TCRP constant domain comprises a cysteine amino acid substitution relative to SEQ ID NO: 2 or SEQ ID NO: 159.

In some embodiments, the first ABM is a first antibody molecule comprising a first heavy and first light chain, and the second ABM is a second antibody molecule comprising a second heavy and second light chain. In some embodiments, the heterodimerization domain promote correct pairing of the first and second heavy chains (e.g., as measure by mass spectrometry).

In some embodiments, the TCRa and TCRP variable domains bind HSA. In some embodiments, the TCRa and TCRP variable domains bind protein A or protein G. In some embodiments, the TCRa and TCRP variable domains bind a tumor antigen (e.g., as described herein).

In some embodiments, the first ABM is a tumor targeting moiety that binds to a cancer antigen; and the second ABM is an immune cell engager. In some embodiments, the immune cell engager is a natural killer (NK) cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager. In some embodiments, the multispecific molecule further comprises a first cytokine molecule. In some embodiments, the multispecific molecule further comprises a first stromal modifying molecule.

In some embodiments, the tumor-targeting moiety comprises an antibody molecule, a receptor molecule (e.g., a receptor, a receptor fragment or functional variant thereof), or a ligand molecule (e.g., a ligand, a ligand fragment or functional variant thereof), or a combination thereof, that binds to the cancer antigen. In some embodiments, the tumor-targeting moiety binds to a cancer antigen present on a hematological cancer, a solid cancer, a metastatic cancer, or a combination thereof. In some embodiments, the cancer antigen is a tumor antigen, a stromal antigen, or a hematological antigen.

In some embodiments, the tumor antigen is present on a solid tumor (e.g., is a solid tumor antigen). In some embodiments, the tumor, e.g., solid tumor, is chosen from one or more of pancreatic (e.g., pancreatic adenocarcinoma), breast, colorectal, lung (e.g., small or non-small cell lung cancer), skin, ovarian, or liver cancer. In some embodiments, the tumor, e.g., solid tumor, antigen is chosen from: PDLl, mesothelin, CD47, gangloside 2 (GD2), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron Kinase, c-Met, Immature laminin receptor, TAG-72, BING-4, Calcium-activated chloride channel 2, Cyclin-B l, 9D7, Ep-CAM, EphA3, Her2/neu, Telomerase, SAP- 1, Survivin, NY-ESO-l/LAGE- 1, PRAME, SSX-2, Melan- A/MART- 1 , Gpl00/pmell7, Tyrosinase, TRP-1/-2, MC 1R, β-catenin, BRCAl/2, CDK4, CML66,

Fibronectin, p53, Ras, TGF-B receptor, AFP, ETA, MAGE, MUC-1, CA- 125, BAGE, GAGE, NY-ESO-1, β-catenin, CDK4, CDC27, CD47, a actinin-4, TRPl/gp75, TRP2, gplOO, Melan- A/MART1, gangliosides, WT1, EphA3, Epidermal growth factor receptor (EGFR), CD20, MART-2, MART- 1, MUC1, MUC2, MUM1, MUM2, MUM3, NA88- 1, NPM, OA1, OGT, RCC, RUI1, RUI2, SAGE, TRG, TRP1, TSTA, Folate receptor alpha, Ll-CAM, CAIX, EGFRvIII, gpA33, GD3, GM2, VEGFR, Intergrins (Integrin alphaVbeta3, Integrin

alpha5Betal), Carbohydrates (Le), IGF1R, EPHA3, TRAILR1, TRAILR2, or RANKL. In some embodiments, the solid tumor antigen is chosen from: PDLl, Mesothelin, GD2, PMSA, CEA, Ron Kinase, or c-Met.

In some embodiments, the multispecific molecule comprises two or three antibody molecules to two or three cancer antigens chosen from mesothelin, PDLl, HER3, IGF1R, FAP, CD123 or CD47. In some embodiments, the stromal antigen is chosen from fibroblast activating protease (FAP), TGF-beta, hyaluronic acid, collagen, e.g., collagen IV, tenascin C, or tenascin W. In some embodiments, the hematological antigen is chosen from CD19, CD33, CD47, CD123, CD20, CD99, CD30, BCMA, CD38, CD22, SLAMF7, or NY-ESOl.

In some embodiments, the immune cell engager comprises an NK cell engager that mediates binding to, and/or activation of, an NK cell. In some embodiments, the NK cell engager is chosen from an antibody molecule, e.g., an antigen binding domain, or ligand that binds to (e.g., activates): NKp30, NKp40, NKp44, NKp46, NKG2D, DNAM1, DAP10, CD16 (e.g., CD16a, CD16b, or both), CRT AM, CD27, PSGL1, CD96, CD100 (SEMA4D), NKp80, CD244 (also known as SLAMF4 or 2B4), SLAMF6, SLAMF7, KIR2DS2, KIR2DS4, KIR3DS 1,

KIR2DS3, KIR2DS5, KIR2DS 1, CD94, NKG2C, NKG2E, or CD160. In some embodiments, the NK cell engager is an antibody molecule, e.g., an antigen binding domain. In some embodiments, the NK cell engager is a ligand. In some embodiments, the NK cell enganger is a ligand of NKp44, NKp46, DAP10, or CD16. In some embodiments, the immune cell engager mediates binding to, or activation of, one or more of a B cell, a macrophage, and/or a dendritic cell.

In some embodiments, the immune cell engager comprises a B cell, macrophage, and/or dendritic cell engager chosen from one or more of CD40 ligand (CD40L) or a CD70 ligand; an antibody molecule that binds to CD40 or CD70; an antibody molecule to OX40; an OX40 ligand (OX40L); an agonist of a Toll-like receptor (e.g., a TLR4, e.g., a constitutively active TLR4 (caTLR4) or a TLR9 agonist); a 41BB; a CD2 agonist; a CD47; or a STING agonist, or a combination thereof. In some embodiments, the B cell engager is a CD40L, an OX40L, or a CD70 ligand, or an antibody molecule that binds to OX40, CD40 or CD70. In some

embodiments, the macrophage cell engager is a CD2 agonist; a CD40L; an OX40L; an antibody molecule that binds to OX40, CD40 or CD70; an agonist of a Toll-like receptor (TLR)(e.g., a TLR4, e.g., a constitutively active TLR4 (caTLR4) or a TLR9 agonist); CD47; or a STING agonist. In some embodiments, the dendritic cell engager is a CD2 agonist, an OX40 antibody, an OX40L, 4 IBB agonist, a Toll-like receptor agonist or a fragment thereof (e.g., a TLR4, e.g., a constitutively active TLR4 (caTLR4)), CD47 agonist, or a STING agonist. In some

embodiments, the STING agonist comprises a cyclic dinucleotide, e.g., a cyclic di-GMP (cdGMP), a cyclic di-AMP (cdAMP), or a combination thereof, optionally with 2', 5' or 3 ',5' phosphate linkages.

In some embodiments, the cytokine molecule is chosen from interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), or interferon gamma, or a fragment or variant thereof, or a combination of any of the aforesaid cytokines. In some embodiments, the cytokine molecule is a monomer or a dimer. In some embodiments, the cytokine molecule further comprises a receptor dimerizing domain, e.g., an IL15Ralpha dimerizing domain. In some embodiments, the cytokine molecule (e.g., IL-15) and the receptor dimerizing domain (e.g., an IL15Ralpha dimerizing domain) are not covalently linked, e.g., are non-covalently associated.

In some embodiments, the wherein the stromal modifying moiety comprises an enzyme molecule that degrades a tumor stroma or extracellular matrix (ECM). In some embodiments, the enzyme molecule is chosen from a hyaluronidase molecule, a collagenase molecule, a chondroitinase molecule, a matrix metalloproteinase molecule (e.g., macrophage

metalloelastase), or a variant (e.g., a fragment) of any of the aforesaid. In some embodiments, the hyaluronidase molecule is chosen from HYALl, HYAL2, or PH-20/SPAM1, or a variant thereof (e.g., a truncated form thereof). In some embodiments, the multispecific molecule further comprises a third ABM(e.g., is a trispecific or trifunctional molecule).

In some embodiments, the multispecific molecule further comprises a fourth ABM (e.g., is a tetraspecific or tetrafunctional molecule).

In some embodiments, the multispecific molecule further comprises a second cytokine (the same or different than the first cytokine). In some embodiments, the multispecific molecule comprises (i) one tumor-targeting moiety; (ii) two immune cell engagers (e.g., same or different immune cell engagers); and (iii) one cytokine molecule. In some embodiments, the multispecific molecule comprises (i) two tumor-targeting moieties (e.g., same or different targeting moieties); (ii) one immune cell engager; and (iii) one cytokine molecule. In some embodiments, the multispecific molecule comprises (i) one tumor-targeting moiety; (ii) one immune cell engager; and (iii) two cytokine molecules (e.g., same or different cytokine molecules).

In some embodiments, the multispecific molecule comprises at least two non-contiguous polypeptide chains. In some embodiments, the first and/or the second ABM comprises an antibody molecule or functional fragment thereof. In some embodiments, the first ABM antibody molecule and the second ABM antibody molecule are, independently, a full antibody (e.g., an antibody that includes at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains), or an antigen-binding fragment (e.g., a Fab, F(ab')2, Fv, a scFv, a single domain antibody, or a diabody (dAb)).

In some embodiments, the first ABM antibody molecule comprises a kappa light chain constant region, or a fragment thereof, and the second ABM antibody molecule comprises a lambda light chain constant region, or a fragment thereof (or vice versa).

In some embodiments, the first ABM antibody molecule and the second ABM antibody molecule have a common light chain variable region.

In an aspect, the disclosure provides, multispecific antibody molecules (e.g., an isolated multispecific antibody), comprising (i) a first antibody molecule; (ii) a second antibody molecule, wherein the first and second antibody molecules do not bind the same antigen, and an Fc domain consisting of two subunits, wherein each subunit comprises a CH2 and a CH3 domain, wherein (a) the CH3 domain of the first subunit is replaced (e.g., entirely replaced) with at least a portion of a TCRa constant domain (or a functional fragment thereof, e.g., a fragment capable of forming stable association with a TCRP constant domain) and the CH3 domain of the second subunit is replaced with at least a portion of a TCRP constant domain (or a functional fragment thereof, e.g., a fragment capable of forming stable association with a TCRa constant domain); or (b) the CH2 domain of the first subunit is replaced with a TCRa variable domain and the CH3 domain of the first subunit is replaced with at least a portion of a TCRa constant domain (or a functional fragment thereof, e.g., a fragment capable of forming stable association with a TCRP constant domain); and the CH2 domain of the second subunit is replaced with a TCRP variable domain and the CH3 domain of the first subunit is replaced with at least a portion of a TCRa constant domain (or a functional fragment thereof, e.g., a fragment capable of forming stable association with a TCRa constant domain).

In an aspect, the disclosure provides, multispecific molecules comprising

(a) a first polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a first antigen binding moiety (ABM) (e.g., wherein the first ABM comprises a VH-CH1 of a first Fab molecule, that binds to, e.g., a cancer antigen, connected, optionally via a linker to, a first subunit of a heterodimerization domain (e.g., an

immunoglobulin CH2 connected to a TCRa constant domain); (b) a second polypeptide chain having the following configuration from N-terminus to C-terminus: a first portion of a second ABM (e.g., wherein the second ABM comprises a VH-CHl of a second Fab molecule, that binds to, e.g., a cancer antigen, connected, optionally via a linker to, a second subunit of a

heterodimerization domain (e.g., an immunoglobulin CH2 connected to a TCRP constant domain); (c) a third polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the first ABM (e.g., a VL-CL of the first Fab, where the VL is of kappa subtype and binds to, e.g., a cancer antigen (e.g., the same cancer antigen bound by the VH-CHl of the first Fab molecule); (d) a fourth polypeptide having the following configuration from N-terminus to C-terminus: a second portion of the second antigen domain (e.g. a VL-CL of the second Fab, where the VL is of lambda subtype and binds to, e.g., a cancer antigen, (e.g., the same cancer antigen bound by the VH-CHl of the second Fab molecule).

In an aspect, the disclosure provides, multispecific molecules comprising (a) a first polypeptide chain having the following configuration from N-terminus to C-terminus: a first portion of a first antigen binding moiety (ABM) (e.g., wherein the first ABM comprises a VH- CHl of a first Fab molecule, that binds to, e.g., a cancer antigen, connected, optionally via a linker to, a first subunit of a heterodimerization domain (e.g., a TCRa variable domain connected to a TCRa constant domain); (b) a second polypeptide chain having the following configuration from N-terminus to C-terminus: a first portion of a second ABM (e.g., wherein the second ABM comprises a VH-CHl of a second Fab molecule, that binds to, e.g., a cancer antigen, connected, optionally via a linker to, a second subunit of a heterodimerization domain (e.g., TCRP variable domain connected to a TCRP constant domain); (c) a third polypeptide having the following configuration from N-terminus to C-terminus: a second portion of the first ABM (e.g., a VL-CL of the first Fab, where the VL is of kappa subtype and binds to, e.g., a cancer antigen (e.g., the same cancer antigen bound by the VH-CHl of the first Fab molecule); (d) a fourth polypeptide having the following configuration from N-terminus to C-terminus: a second portion of the second antigen domain (e.g. a VL-CL of the second Fab, where the VL is of lambda subtype and binds to, e.g., a cancer antigen, (e.g., the same cancer antigen bound by the VH-CHl of the second Fab molecule). In an aspect, the disclosure provides isolated nucleic acid molecules encoding the multispecific molecule described herein.

In an aspect, the disclosure provides, isolated nucleic acid molecules, which comprises a nucleotide sequence encoding any of the multispecific molecules described herein, or a nucleotide sequence substantially homologous thereto (e.g., at least 95% to 99.9% identical thereto).

In an aspect, the disclosure provides, vectors, e.g., an expression vector, comprising one or more of the nucleic acid molecules described herein.

In an aspect, the disclosure provides, host cells comprising a nucleic acid molecule or a vector described herein.

In an aspect, the disclosure provides, pharmaceutical compositions comprising the multispecific molecule described herein and a pharmaceutically acceptable carrier, excipient, or stabilizer.

In an aspect, the disclosure provides, methods of making, e.g., producing, a multispecific molecule described herein, comprising culturing a host cell described herein, under suitable conditions, e.g., conditions suitable for gene expression and/or heterodimerization.

In an aspect, the disclosure provides, methods of making, e.g., producing, the

multispecific molecule (e.g., multispecific antibody molecule) described herein, comprising (a) generating a first antibody (e.g., a human antibody) comprising (i) a first heavy chain comprising a CH2 domain connected (optionally via a linker) to a first non-immunoglobulin dimerization domain (e.g., a TCRa constant domain) and (ii) a first light chain (e.g., a kappa light chain); (b) generating a second antibody (e.g., a human antibody) comprising a second heavy chain comprising a CH2 domain connected (optionally via a linker) to a second non-immunoglobulin dimerization domain (e.g., a TCRP constant domain) and (ii) a second light chain (e.g., a lambda light chain), wherein the first and the second non-immunoglobulin dimerization domains are not the same; (c) transfecting a cell (or cells) with a nucleic acid encoding the amino acid sequence of the first antibody and the second antibody; (d) culturing the cell (or cells) under suitable conditions, e.g., conditions suitable for gene expression; (e) purifying the antibody (e.g., using Protein A); (f) optionally determining the presence of the first and second heavy chain (e.g. via gel electrophoresis under reducing conditions); and (g) optionally determining the presence of correctly paired first and second heavy chains with the first and the second light chains, respectively (e.g., via mass spectrometry).

In an aspect, the disclosure provides, methods of manufacturing a multispecific molecule described herein, comprising purifying the multispecific molecule using a Protein A column.

In an aspect, the disclosure provides, methods of manufacturing a multispecific molecule described herein, comprising purifying the multispecific molecule using a Protein G column

In an aspect, the disclosure provides, methods of treating a cancer, comprising administering to a subject in need thereof a multispecific molecule described herein, wherein the multispecific antibody is administered in an amount effective to treat the cancer.

In some embodiments, the cancer is a solid tumor cancer, or a metastatic lesion. In some embodiments, the solid tumor cancer is one or more of pancreatic (e.g., pancreatic

adenocarcinoma), breast, colorectal, lung (e.g., small or non-small cell lung cancer), skin, ovarian, or liver cancer. In some embodiments, the cancer is a hematological cancer. In some embodiments, the method further comprises administering a second therapeutic treatment. In some embodiments, the second therapeutic treatment comprises a therapeutic agent (e.g., a chemotherapeutic agent, a biologic agent, hormonal therapy), radiation, or surgery. In some embodiments, the therapeutic agent is selected from: a chemotherapeutic agent, or a biologic agent. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS FIGs. 1A and IB show topology maps of 5HY9 and 4WW1 respectively. 5HY9 is the structure of a KiH Fc showing the domain linkage between CH2 and CH3, which is used to form the heterodimer. 4WW1 is the structure of TCR showing the linkage between the variable domain and constant domain, which is used to form the heterodimer.

FIGs. 2A and 2B show the overall alignment of the knobs into holes CH3 domain with the TCR constant domain.

FIGs. 3A and 3B are flattened topology views, showing the CH3 knob/TCRoc constant domain (SEQ ID NOs. 169 and 168, respectively) and the CH3 hole/TCR constant domain (SEQ ID NOs. 171 and 170, respectively) topology alignments based on FIGs. 2A and 2B.

FIGs. 4A and 4B depict schematic representations of multispecific molecules of the present disclosure. FIG. 4A shows a multispecific molecule comprising two heavy chains, one kappa light chain, and one lambda light chain. The two heavy chains comprise knob-into-hole mutations in the CH3 domains. Multispecific molecule 1 tested in Example 2 has the configuration shown in FIG. 4A. FIG. 4B shows a multispecific molecule where the CH3 domains of the two heavy chains are replaced by a TCRa constant domain and a TCRP constant domain, respectively. Multispecific molecule 2 tested in Example 3 has the configuration shown in FIG. 4B.

FIG. 5. Gel of reduced samples of multispecific molecule 1 following kappa/lambda select analysis. Lane 1 is the load, lane 2 is the flow-through from the KappaSelect column, lane 3 is the elution from the KappaSelect column, lane 4 is the flow-through from the

LambdaFabSelect column, and lane 5 is the elution from the LambdaFabSelect column.

FIG. 6. Gel of multispecific molecule 2.

FIG. 7. Size exclusion chromatogram of multispecific molecule 2.

FIG. 8. Gel of non-reduced samples of multispecific molecule 2 following kappa/lambda select analysis. Lane 1 is the load, lane 2 is the flow-through from the KappaSelect column, lane 3 is the elution from the KappaSelect column, lane 4 is the flow-through from the

LambdaFabSelect column, and lane 5 is the elution from the LambdaFabSelect column.

DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are multispecific molecules (also referred to herein as "multifunctional molecules") (e.g., bispecific molecules, e.g., bispecific antibodies) that include non- immunoglobulin dimerization domains (e.g., naturally occurring dimerization domains, e.g., TCR a and β constant domains). Without being bound by theory, the multispecific molecules disclosed herein are expected to provide stable correctly assembled multispecific molecules (e.g., bispecific antibodies) retaining a natural immunoglobulin like structure, comprising a non- immunoglobulin heterodimerization domain (e.g., TCR a and β constant domains). Accordingly, provided herein are, inter alia, multispecific molecules (e.g., multispecific antibody molecules) that include the aforesaid non-immunoglobulin dimerization domains, nucleic acids encoding the same, methods of producing the aforesaid molecules (e.g., in a single cell), and methods of treating a cancer using the aforesaid molecules.

Similarity ofFc and TCR dimerization domains

The overall structure of the α/β T-cell receptor (TCR) is similar to that of the IgG Fab region with an overall alignment of Coc carbons with a RMSD of 6 A vs. 13 A for the Fc region. Although the relationship between the CH2 and CH3 domains of the Fc region is dissimilar to the relationship between the TCR constant and variable domains, as elucidated herein the constant domain of the TCR interacts to form a heterodimer in a fashion comparable to that of the knobs into holes CH3 domains. Superposition of the CH3 domains from the structure of the knobs into holes Fc domain, RCSB code 5HY9, with the constant domains of the α/β TCR, RCSB code 4WW1, results in a RMSD of 2.6 A ² for all C carbons and 0.5 A ² for those in the β-strands forming the core of the IgG fold. FIGs. 1A and IB show topology maps (A. Stivala, M. Wybrow, A. Wirth, J. Whisstock and P. Stuckey 2011 Automatic generation of protein structure cartoons with Pro-origami Bioinformatics 27(23):3315-3316) of 5HY9 and 4WW1 respectively, while FIGs. 2A and 2B show the overall alignment of the knobs into holes CH3 domains with the TCR constant domains. The fold for both CH3 domains in 5HY9 is classified by SCOP as b.1.1.2, CI set domains or antibody constant domain like (Murzin A. G., Brenner S. E., Hubbard T., Chothia C. (1995). SCOP: a structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol. 247, 536-540.), with the domain defined by 7 β-strands forming 2 sheets which are connected via a disulfide. The TCRβ constant domain is also classified as b.1.1.2 while TCRa constant domain is classified as b.1.1.0, not a true immunoglobulin family due to one of the β-sheets missing. FIGs. 3A and 3B show the CH3 knob/TCRoc constant domain and the CH3 hole/TCRβ constant domain topology alignments based on FIGs. 2A and 2B. Without wishing to be bound by theory, IgG CH3 domain and TCR constant domain are similar in structure and relative dimer formation.

The constant domain of the /β TCR can substitute for the CH3 domain in the Fc region to make immunoglobulin heavy chain heterodimers.

Certain terms are defined below.

As used herein a "tumor-targeting moiety," refers to a binding agent that recognizes or associates with, e.g., binds to, a target in a cancer cell. The tumor-targeting moiety can be an antibody molecule, a receptor molecule (e.g., a full length receptor, receptor fragment, or fusion thereof (e.g., a receptor-Fc fusion)), or a ligand molecule (e.g., a full length ligand, ligand fragment, or fusion thereof (e.g., a ligand-Fc fusion)) that binds to the cancer antigen (e.g., the tumor and/or the stromal antigen). In embodiments, the tumor-targeting moiety specifically binds to the target tumor, e.g., binds preferentially to the target tumor. For example, when the tumor-targeting moiety is an antibody molecule, it binds to the cancer antigen (e.g., the tumor antigen and/or the stromal antigen) with a dissociation constant of less than about 10 nM, and more typically, 10 - 100 pM.

As used herein, an "immune cell engager" refers to one or more binding specificities that bind and/or activate an immune cell, e.g., a cell involved in an immune response. In

embodiments, the immune cell is chosen from an NK cell, a B cell, a dendritic cell, and/or the macrophage cell. The immune cell engager can be an antibody molecule, a receptor molecule (e.g., a full length receptor, receptor fragment, or fusion thereof), or a ligand molecule (e.g., a full length ligand, ligand fragment, or fusion thereof) that binds to the immune cell antigen (e.g., the NK cell antigen, the B cell antigen, the dendritic cell antigen, and/or the macrophage cell antigen). In embodiments, the immune cell engager specifically binds to the target immune cell, e.g., binds preferentially to the target immune cell. For example, when the immune cell engager is an antibody molecule, it binds to the immune cell antigen (e.g., the NK cell antigen, the B cell antigen, the dendritic cell antigen, and/or the macrophage cell antigen) with a dissociation constant of less than about 10 nM, and more typically, 10 - 100 pM.

As used herein, a "cytokine molecule" refers to full length, a fragment or a variant of a cytokine; a cytokine further comprising a receptor domain, e.g., a cytokine receptor dimerizing domain; or an agonist of a cytokine receptor, e.g., an antibody molecule (e.g., an agonistic antibody) to a cytokine receptor, that elicits at least one activity of a naturally-occurring cytokine. In some embodiments the cytokine molecule is chosen from interleukin-2 (IL-2), interleukin- 12 (IL- 12), interleukin- 15 (IL- 15), interleukin- 18 (IL- 18), interleukin-21 (IL-21), or interferon gamma, or a fragment or variant thereof, or a combination of any of the aforesaid cytokines. The cytokine molecule can be a monomer or a dimer. In embodiments, the cytokine molecule can further include a cytokine receptor dimerizing domain. In other embodiments, the cytokine molecule is an agonist of a cytokine receptor, e.g., an antibody molecule (e.g., an agonistic antibody) to a cytokine receptor chosen from an IL-15Ra or IL-21R.

As used herein, the term "molecule" as used in, e.g., antibody molecule, cytokine molecule, receptor molecule, includes full-length, naturally-occurring molecules, as well as variants, e.g., functional variants (e.g., truncations, fragments, mutated (e.g., substantially similar sequences) or derivatized form thereof), so long as at least one function and/or activity of the unmodified (e.g., naturally-occurring) molecule remains.

The term "functional variant" refers to polypeptides that have a substantially identical amino acid sequence to the naturally-occurring sequence, or are encoded by a substantially identical nucleotide sequence, and are capable of having one or more activities of the naturally- occurring sequence.

As used herein, the articles "a" and "an" refer to one or more than one, e.g. , to at least one, of the grammatical object of the article. The use of the words "a" or "an" when used in conjunction with the term "comprising" herein may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."

As used herein, "about" and "approximately" generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given range of values.

"Antibody molecule" as used herein refers to a protein, e.g., an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain sequence. An antibody molecule includes e.g., antibodies (e.g., full-length antibodies) and antibody fragments. In an embodiment, an antibody molecule comprises an antigen binding or functional fragment of a full length antibody, or a full length immunoglobulin chain. For example, a full-length antibody is an immunoglobulin (Ig) molecule (e.g., an IgG antibody) that is naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes). In embodiments, an antibody molecule refers to an immunologically active, antigen-binding portion of an immunoglobulin molecule, such as an antibody fragment. An antibody fragment, e.g., functional fragment, is a portion of an antibody, e.g., Fab, Fab', F(ab') ₂ , F(ab) ₂ , variable fragment (Fv), domain antibody (dAb), or single chain variable fragment (scFv). A functional antibody fragment binds to the same antigen as that recognized by the intact (e.g., full-length) antibody. The terms "antibody fragment" or "functional fragment" also include isolated fragments consisting of the variable regions, such as the "Fv" fragments consisting of the variable regions of the heavy and light chains or recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker ("scFv proteins"). In some embodiments, an antibody fragment does not include portions of antibodies without antigen binding activity, such as Fc fragments or single amino acid residues. Exemplary antibody molecules include full length antibodies and antibody fragments, e.g., dAb (domain antibody), single chain, Fab, Fab', and F(ab') ₂ fragments, and single chain variable fragments (scFvs).

As used herein, a "CH2 domain" refers to an immunoglobulin CH2 domain, e.g., an

IgGl, an IgG2, an IgG3, an IgG4 CH2 domain, or any fragment thereof.

As used herein, a "CH3 domain" refers to an immunoglobulin CH3 domain, e.g., an IgGl, an IgG2, an IgG3, an IgG4 CH3 domain, or any fragment thereof.

As used herein, an "immunoglobulin variable domain sequence" refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations that are compatible with formation of the protein structure.

In embodiments, an antibody molecule is monospecific, e.g., it comprises binding specificity for a single epitope. In some embodiments, an antibody molecule is multispecific, e.g., it comprises a plurality of immunoglobulin variable domain sequences, where a first immunoglobulin variable domain sequence has binding specificity for a first epitope and a second immunoglobulin variable domain sequence has binding specificity for a second epitope. In some embodiments, an antibody molecule is a bispecific antibody molecule. "Bispecific antibody molecule" as used herein refers to an antibody molecule that has specificity for more than one (e.g., two, three, four, or more) epitope.

"Antigen" (Ag) as used herein refers to a molecule that can provoke an immune response, e.g., involving activation of certain immune cells and/or antibody generation. The terms

"antigen" and "epitope" are used synonymously herein. Any macromolecule, including almost all proteins or peptides, can be an antigen. Antigens can also be derived from genomic recombinant or DNA. For example, any DNA comprising a nucleotide sequence or a partial nucleotide sequence that encodes a protein capable of eliciting an immune response encodes an "antigen." In embodiments, an antigen does not need to be encoded solely by a full length nucleotide sequence of a gene, nor does an antigen need to be encoded by a gene at all. In embodiments, an antigen can be synthesized or can be derived from a biological sample, e.g., a tissue sample, a tumor sample, a cell, or a fluid with other biological components. As used herein, a "tumor antigen" or interchangeably, a "cancer antigen" includes any molecule present on, or associated with, a cancer, e.g., a cancer cell or a tumor microenvironment that can provoke an immune response. As used, herein an "immune cell antigen" includes any molecule present on, or associated with, an immune cell that can provoke an immune response.

The "antigen-binding site" or "binding portion" of an antibody molecule refers to the part of an antibody molecule, e.g., an immunoglobulin (Ig) molecule that participates in antigen binding. In embodiments, the antigen binding site is formed by amino acid residues of the variable (V) regions of the heavy (H) and light (L) chains. Three highly divergent stretches within the variable regions of the heavy and light chains, referred to as hypervariable regions, are disposed between more conserved flanking stretches called "framework regions," (FRs). FRs are amino acid sequences that are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In embodiments, in an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface, which is complementary to the three-dimensional surface of a bound antigen. The three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions," or "CDRs." The framework region and CDRs have been defined and described, e.g., in Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of

Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917. Each variable chain (e.g., variable heavy chain and variable light chain) is typically made up of three CDRs and four FRs, arranged from amino-terminus to carboxy- terminus in the amino acid order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

As used herein, the term a "TCRa constant domain" refers to a portion of a TCR that is encoded by the TRAC gene, or a fragment or variant thereof. The term a "TCRP constant domain" refers to a portion of a TCR that is encoded by the TRBC1 gene or TRBC2 gene, or a fragment or variant thereof.

"Cancer" as used herein can encompass all types of oncogenic processes and/or cancerous growths. In embodiments, cancer includes primary tumors as well as metastatic tissues or malignantly transformed cells, tissues, or organs. In embodiments, cancer

encompasses all histopathologies and stages, e.g., stages of invasiveness/severity, of a cancer. In embodiments, cancer includes relapsed and/or resistant cancer. The terms "cancer" and "tumor" can be used interchangeably. For example, both terms encompass solid and liquid tumors. As used herein, the term "cancer" or "tumor" includes premalignant, as well as malignant cancers and tumors.

As used herein, an "immune cell" refers to any of various cells that function in the immune system, e.g., to protect against agents of infection and foreign matter. In embodiments, this term includes leukocytes, e.g., neutrophils, eosinophils, basophils, lymphocytes, and monocytes. Innate leukocytes include phagocytes (e.g., macrophages, neutrophils, and dendritic cells), mast cells, eosinophils, basophils, and natural killer cells. Innate leukocytes identify and eliminate pathogens, either by attacking larger pathogens through contact or by engulfing and then killing microorganisms, and are mediators in the activation of an adaptive immune response. The cells of the adaptive immune system are special types of leukocytes, called lymphocytes. B cells and T cells are important types of lymphocytes and are derived from hematopoietic stem cells in the bone marrow. B cells are involved in the humoral immune response, whereas T cells are involved in cell-mediated immune response. The term "immune cell" includes immune effector cells.

"Immune effector cell," as that term is used herein, refers to a cell that is involved in an immune response, e.g., in the promotion of an immune effector response. Examples of immune effector cells include, but are not limited to, T cells, e.g., alpha/beta T cells and gamma/delta T cells, B cells, natural killer (NK) cells, natural killer T (NK T) cells, and mast cells. The term "effector function" or "effector response" refers to a specialized function of a cell. Effector function of a T cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines.

The compositions and methods of the present invention encompass polypeptides and nucleic acids having the sequences specified, or sequences substantially identical or similar thereto, e.g., sequences at least 85%, 90%, 95% identical or higher to the sequence specified. In the context of an amino acid sequence, the term "substantially identical" is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and/or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 85%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein.

In the context of nucleotide sequence, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein.

Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.

To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g. , gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology").

The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453 ) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences described herein can be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and

XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention.

BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al, (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs {e.g., XBLAST and

NBLAST) can be used. See http://www.ncbi.nlm.nih.gov.

It is understood that the molecules of the present invention may have additional conservative or non-essential amino acid substitutions, which do not have a substantial effect on their functions.

The term "amino acid" is intended to embrace all molecules, whether natural or synthetic, which include both an amino functionality and an acid functionality and capable of being included in a polymer of naturally-occurring amino acids. Exemplary amino acids include naturally-occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs having variant side chains; and all stereoisomers of any of any of the foregoing. As used herein the term "amino acid" includes both the D- or L- optical isomers and peptidomimetics.

A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains {e.g., lysine, arginine, histidine), acidic side chains {e.g., aspartic acid, glutamic acid), uncharged polar side chains {e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains {e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains {e.g., threonine, valine, isoleucine) and aromatic side chains {e.g., tyrosine, phenylalanine, tryptophan, histidine).

The terms "polypeptide", "peptide" and "protein" (if single chain) are used

interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non- amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. The polypeptide can be isolated from natural sources, can be a produced by recombinant techniques from a eukaryotic or prokaryotic host, or can be a product of synthetic procedures.

The terms "nucleic acid," "nucleic acid sequence," "nucleotide sequence," or

"polynucleotide sequence," and "polynucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. The polynucleotide may be either single- stranded or double-stranded, and if single-stranded may be the coding strand or non-coding (antisense) strand. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a non-natural arrangement.

The term "isolated," as used herein, refers to material that is removed from its original or native environment (e.g. , the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated by human intervention from some or all of the co-existing materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of the environment in which it is found in nature.

Various aspects of the invention are described in further detail below. Additional definitions are set out throughout the specification. Antibody Molecules

In one embodiment, the antibody molecule binds to a cancer antigen, e.g., a tumor antigen or a stromal antigen. In some embodiments, the cancer antigen is, e.g., a mammalian, e.g., a human, cancer antigen. In other embodiments, the antibody molecule binds to an immune cell antigen, e.g., a mammalian, e.g., a human, immune cell antigen. For example, the antibody molecule binds specifically to an epitope, e.g., linear or conformational epitope, on the cancer antigen or the immune cell antigen.

In an embodiment, an antibody molecule is a monospecific antibody molecule and binds a single epitope. E.g. , a monospecific antibody molecule having a plurality of immunoglobulin variable domain sequences, each of which binds the same epitope.

In an embodiment an antibody molecule is a multispecific antibody molecule, e.g. , it comprises a plurality of immunoglobulin variable domains sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In an embodiment the first and second epitopes are on the same antigen, e.g. , the same protein (or subunit of a multimeric protein). In an embodiment the first and second epitopes overlap. In an embodiment the first and second epitopes do not overlap. In an embodiment the first and second epitopes are on different antigens, e.g. , the different proteins (or different subunits of a multimeric protein). In an embodiment a multispecific antibody molecule comprises a third, fourth or fifth immunoglobulin variable domain. In an embodiment, a multispecific antibody molecule is a bispecific antibody molecule, a trispecific antibody molecule, or a tetraspecific antibody molecule.

In an embodiment a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope. In an embodiment the first and second epitopes are on the same antigen, e.g. , the same protein (or subunit of a multimeric protein). In an embodiment the first and second epitopes overlap. In an embodiment the first and second epitopes do not overlap. In an embodiment the first and second epitopes are on different antigens, e.g. , the different proteins (or different subunits of a multimeric protein). In an embodiment a bispecific antibody molecule comprises a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a first epitope and a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a scFv or a Fab, or fragment thereof, have binding specificity for a first epitope and a scFv or a Fab, or fragment thereof, have binding specificity for a second epitope. In an embodiment, an antibody molecule comprises a diabody, and a single-chain molecule, as well as an antigen-binding fragment of an antibody (e.g., Fab, F(ab') ₂ , and Fv). For example, an antibody molecule can include a heavy (H) chain variable domain sequence

(abbreviated herein as VH), and a light (L) chain variable domain sequence (abbreviated herein as VL). In an embodiment an antibody molecule comprises or consists of a heavy chain and a light chain (referred to herein as a half antibody. In another example, an antibody molecule includes two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequence, thereby forming two antigen binding sites, such as Fab, Fab', F(ab') ₂ , Fc, Fd, Fd', Fv, single chain antibodies (scFv for example), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which may be produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies. These functional antibody fragments retain the ability to selectively bind with their respective antigen or receptor. Antibodies and antibody fragments can be from any class of antibodies including, but not limited to, IgG, IgA, IgM, IgD, and IgE, and from any subclass (e.g., IgGl, IgG2, IgG3, and IgG4) of antibodies. The a preparation of antibody molecules can be monoclonal or polyclonal. An antibody molecule can also be a human, humanized, CDR- grafted, or in vitro generated antibody. The antibody can have a heavy chain constant region chosen from, e.g., IgGl, IgG2, IgG3, or IgG4. The antibody can also have a light chain chosen from, e.g., kappa or lambda. The term "immunoglobulin" (Ig) is used interchangeably with the term "antibody" herein.

Examples of antigen-binding fragments of an antibody molecule include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a diabody (dAb) fragment, which consists of a VH domain; (vi) a camelid or camelized variable domain; (vii) a single chain Fv (scFv), see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883); (viii) a single domain antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Antibody molecules include intact molecules as well as functional fragments thereof. Constant regions of the antibody molecules can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function).

Antibody molecules can also be single domain antibodies. Single domain antibodies can include antibodies whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. Single domain antibodies may be any of the art, or any future single domain antibodies. Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, fish, shark, goat, rabbit, and bovine. According to another aspect of the invention, a single domain antibody is a naturally occurring single domain antibody known as heavy chain antibody devoid of light chains. Such single domain antibodies are disclosed in WO 9404678, for example. For clarity reasons, this variable domain derived from a heavy chain antibody naturally devoid of light chain is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from antibodies raised in Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides Camelidae may produce heavy chain antibodies naturally devoid of light chain; such VHHs are within the scope of the invention.

The VH and VL regions can be subdivided into regions of hypervariability, termed "complementarity determining regions" (CDR), interspersed with regions that are more conserved, termed "framework regions" (FR or FW).

The extent of the framework region and CDRs has been precisely defined by a number of methods (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242;

Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917; and the AbM definition used by Oxford Molecular's AbM antibody modeling software. See, generally, e.g., Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer- Verlag, Heidelberg). The terms "complementarity determining region," and "CDR," as used herein refer to the sequences of amino acids within antibody variable regions which confer antigen specificity and binding affinity. In general, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDRl, LCDR2, LCDR3).

The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of known schemes, including those described by Kabat et al. (1991),

"Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 ("Chothia" numbering scheme). As used herein, the CDRs defined according the "Chothia" number scheme are also sometimes referred to as "hypervariable loops."

For example, under Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDRl), 50-56 (LCDR2), and 89-97 (LCDR3). Under Chothia, the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3); and the amino acid residues in VL are numbered 26-32 (LCDRl), 50-52 (LCDR2), and 91-96 (LCDR3).

Each VH and VL typically includes three CDRs and four FRs, arranged from amino- terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

The antibody molecule can be a polyclonal or a monoclonal antibody.

The terms "monoclonal antibody" or "monoclonal antibody composition" as used herein refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. A monoclonal antibody can be made by hybridoma technology or by methods that do not use hybridoma technology {e.g., recombinant methods).

The antibody can be recombinantly produced, e.g., produced by phage display or by combinatorial methods.

Phage display and combinatorial methods for generating antibodies are known in the art (as described in, e.g., Ladner et al. U.S. Patent No. 5,223,409; Kang et al. International

Publication No. WO 92/18619; Dower et al. International Publication No. WO 91/17271; Winter et al. International Publication WO 92/20791; Markland et al. International Publication No. WO 92/15679; Breitling et al. International Publication WO 93/01288; McCafferty et al.

International Publication No. WO 92/01047; Garrard et al. International Publication No. WO 92/09690; Ladner et al. International Publication No. WO 90/02809; Fuchs et al. (1991)

Bio/Technology 9: 1370-1372; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246: 1275-1281; Griffths et al. (1993) EMBO J 12:725-734; Hawkins et al.

(1992) JMol Biol 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991) Bio/Technology 9: 1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982, the contents of all of which are incorporated by reference herein).

In one embodiment, the antibody is a fully human antibody {e.g., an antibody made in a mouse which has been genetically engineered to produce an antibody from a human

immunoglobulin sequence), or a non-human antibody, e.g., a rodent (mouse or rat), goat, primate {e.g., monkey), camel antibody. Preferably, the non-human antibody is a rodent (mouse or rat antibody). Methods of producing rodent antibodies are known in the art.

Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al.

International Application WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741 ; Lonberg et al. International Application WO 92/03918; Kay et al. International Application 92/03917; Lonberg, N. et al. 1994 Nature 368:856-859; Green, L.L. et al. 1994 Nature Genet. 7: 13-21; Morrison, S.L. et al. 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman et al. 1993 Year Immunol 7:33-40; Tuaillon et al. 1993 PNAS 90:3720-3724; Bruggeman et al. 1991 Eur J Immunol 21: 1323-1326).

An antibody molecule can be one in which the variable region, or a portion thereof, e.g., the CDRs, are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibody molecules generated in a non- human organism, e.g., a rat or mouse, and then modified, e.g., in the variable framework or constant region, to decrease antigenicity in a human are within the invention. An "effectively human" protein is a protein that does substantially not evoke a neutralizing antibody response, e.g., the human anti-murine antibody (HAMA) response.

HAMA can be problematic in a number of circumstances, e.g., if the antibody molecule is administered repeatedly, e.g., in treatment of a chronic or recurrent disease condition. A HAMA response can make repeated antibody administration potentially ineffective because of an increased antibody clearance from the serum (see, e.g., Saleh et al _^ Cancer Immunol.

Immunother., 32: 180-190 (1990)) and also because of potential allergic reactions (see, e.g., LoBuglio et al, Hybridoma, 5:5117-5123 (1986)).

Chimeric antibodies can be produced by recombinant DNA techniques known in the art (see Robinson et al., International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988 Science 240: 1041-1043); Liu et al. (1987) PNAS 84:3439-3443; Liu et al., 1987, J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al, 1987, Cane. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al, 1988, J. Natl Cancer Inst. 80: 1553-1559).

A humanized or CDR-grafted antibody will have at least one or two but generally all three recipient CDRs (of heavy and or light immuoglobulin chains) replaced with a donor CDR. The antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding to the antigen. Preferably, the donor will be a rodent antibody, e.g., a rat or mouse antibody, and the recipient will be a human framework or a human consensus framework. Typically, the immunoglobulin providing the CDRs is called the "donor" and the immunoglobulin providing the framework is called the "acceptor." In one embodiment, the donor immunoglobulin is a non-human (e.g., rodent). The acceptor framework is a naturally- occurring (e.g., a human) framework or a consensus framework, or a sequence about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto.

As used herein, the term "consensus sequence" refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g.,

Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. A "consensus framework" refers to the framework region in the consensus immunoglobulin sequence.

An antibody molecule can be humanized by methods known in the art (see e.g.,

Morrison, S. L., 1985, Science 229: 1202- 1207, by Oi et al., 1986, BioTechniques 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US 5,693,762, the contents of all of which are hereby incorporated by reference).

Humanized or CDR-grafted antibody molecules can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDRs of an immunoglobulin chain can be replaced. See e.g., U.S. Patent 5,225,539; Jones et al. 1986 Nature 321 :552-525; Verhoeyan et al. 1988 Science 239: 1534; Beidler et al. 1988 J. Immunol. 141 :4053-4060; Winter US 5,225,539, the contents of all of which are hereby expressly incorporated by reference. Winter describes a CDR-grafting method which may be used to prepare the humanized antibodies of the present invention (UK Patent Application GB 2188638A, filed on March 26, 1987; Winter US

5,225,539), the contents of which is expressly incorporated by reference.

Also within the scope of the invention are humanized antibody molecules in which specific amino acids have been substituted, deleted or added. Criteria for selecting amino acids from the donor are described in US 5,585,089, e.g. , columns 12-16 of US 5,585,089, e.g., columns 12-16 of US 5,585,089, the contents of which are hereby incorporated by reference. Other techniques for humanizing antibodies are described in Padlan et al. EP 519596 Al, published on December 23, 1992.

The antibody molecule can be a single chain antibody. A single-chain antibody (scFV) may be engineered (see, for example, Colcher, D. et al. (1999) Ann N Y Acad Sci 880:263-80; and Reiter, Y. (1996) Clin Cancer Res 2:245-52). The single chain antibody can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target protein.

In yet other embodiments, the antibody molecule has a heavy chain constant region chosen from, e.g., the heavy chain constant regions of IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE; particularly, chosen from, e.g., the (e.g., human) heavy chain constant regions of IgGl, IgG2, IgG3, and IgG4. In another embodiment, the antibody molecule has a light chain constant region chosen from, e.g., the (e.g., human) light chain constant regions of kappa or lambda. The constant region can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, and/or complement function). In one embodiment the antibody has: effector function; and can fix complement. In other embodiments the antibody does not; recruit effector cells; or fix complement. In another embodiment, the antibody has reduced or no ability to bind an Fc receptor. For example, it is a isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor, e.g. , it has a mutagenized or deleted Fc receptor binding region.

Methods for altering an antibody constant region are known in the art. Antibodies with altered function, e.g. altered affinity for an effector ligand, such as FcR on a cell, or the C I component of complement can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see e.g., EP 388,151 Al, U.S. Pat. No. 5,624,821 and U.S. Pat. No. 5,648,260, the contents of all of which are hereby incorporated by reference). Similar type of alterations could be described which if applied to the murine, or other species immunoglobulin would reduce or eliminate these functions.

An antibody molecule can be derivatized or linked to another functional molecule (e.g., another peptide or protein). As used herein, a "derivatized" antibody molecule is one that has been modified. Methods of derivatization include but are not limited to the addition of a fluorescent moiety, a radionucleotide, a toxin, an enzyme or an affinity ligand such as biotin. Accordingly, the antibody molecules of the invention are intended to include derivatized and otherwise modified forms of the antibodies described herein, including immunoadhesion molecules. For example, an antibody molecule can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a strep tavidin core region or a polyhistidine tag).

One type of derivatized antibody molecule is produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies). Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate). Such linkers are available from Pierce

Chemical Company, Rockford, 111. Non-immunoglobulin Heterodimerization Domains

Non-immunoglobulin heterodimerization domains described herein include, e.g., TCRa constant domain and TCRP constant domain.

TCRa Constant Domain

In some embodiments, the TCRa domain comprises the WT human TCRa constant domain having the following amino acid sequence (human WT full length TCRa constant domain):

Uniprot Reference: P01848

PNIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKS NSAVAWSNKS DFACANAFNNSI IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLW

ss (SEQ ID NO: 158).

In some embodiments, the TCRa domain comprises a fragment of SEQ ID NO: 158.

In some embodiments, the TCRa domain comprises or consists of amino acids 1-85 of SEQ ID NO: 158.

In some embodiments, the TCRa domain comprises or consists of the following amino acid sequence:

PDIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKS NSAVAWSNKS DFACANAFNNSI IPEDTFFPSPE (SEQ ID NO: 1).

In some embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 158.

In some embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, or 80 contiguous amino acids of SEQ ID NO: 1.

In some embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 158, with no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutions. In some embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, or 80 contiguous amino acids of SEQ ID NO: 1, with no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutions.

In some embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 158, with 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more amino acid substitutions. In some embodiments, the TCRa domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 1, withl, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more amino acid substitutions.

In some embodiments, the TCRP domain comprises the WT human TCRP constant domain having the following amino acid sequence (human WT full length TCRP constant domain):

Uniprot Reference: P01850

EDLNKVFPPEVAVFEP SEAE I S HTQKATLVCLATGFFPDHVEL SWWVNGKEVH S GVS TDP QP LKEQPALND SRYCL S SRLRVSATFWQNPRNHFRCQVQFYGL SENDEWTQDRAKPVTQ I VSAEAWGRADCGF T SVS YQQGVL SAT I LYE I LLGKATLYAVLVSALVLMAMVKRKDF (SEQ ID

NO: 159).

In some embodiments, the TCRP domain comprises a fragment of SEQ ID NO: 159. In some embodiments, the TCRP domain comprises or consists of amino acids 1-130 of SEQ ID NO: 159.

In some embodiments, the TCRP constant domain comprises or consists of the following amino acid sequence:

EDLNKVFPPEVALFEP SEAE I S HTQKATLVCLATGFYPDHVELSWWVNGKEVHS GVCTDPQP LKEQPALN DSRYALS SRLRVSATFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD (SEQ ID NO:

2).

In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30,

40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, or 170 contiguous amino acids of SEQ ID NO: 159.

In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, or 130 contiguous amino acids of SEQ ID NO: 2.

In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30,

40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, or 170 contiguous amino acids of SEQ ID NO: 159, with no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutions. In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, or 130 contiguous amino acids of SEQ ID NO: 2, with no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutions.

In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30,

40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, or 170 contiguous amino acids of SEQ ID NO: 159, with 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more amino acid substitutions. In some embodiments, the TCRP domain comprises or consists of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, or 130 contiguous amino acids of SEQ ID NO: 2, with 1, 2, 3, 4, 5, 5, 6, 7, 8, 9, 10, or more amino acid substitutions.

In some embodiments, the multispecific molecules disclosed herein include a portion immunoglobulin constant region (e.g., an Fc region) (e.g., CH2 domain of an Fc). Exemplary Fc regions can be chosen from the heavy chain constant regions of IgGl, IgG2, IgG3 or IgG4; more particularly, the CH2 heavy chain constant region of human IgGl, IgG2, IgG3, or IgG4.

In some embodiments, the immunoglobulin chain constant region (e.g., CH2 of the Fc region) is altered, e.g., mutated, to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function.

In some embodiments, a linker is present between the CH2 and TCRa and TCRP domain.

In some embodiments, the TCRa and/or β constant domain is altered, e.g., mutated, to increase or decrease dimerization. For example, dimerization of the chain is enhanced by introducing a cysteine residue in the TCRa and TCRP domains creating an engineered disulfide, such that a greater ratio of heteromultimer to homomultimer forms, e.g., relative to a non- engineered interface.

In other embodiments, the multispecific molecule includes a half-life extender, e.g., a human serum albumin or an antibody molecule to human serum albumin.

Multispecific Molecules

Exemplary Formats In embodiments, multispecific molecules, e.g., antibody molecules, can comprise more than one antigen-binding site, where different sites are specific for different antigens. In embodiments, multispecific antibody molecules can bind more than one (e.g., two or more) epitopes on the same antigen. In embodiments, multispecific antibody molecules comprise an antigen -binding site specific for a target cell (e.g., cancer cell) and a different antigen-binding site specific for an immune effector cell. In one embodiment, the multispecific antibody molecule is a bispecific antibody molecule. Bispecific antibody molecules can be classified into five different structural groups: (i) bispecific immunoglobulin G (BsIgG); (ii) IgG appended with an additional antigen-binding moiety; (iii) bispecific antibody fragments; (iv) bispecific fusion proteins; and (v) bispecific antibody conjugates.

BsIgG is a format that is monovalent for each antigen. Exemplary BsIgG formats include but are not limited to crossMab, DAF (two-in-one), DAF (four- in-one), DutaMab, DT-IgG, , , charge pair, Fab-arm exchange, , triomab, LUZ-Y, Fcab, κλ-body, orthogonal Fab. See Spiess et al. Mol. Immunol. 67(2015):95-106. Exemplary BsIgGs include catumaxomab (Fresenius Biotech, Trion Pharma, Neopharm), which contains an anti-CD3 arm and an anti-EpCAM arm; and ertumaxomab (Neovii Biotech, Fresenius Biotech), which targets CD3 and HER2BsIgG can be produced by separate expression of the component antibodies in different host cells and subsequent purification/assembly into a BsIgG. BsIgG can also be produced by expression of the component antibodies in a single host cell. BsIgG can be purified using affinity

chromatography, e.g., using protein A and sequential pH elution.

IgG appended with an additional antigen-binding moiety is another format of bispecific antibody molecules. For example, monospecific IgG can be engineered to have bispecificity by appending an additional antigen -binding unit onto the monospecific IgG, e.g., at the N- or C- terminus of either the heavy or light chain. Exemplary additional antigen-binding units include single domain antibodies (e.g., variable heavy chain or variable light chain), engineered protein scaffolds, and paired antibody variable domains (e.g., single chain variable fragments or variable fragments). See Id. Examples of appended IgG formats include dual variable domain IgG (DVD-Ig), IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, zybody, and D VI- IgG (four- in-one). See Spiess et al. Mol. Immunol. 67(2015):95- 106. An example of an IgG-scFv is MM- 141 (Merrimack Pharmaceuticals), which binds IGF-1R and HER3. Examples of DVD-Ig include ABT-981 (Abb Vie), which binds IL- la and IL-Ιβ; and ABT-122 (Abb Vie), which binds TNF and IL- 17A.

Bispecific antibody fragments (BsAb) are a format of bispecific antibody molecules that lack some or all of the antibody constant domains. For example, some BsAb lack an Fc region. In embodiments, bispecific antibody fragments include heavy and light chain regions that are connected by a peptide linker that permits efficient expression of the BsAb in a single host cell. Exemplary bispecific antibody fragments include but are not limited to nanobody, nanobody- HAS, BiTE, Diabody, DART, TandAb, scDiabody, scDiabody-non-immunoglobulin

heterodimerization domain (e.g., TCR constant domain α/β), Diabody-non-immunoglobulin heterodimerization domain (e.g., TCR constant domain α/β), triple body, miniantibody, minibody, TriBi minibody, scFv-non-immunoglobulin heterodimerization domain (e.g., TCR constant domain α/β) KIH, Fab-scFv, scFv-CH-CL-scFv, F(ab')2, F(ab')2-scFv2, scFv-KIH, Fab-scFv-Fc, tetravalent HCAb, scDiabody-Fc, Diabody-Fc, tandem scFv-Fc, and intrabody. See Id. For example, the BiTE format comprises tandem scFvs, where the component scFvs bind to CD3 on T cells and a surface antigen on cancer cells

Bispecific fusion proteins include antibody fragments linked to other proteins, e.g., to add additional specificity and/or functionality. An example of a bispecific fusion protein is an immTAC, which comprises an anti-CD3 scFv linked to an affinity-matured T-cell receptor that recognizes HLA-presented peptides. In embodiments, the dock-and-lock (DNL) method can be used to generate bispecific antibody molecules with higher valency. Also, fusions to albumin binding proteins or human serum albumin can be extend the serum half-life of antibody fragments. See Id.

In embodiments, chemical conjugation, e.g., chemical conjugation of antibodies and/or antibody fragments, can be used to create BsAb molecules. See Id. An exemplary bispecific antibody conjugate includes the CovX-body format, in which a low molecular weight drug is conjugated site-specifically to a single reactive lysine in each Fab arm or an antibody or fragment thereof. In embodiments, the conjugation improves the serum half-life of the low molecular weight drug. An exemplary CovX-body is CVX-241 (NCT01004822), which comprises an antibody conjugated to two short peptides inhibiting either VEGF or Ang2. See Id.

The antibody molecules can be produced by recombinant expression, e.g., of at least one or more component, in a host system. Exemplary host systems include eukaryotic cells (e.g., mammalian cells, e.g., CHO cells, or insect cells, e.g., SF9 or S2 cells) and prokaryotic cells (e.g., E. coli). Bispecific antibody molecules can be produced by separate expression of the components in different host cells and subsequent purification/assembly. Alternatively, the antibody molecules can be produced by expression of the components in a single host cell.

Purification of bispecific antibody molecules can be performed by various methods such as affinity chromatography, e.g., using protein A and sequential pH elution. In other embodiments, affinity tags can be used for purification, e.g., histidine-containing tag, myc tag, or streptavidin tag.

CDR-grafted scaffolds

In embodiments, the antibody molecule is a CDR-grafted scaffold domain. In embodiments, the scaffold domain is based on a fibronectin domain, e.g., fibronectin type III domain. The overall fold of the fibronectin type III (Fn3) domain is closely related to that of the smallest functional antibody fragment, the variable domain of the antibody heavy chain. There are three loops at the end of Fn3; the positions of BC, DE and FG loops approximately correspond to those of CDR1, 2 and 3 of the VH domain of an antibody. Fn3 does not have disulfide bonds; and therefore Fn3 is stable under reducing conditions, unlike antibodies and their fragments (see, e.g., WO 98/56915; WO 01/64942; WO 00/34784). An Fn3 domain can be modified (e.g., using CDRs or hypervariable loops described herein) or varied, e.g., to select domains that bind to an antigen/marker/cell described herein.

In embodiments, a scaffold domain, e.g., a folded domain, is based on an antibody, e.g., a

"minibody" scaffold created by deleting three beta strands from a heavy chain variable domain of a monoclonal antibody (see, e.g., Tramontano et al., 1994, J Mol. Recognit. 7:9; and Martin et al., 1994, EMBO J. 13:5303-5309). The "minibody" can be used to present two hypervariable loops. In embodiments, the scaffold domain is a V-like domain (see, e.g., Coia et al. WO 99/45110) or a domain derived from tendamistatin, which is a 74 residue, six-strand beta sheet sandwich held together by two disulfide bonds (see, e.g., McConnell and Hoess, 1995, J Mol. Biol. 250:460). For example, the loops of tendamistatin can be modified (e.g., using CDRs or hypervariable loops) or varied, e.g., to select domains that bind to a marker/antigen/cell described herein. Another exemplary scaffold domain is a beta-sandwich structure derived from the extracellular domain of CTLA-4 (see, e.g., WO 00/60070). Other exemplary scaffold domains include but are not limited to T-cell receptors; MHC proteins; extracellular domains (e.g., fibronectin Type III repeats, EGF repeats); protease inhibitors (e.g., Kunitz domains, ecotin, BPTI, and so forth); TPR repeats; trifoil structures; zinc finger domains; DNA-binding proteins; particularly monomeric DNA binding proteins; RNA binding proteins; enzymes, e.g., proteases (particularly inactivated proteases), RNase;

chaperones, e.g., thioredoxin, and heat shock proteins; and intracellular signaling domains (such as SH2 and SH3 domains). See, e.g., US 20040009530 and US 7,501,121, incorporated herein by reference.

In embodiments, a scaffold domain is evaluated and chosen, e.g., by one or more of the following criteria: (1) amino acid sequence, (2) sequences of several homologous domains, (3) 3- dimensional structure, and/or (4) stability data over a range of pH, temperature, salinity, organic solvent, oxidant concentration. In embodiments, the scaffold domain is a small, stable protein domain, e.g., a protein of less than 100, 70, 50, 40 or 30 amino acids. The domain may include one or more disulfide bonds or may chelate a metal, e.g., zinc.

Exemplary structures of the multifunctional molecules defined herein are described below. Exemplary structures are further described in: Weidle U et al. (2013) The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer. Cancer Genomics & Proteomics 10: 1-18 (2013); and Spiess C et al. (2015) Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular Immunology 67: 95-106; the full contents of each of which is incorporated by reference herein).

Antibody-Based Fusions

A variety of formats can be generated which contain additional binding entities attached to the N or C terminus of antibodies. These fusions with single chain or disulfide stabilized Fvs or Fabs result in the generation of tetravalent molecules with bivalent binding specificity for each antigen. Combinations of scFvs and scFabs with IgGs enable the production of molecules which can recognize three or more different antigens.

Antibody-Fab Fusion

Antibody-Fab fusions are bispecific antibodies comprising a traditional antibody to a first target and a Fab to a second target fused to the C terminus of the antibody heavy chain. Commonly the antibody and the Fab will have a common light chain. Antibody fusions can be produced by (1) engineering the DNA sequence of the target fusion, and (2) transfecting the target DNA into a suitable host cell to express the fusion protein. It seems like the antibody-scFv fusion may be linked by a (Gly)-Ser linker between the C-terminus of the non-immunoglobulin heterodimerization domain and the N-terminus of the scFv, as described by Coloma, J. et al. (1997) Nature Biotech 15: 159.

Antibody-scFv Fusion

Antibody-scFv Fusions, are bispecific antibodies comprising a traditional antibody and a scFv of unique specificity fused to the C terminus of the antibody heavy chain. The scFv can be fused to the C terminus through the Heavy Chain of the scFv either directly or through a linker peptide. Antibody fusions can be produced by (1) engineering the DNA sequence of the target fusion, and (2) transfecting the target DNA into a suitable host cell to express the fusion protein. It seems like the antibody-scFv fusion may be linked by a (Gly)-Ser linker between the C- terminus of the non-immunoglobulin heterodimerization domain and the N-terminus of the scFv, as described by Coloma, J. et al. (1997) Nature Biotech 15: 159.

Lambda/Kappa Formats

Multispecific molecules (e.g., multispecific antibody molecules) that include the lambda light chain polypeptide and a kappa light chain polypeptides, can be used to allow for heterodimerization (e.g., correct pairing of the light chains). Methods for generating bispecific antibody molecules comprising the lambda light chain polypeptide and a kappa light chain polypeptides are disclosed in USSN 62/399,319 filed on September 23, 2016 and

WO2018/057955, incorporated herein by reference in their entirety.

In embodiments, the multispecific molecule is a multispecific antibody molecule, e.g., an antibody molecule comprising two binding specificities, e.g., a bispecific antibody molecule. The multispecific antibody molecule includes:

a lambda light chain polypeptide 1 (LLCP1) specific for a first epitope;

a heavy chain polypeptide 1 (HCP1) specific for the first epitope;

a kappa light chain polypeptide 2 (KLCP2) specific for a second epitope; and

a heavy chain polypeptide 2 (HCP2) specific for the second epitope. "Lambda light chain polypeptide 1 (LLCPl)", as that term is used herein, refers to a polypeptide comprising sufficient light chain (LC) sequence, such that when combined with a cognate heavy chain variable region, can mediate specific binding to its epitope and complex with an HCPl. LLCPl and "Lambda light chain polypeptide (LLCP)" are used interchangeably. In an embodiment it comprises all or a fragment of a CHI region. In an embodiment, an LLCPl comprises LC-CDR1, LC-CDR2, LC-CDR3, FRl, FR2, FR3, FR4, and CHI, or sufficient sequence therefrom to mediate specific binding of its epitope and complex with an HCPl.

LLCPl, together with its HCPl, provide specificity for a first epitope (while KLCP2, together with its HCP2, provide specificity for a second epitope). As described elsewhere herein, LLCPl has a higher affinity for HCPl than for HCP2.

"Kappa light chain polypeptide 2 (KLCP2)", as that term is used herein, refers to a polypeptide comprising sufficient light chain (LC) sequence, such that when combined with a cognate heavy chain variable region, can mediate specific binding to its epitope and complex with an HCP2. KLCP2 and "Kappa light chain polypeptide (KLCP)" are used interchangeably. In an embodiments it comprises all or a fragment of a CHI region. In an embodiment, a KLCP2 comprises LC-CDR1, LC-CDR2, LC-CDR3, FRl, FR2, FR3, FR4, and CHI, or sufficient sequence therefrom to mediate specific binding of its epitope and complex with an HCP2.

KLCP2, together with its HCP2, provide specificity for a second epitope (while LLCPl, together with its HCPl, provide specificity for a first epitope).

"Heavy chain polypeptide 1 (HCPl)", as that term is used herein, refers to a polypeptide comprising sufficient heavy chain (HC) sequence, e.g., HC variable region sequence, such that when combined with a cognate LLCPl, can mediate specific binding to its epitope and complex with an HCPl. In an embodiments it comprises all or a fragment of a CHlregion. In an embodiment, it comprises all or a fragment of a CH2 and/or CH3 region. In an embodiment an HCPl comprises HC-CDRl, HC-CDR2, HC-CDR3, FRl, FR2, FR3, FR4, CHI, CH2, and CH3, or sufficient sequence therefrom to: (i) mediate specific binding of its epitope and complex with an LLCPl, (ii) to complex preferentially, as described herein to LLCPl as opposed to KLCP2; and (iii) to complex preferentially, as described herein, to an HCP2, as opposed to another molecule of HCPl. HCPl, together with its LLCPl, provide specificity for a first epitope (while KLCP2, together with its HCP2, provide specificity for a second epitope). "Heavy chain polypeptide 2 (HCP2)", as that term is used herein, refers to a polypeptide comprising sufficient heavy chain (HC) sequence, e.g., HC variable region sequence, such that when combined with a cognate LLCP1, can mediate specific binding to its epitope and complex with an HCPl. In an embodiments it comprises all or a fragment of a CHlregion. In an embodiments it comprises all or a fragment of a CH2 and/or CH3 region. In an embodiment an HCPl comprises HC-CDRl, HC-CDR2, HC-CDR3, FRl, FR2, FR3, FR4, CHI, CH2, and CH3, or sufficient sequence therefrom to: (i) mediate specific binding of its epitope and complex with an KLCP2, (ii) to complex preferentially, as described herein to KLCP2 as opposed to LLCP1; and (iii) to complex preferentially, as described herein, to an HCPl, as opposed to another molecule of HCP2. HCP2, together with its KLCP2, provide specificity for a second epitope (while LLCP1, together with its HCPl, provide specificity for a first epitope).

As used herein, preferential pairing of a heavy chain polypeptide and a light chain polypeptide refers to the condition, where the heavy chain polypeptide and the light chain polypeptide preferentially bind to each other, over an unrelated heavy chain polypeptide, or an unrelated light chain polypeptide. In one embodiment, the heavy chain polypeptide binds to the light chain polypeptide with a higher affinity than when the heavy chain polypeptide binds to an unrelated light chain polypeptide. In one embodiment, the light chain polypeptide binds to the heavy chain polypeptide with a higher affinity than when the light chain polypeptide binds to an unrelated heavy chain polypeptide.

As used here, a percent binding between a first heavy chain polypeptide and a first light chain polypeptide in the presence of a competing polypeptide (e.g., a second heavy chain polypeptide or a second light chain polypeptide) refers to the amount of binding between the first heavy chain polypeptide and the first light chain polypeptide in the presence of the competing polypeptide, relative to the amount of binding between the first heavy chain polypeptide and the first light chain polypeptide in the absence of any competing polypeptide (the latter was set to 100%). In one embodiment, the percent binding was measured when the first heavy chain polypeptide, the first light chain polypeptide, and the competing polypeptide are present at 1: 1: 1. In one embodiment, the percent binding was measured when the first heavy chain polypeptide, the first light chain polypeptide, and the competing polypeptide are present at 1: 1: 1, wherein the competing polypeptide is a second light chain polypeptide. In one embodiment, the percent binding was measured by an assay described herein, e.g., the NanoBiT assay described in In some embodiments of the multispecific antibody molecule disclosed herein:

LLCP1 has a higher affinity for HCPl than for HCP2; and/or

KLCP2 has a higher affinity for HCP2 than for HCPl.

In embodiments, the affinity of LLCP1 for HCPl is sufficiently greater than its affinity for HCP2, such that under preselected conditions, e.g., in aqueous buffer, e.g., at pH 7, in saline, e.g., at pH 7, or under physiological conditions, at least 75%, 80, 90, 95, 98, 99, 99.5, or 99.9 % of the multispecific antibody molecule molecules have a LLCPlcomplexed, or interfaced with, a HCPl.

In some embodiments of the multispecific antibody molecule disclosed herein:

the HCPl has a greater affinity for HCP2, than for a second molecule of HCPl; and/or the HCP2 has a greater affinity for HCPl, than for a second molecule of HCP2.

In embodiments, the affinity of HCPl for HCP2 is sufficiently greater than its affinity for a second molecule of HCPl, such that under preselected conditions, e.g., in aqueous buffer, e.g., at pH 7, in saline, e.g., at pH 7, or under physiological conditions, at least 75%, 80, 90, 95, 98, 99 99.5 or 99.9 % of the multispecific antibody molecule molecules have a HCPlcomplexed, or interfaced with, a HCP2.

In another aspect, disclosed herein is a method for making, or producing, a multispecific antibody molecule. The method includes:

(i) providing a first heavy chain polypeptide (e.g., a heavy chain polypeptide comprising one, two, three or all of a first heavy chain variable region (first VH), a first CHI, a first heavy chain constant region (e.g., a first CH2, a first CH3, or both));

(ii) providing a second heavy chain polypeptide (e.g., a heavy chain polypeptide comprising one, two, three or all of a second heavy chain variable region (second VH), a second CHI, a second heavy chain constant region (e.g., a second CH2, a second CH3, or both));

(iii) providing a lambda chain polypeptide (e.g., a lambda light variable region (VT_A), a lambda light constant chain (VT_A), or both) that preferentially associates with the first heavy chain polypeptide (e.g., the first VH); and (iv) providing a kappa chain polypeptide (e.g., a lambda light variable region (VLK), a lambda light constant chain (VLK), or both) that preferentially associates with the second heavy chain polypeptide (e.g., the second VH),

under conditions where (i)-(iv) associate.

In embodiments, the first and second heavy chain polypeptides form an Fc interface that enhances heterodimerization.

In embodiments, (i)-(iv) (e.g., nucleic acid encoding (i)-(iv)) are introduced in a single cell, e.g., a single mammalian cell, e.g., a CHO cell. In embodiments, (i)-(iv) are expressed in the cell.

In embodiments, (i)-(iv) (e.g., nucleic acid encoding (i)-(iv)) are introduced in different cells, e.g., different mammalian cells, e.g., two or more CHO cell. In embodiments, (i)-(iv) are expressed in the cells.

In one embodiments, the method further comprises purifying a cell-expressed antibody molecule, e.g., using a lambda- and/or- kappa-specific purification, e.g., affinity

chromatography.

In embodiments, the method further comprises evaluating the cell-expressed

multispecific antibody molecule. For example, the purified cell-expressed multispecific antibody molecule can be analyzed by techniques known in the art, include mass spectrometry. In one embodiment, the purified cell-expressed antibody molecule is cleaved, e.g., digested with papain to yield the Fab moieties and evaluated using mass spectrometry.

In embodiments, the method produces correctly paired kappa/lambda multispecific, e.g., bispecific, antibody molecules in a high yield, e.g., at least 75%, 80, 90, 95, 98, 99 99.5 or 99.9 %.

In other embodiments, the multispecific, e.g., a bispecific, antibody molecule that includes:

(i) a first heavy chain polypeptide (HCPl) (e.g., a heavy chain polypeptide comprising one, two, three or all of a first heavy chain variable region (first VH), a first CHI, a first heavy chain constant region (e.g., a first CH2, a first CH3, or both)), e.g., wherein the HCPl binds to a first epitope;

(ii) a second heavy chain polypeptide (HCP2) (e.g., a heavy chain polypeptide comprising one, two, three or all of a second heavy chain variable region (second VH), a second CHI, a second heavy chain constant region (e.g., a second CH2, a second CH3, or both)), e.g., wherein the HCP2 binds to a second epitope;

(iii) a lambda light chain polypeptide (LLCPl) (e.g., a lambda light variable region (VL1), a lambda light constant chain (VL1), or both) that preferentially associates with the first heavy chain polypeptide (e.g., the first VH), e.g., wherein the LLCPl binds to a first epitope; and

(iv) a kappa light chain polypeptide (KLCP2) (e.g., a lambda light variable region (VLk), a lambda light constant chain (VLk), or both) that preferentially associates with the second heavy chain polypeptide (e.g., the second VH), e.g., wherein the KLCP2 binds to a second epitope.

In embodiments, the first and second heavy chain polypeptides form an Fc interface that enhances heterodimerization. In embodiments, the multispecific antibody molecule has a first binding specificity that includes a hybrid VLl-CLl heterodimerized to a first heavy chain variable region connected to the Fc constant, CH2-CH3 domain (having a knob modification) and a second binding specificity that includes a hybrid VLk-CLk heterodimerized to a second heavy chain variable region connected to the Fc constant, CH2-CH3 domain (having a hole

modification).

Accordingly, in one aspect, disclosed herein is a multispecific antibody molecule, e.g., an antibody molecule comprising two binding specificities, e.g., a bispecific antibody molecule. The multispecific antibody molecule comprises:

i) a first antigen-binding domain that binds to a first antigen, wherein the first antigen- binding domain comprises:

a) a first heavy chain polypeptide (HCP1) comprising: a first heavy chain variable region sequence (HCVRS) sufficient that, when paired with i)b) allows the first antigen- binding domain to bind to the first antigen; and

b) a lambda light chain polypeptide (LLCP) comprising: a lambda light chain variable region sequence (LLCVRS) sufficient that, when paired with i)a) allows the first antigen-binding domain to bind to the first antigen; and

ii) a second antigen-binding domain that binds to a second antigen, wherein the second antigen -binding domain comprises: a) a second heavy chain polypeptide (HCP2) comprising: a second heavy chain variable region sequence (HCVRS) sufficient that, when paired with ii)b) allows the second antigen-binding domain to bind to the second antigen; and

b) a kappa light chain polypeptide (KLCP) comprising: a kappa light chain variable region sequence (KLCVRS) sufficient that, when paired with ii)a) allows the second antigen-binding domain to bind to the second antigen.

In one embodiment, 1) the first HCVRS has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a first heavy chain germline sequence selected from column 2 of Table 9; 2) the LLCVRS has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a lambda light chain germline sequence selected from column 3 of Table 9; 3) the second HCVRS has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a second heavy chain germline sequence selected from column 4 of Table 9; or 4) the KLCVRS has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a kappa light chain germline sequence selected from column 5 of Table 9.

In one embodiment, the first HCVRS has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a first heavy chain germline sequence selected from column 2 of Table 9. In one embodiment, the first heavy chain germline sequence and the lambda light chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence, the lambda light chain germline sequence, and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the second heavy chain germline sequence and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the second heavy chain germline sequence, the kappa light chain germline sequence, and the lambda light chain germline sequence are selected from a single row of Table 9. In one embodiment, at least two (e.g., two, three, or all) of the following: the first heavy chain germline sequence, the lambda light chain germline sequence, the second heavy chain germline sequence, and the kappa light chain germline sequence, are selected from a single row of Table 9. In one embodiment, the LLCVRS has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a lambda light chain germline sequence selected from column 3 of Table 9. In one embodiment, the first heavy chain germline sequence and the lambda light chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence, the lambda light chain germline sequence, and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the second heavy chain germline sequence and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the second heavy chain germline sequence, the kappa light chain germline sequence, and the lambda light chain germline sequence are selected from a single row of Table 9. In one embodiment, at least two (e.g., two, three, or all) of the following: the first heavy chain germline sequence, the lambda light chain germline sequence, the second heavy chain germline sequence, and the kappa light chain germline sequence, are selected from a single row of Table 9. In one embodiment, the second HCVRS has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a second heavy chain germline sequence selected from column 4 of Table 9. In one embodiment, the first heavy chain germline sequence and the lambda light chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence, the lambda light chain germline sequence, and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the second heavy chain germline sequence and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the second heavy chain germline sequence, the kappa light chain germline sequence, and the lambda light chain germline sequence are selected from a single row of Table 9. In one embodiment, at least two (e.g., two, three, or all) of the following: the first heavy chain germline sequence, the lambda light chain germline sequence, the second heavy chain germline sequence, and the kappa light chain germline sequence, are selected from a single row of Table 9.

In one embodiment, the KLCVRS has at least 75, 80, 85, 90, 95, 98, or 100% sequence identity with a kappa light chain germline sequence selected from column 5 of Table 9. In one embodiment, the first heavy chain germline sequence and the lambda light chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence, the lambda light chain germline sequence, and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the second heavy chain germline sequence and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the second heavy chain germline sequence, the kappa light chain germline sequence, and the lambda light chain germline sequence are selected from a single row of Table 9. In one embodiment, at least two (e.g., two, three, or all) of the following: the first heavy chain germline sequence, the lambda light chain germline sequence, the second heavy chain germline sequence, and the kappa light chain germline sequence, are selected from a single row of Table 9.

In one embodiment, the first heavy chain germline sequence and the lambda light chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence and the second heavy chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the lambda light chain germline sequence and the second heavy chain germline sequence are selected from a single row of Table 9. In one embodiment, the lambda light chain germline sequence and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the second heavy chain germline sequence and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence, the lambda light chain germline sequence, and the second heavy chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence, the lambda light chain germline sequence, and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence, the second heavy chain germline sequence, and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the lambda light chain germline sequence, the second heavy chain germline sequence, and the kappa light chain germline sequence are selected from a single row of Table 9. In one embodiment, the first heavy chain germline sequence, the lambda light chain germline sequence, the second heavy chain germline sequence, and the kappa light chain germline sequence are selected from a single row of Table 9.

In certain embodiments of the foregoing aspects, the multispecific antibody molecule further comprises an accessory moiety, wherein the accessory moiety has a property chosen from:

1) the accessory moiety has a molecular weight of at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 kDa;

2) the accessory moiety comprises a polypeptide having at least 30, 40, 50, 60, 70, 80, 90, or 100 amino acid residues;

3) the accessory moiety comprises a polypeptide having the ability to modulate the activity of an immune cell, e.g., a T cell, a B cell, an antigen presenting cell (APC), or an NK cell; or

4) the accessory moiety is chosen from one or more of an immune cell engager (e.g., a CD40 agonist, e.g., a CD40L polypeptide or an agonistic anti-CD40 antibody molecule, or a PD-

1 binding moiety, e.g., a PD-1 binding sequence of PDL-1 or an anti-PD-1 antibody molecule), a cytokine molecule (e.g. an IL-2 molecule), a cytokine antagonist (e.g., a TGF-β antagonist), an enzyme, a toxin, or a labeling agent. In one aspect, disclosed herein is a multispecific antibody molecule comprising:

i) a first antigen-binding domain that binds to a first antigen, wherein the first antigen- binding domain comprises:

a) a first heavy chain polypeptide (HCP1) comprising: a first heavy chain variable region sequence (HCVRS) sufficient that, when paired with i)b) allows the first antigen- binding domain to bind to the first antigen; and

b) a lambda light chain polypeptide (LLCP) comprising: a lambda light chain variable region sequence (LLCVRS) sufficient that, when paired with i)a) allows the first antigen-binding domain to bind to the first antigen; and

ii) a second antigen-binding domain that binds to a second antigen, wherein the second antigen -binding domain comprises: a) a second heavy chain polypeptide (HCP2) comprising: a second heavy chain variable region sequence (HCVRS) sufficient that, when paired with ii)b) allows the second antigen-binding domain to bind to the second antigen; and

b) a kappa light chain polypeptide (KLCP) comprising: a kappa light chain variable region sequence (KLCVRS) sufficient that, when paired with ii)a) allows the second antigen-binding domain to bind to the second antigen, wherein:

the multispecific antibody molecule further comprises an accessory moiety, wherein the accessory moiety has a property chosen from:

1) the accessory moiety has a molecular weight of at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 kDa;

2) the accessory moiety comprises a polypeptide having at least 30, 40, 50, 60, 70, 80, 90, or 100 amino acid residues;

3) the accessory moiety comprises a polypeptide having the ability to modulate the activity of an immune cell, e.g., a T cell, a B cell, an antigen presenting cell (APC), or an NK cell; or

4) the accessory moiety is chosen from one or more of an immune cell engager (e.g., a CD40 agonist, e.g., a CD40L polypeptide or an agonistic anti-CD40 antibody molecule, or a PD- 1 binding moiety, e.g., a PD-1 binding sequence of PDL-1 or an anti-PD-1 antibody molecule), a cytokine molecule (e.g. an IL-2 molecule), a cytokine antagonist (e.g., a TGF-β antagonist), an enzyme, a toxin, or a labeling agent.

In one embodiment, the accessory moiety has a molecular weight of at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 kDa. In one embodiment, the accessory moiety comprises a polypeptide having at least 30, 40, 50, 60, 70, 80, 90, or 100 amino acid residues. In one embodiment, the accessory moiety comprises a polypeptide having the ability to modulate the activity of an immune cell, e.g., a T cell, a B cell, an antigen presenting cell (APC), or an NK cell. In one embodiment, the accessory moiety is chosen from one or more of an immune cell engager (e.g., a CD40 agonist, e.g., a CD40L polypeptide or an agonistic anti-CD40 antibody molecule, or a PD-1 binding moiety, e.g., a PD-1 binding sequence of PDL-1 or an anti-PD-1 antibody molecule), a cytokine molecule (e.g. an IL-2 molecule), a cytokine antagonist (e.g., a TGF-β antagonist), an enzyme, a toxin, or a labeling agent. In one embodiment, the accessory moiety is fused to the polypeptide of a , b, c, or d of the multispecific antibody molecule. In one embodiment, the accessory moiety is fused to any of the following: the HCP1, first HCVRS, LLCP, LLCVRS, HCP2, second HCVRS, KLCP, or KLCVRS of the multispecific antibody molecule, e.g., the C-terminus or N-terminus of HCP1, first HCVRS, LLCP, LLCVRS, HCP2, second HCVRS, KLCP, or KLCVRS of the multispecific antibody molecule. In one embodiment, the accessory moiety is fused to the HCP1. In one embodiment, the accessory moiety is fused to the first HCVRS (e.g., the C-terminus or N- terminus of the first HCVRS). In one embodiment, the accessory moiety is fused to the LLCP (e.g., the C-terminus or N-terminus of the LLCP). In one embodiment, the accessory moiety is fused to the LLCVRS (e.g., the C-terminus or N-terminus of the LLCVRS). In one embodiment, the accessory moiety is fused to the HCP2 (e.g., the C-terminus or N-terminus of the HCP2). In one embodiment, the accessory moiety is fused to the second HCVRS (e.g., the C-terminus or N- terminus of the second HCVRS). In one embodiment, the accessory moiety is fused to the KLCP (e.g., the C-terminus or N-terminus of the KLCP). In one embodiment, the accessory moiety is fused to the KLCVRS (e.g., the C-terminus or N-terminus of the KLCVRS). In one embodiment, the HCP1 comprises a first heavy chain constant region sequence (HCCRS) (e.g., CHI, CH2, and CH3 sequences), wherein the accessory moiety is fused to the first HCCRS, e.g., the C-terminus of the first HCCRS. In one embodiment, the HCP2 comprises a second heavy chain constant region sequence (HCCRS) (e.g., CHI, CH2, and CH3 sequences), wherein the accessory moiety is fused to the second HCCRS, e.g., the C-terminus of the second HCCRS. In one embodiment, the LLCP comprises a lambda light chain constant region sequence

(LLCCRS), wherein the accessory moiety is fused to the LLCCRS, e.g., the C-terminus of the LLCCRS. In one embodiment, the KLCP comprises a kappa light chain constant region sequence (KLCCRS), wherein the accessory moiety is fused to the KLCCRS, e.g., the C- terminus of the KLCCRS .

In one embodiment, the multispecific antibody molecule comprises one or more (e.g., two, three, four, five, or more) accessory molecule. In one embodiment, the multispecific antibody molecule comprises a first accessory moiety and a second accessory moiety, wherein the first or second accessory moiety has a property chosen from:

1) the first or second accessory moiety has a molecular weight of at least 10, 20, 30, 40,

50, 60, 70, 80, 90, or 100 kDa; 2) the first or second accessory moiety comprises a polypeptide having at least 30, 40, 50, 60, 70, 80, 90, or 100 amino acid residues;

3) the first or second accessory moiety comprises a polypeptide having the ability to modulate the active of an immune cell, e.g., a T cell, a B cell, an antigen presenting cell (APC), or an NK cell; or

4) the first or second accessory moiety is chosen from one or more of an immune cell engager (e.g., a CD40 agonist, e.g., a CD40L polypeptide or an agonistic anti-CD40 antibody molecule, or a PD-1 binding moiety, e.g., a PD-1 binding sequence of PDL-1 or an anti-PD-1 antibody molecule), a cytokine molecule (e.g. an IL-2 molecule), a cytokine antagonist (e.g., a TGF-β antagonist), an enzyme, a toxin, or a labeling agent.

In one embodiment, the first and second accessory moieties are the same. In one embodiment, the first and second accessory moieties are different. In one embodiment, i) the first accessory moiety is fused to the HCPl or HCP2, e.g., the C-terminus of the HCPl or HCP2; and ii) the second accessory moiety is fused to the LLCP or KLCP, e.g., the C-terminus of the LLCP or KLCP. In one embodiment, i) the first accessory moiety is fused to the HCPl, e.g., the C-terminus of the HCPl; and ii) the second accessory moiety is fused to the LLCP, e.g., the C- terminus of the LLCP. In one embodiment, i) the first accessory moiety is fused to the HCPl, e.g., the C-terminus of the HCPl; and ii) the second accessory moiety is fused to the KLCP, e.g., the C-terminus of the KLCP. In one embodiment, i) the first accessory moiety is fused to the HCP2, e.g., the C-terminus of the HCP2; and ii) the second accessory moiety is fused to the LLCP, e.g., the C-terminus of the LLCP. In one embodiment, i) the first accessory moiety is fused to the HCP2, e.g., the C-terminus of the HCP2; and ii) the second accessory moiety is fused to the KLCP, e.g., the C-terminus of the KLCP. In one embodiment, i) the first accessory moiety is fused to the KLCP, e.g., the C-terminus of the KLCP; and ii) the second accessory moiety is fused to the LLCP, e.g., the C-terminus of the LLCP. In one embodiment, i) the first accessory moiety is fused to the LLCP, e.g., the C-terminus of the LLCP; and ii) the second accessory moiety is fused to the KLCP, e.g., the C-terminus of the KLCP. In one embodiment, i) the HCPl comprises a first heavy chain constant region sequence (HCCRS) (e.g., CHI, CH2, and CH3 sequences), wherein the first accessory moiety is fused to the first HCCRS, e.g., the C- terminus of the first HCCRS; and ii) the LLCP comprises a lambda light chain constant region sequence (LLCCRS), wherein the second accessory moiety is fused to the LLCCRS, e.g., the C- terminus of the LLCCRS. In one embodiment, i) the HCP2 comprises a second heavy chain constant region sequence (HCCRS) (e.g., CHI, CH2, and CH3 sequences), wherein the accessory moiety is fused to the second HCCRS, e.g., the C-terminus of the second HCCRS; and ii) the KLCP comprises a kappa light chain constant region sequence (KLCCRS), wherein the accessory moiety is fused to the KLCCRS, e.g., the C-terminus of the KLCCRS. In one embodiment, i) the HCPl comprises a first heavy chain constant region sequence (HCCRS) (e.g., CHI, CH2, and CH3 sequences), wherein the first accessory moiety is fused to the first HCCRS, e.g., the C-terminus of the first HCCRS; and ii) the KLCP comprises a kappa light chain constant region sequence (KLCCRS), wherein the accessory moiety is fused to the KLCCRS, e.g., the C- terminus of the KLCCRS. In one embodiment, i) the HCP2 comprises a second heavy chain constant region sequence (HCCRS) (e.g., CHI, CH2, and CH3 sequences), wherein the accessory moiety is fused to the second HCCRS, e.g., the C-terminus of the second HCCRS; and ii) the LLCP comprises a lambda light chain constant region sequence (LLCCRS), wherein the second accessory moiety is fused to the LLCCRS, e.g., the C-terminus of the LLCCRS.

In certain embodiments of the foregoing aspects, the multispecific antibody molecule comprises:

i) a) the HCPl comprises a first heavy chain constant region sequence (HCCRS) (e.g., a first CHI sequence),

i)b) the LLCP comprises a lambda light chain constant region sequence (LLCCRS), ii) a) the HCP2 comprises a second heavy chain constant region sequence (HCCRS) (e.g., a second CHI sequence), and

ii)b) the KLCP comprises a kappa light chain constant region sequence (KLCCRS), wherein:

1) the multispecific antibody molecule does not comprise a mutation in the first

HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCPl and the LLCP, compared with pairing of the HCPl and the LLCP without the mutation, or the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence) that promotes the preferential pairing of the HCPl and the LLCP, compared with pairing of the HCPl and the LLCP without the mutation; and 2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation, or the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation.

In one aspect, disclosed herein is a multispecific antibody comprising:

i) a first antigen-binding domain that binds to a first antigen, wherein the first antigen- binding domain comprises:

a) a first heavy chain polypeptide (HCP1) comprising: a first heavy chain variable region sequence (HCVRS) sufficient that, when paired with i)b) allows the first antigen- binding domain to bind to the first antigen; and a first heavy chain constant region sequence (HCCRS) (e.g., a first CHI sequence), and

b) a lambda light chain polypeptide (LLCP) comprising: a lambda light chain variable region sequence (LLCVRS) sufficient that, when paired with i)a) allows the first antigen-binding domain to bind to the first antigen; and a lambda light chain constant region sequence (LLCCRS), and

ii) a second antigen-binding domain that binds to a second antigen, wherein the second antigen-binding domain comprises:

a) a second heavy chain polypeptide (HCP2) comprising: a second heavy chain variable region sequence (HCVRS) sufficient that, when paired with ii)b) allows the second antigen-binding domain to bind to the second antigen; and a second heavy chain constant region sequence (HCCRS) (e.g., a second CHI sequence) and

b) a kappa light chain polypeptide (KLCP) comprising: a kappa light chain variable region sequence (KLCVRS) sufficient that, when paired with ii)a) allows the second antigen-binding domain to bind to the second antigen; and a kappa light chain constant region sequence (KLCCRS), wherein:

1) the multispecific antibody molecule does not comprise a mutation in the first

HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP1 and the LLCP, compared with pairing of the HCP1 and the LLCP without the mutation, or the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence) that promotes the preferential pairing of the HCP1 and the LLCP, compared with pairing of the HCP1 and the LLCP without the mutation; and

2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation, or the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation.

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP1 and the LLCP, compared with pairing of the HCP1 and the LLCP without the mutation; and

2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation.

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP1 and the LLCP, compared with pairing of the HCP1 and the LLCP without the mutation; and

2) the multispecific antibody molecule does not comprise a mutation in the KLCCRS

(e.g., a mutation relative to a naturally existing kappa light chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation.

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence) that promotes the preferential pairing of the HCP1 and the LLCP, compared with pairing of the HCP1 and the LLCP without the mutation; and

2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation.

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence) that promotes the preferential pairing of the HCP1 and the LLCP, compared with pairing of the HCP1 and the LLCP without the mutation; and

2) the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation.

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP1 and the LLCP, compared with pairing of the HCP1 and the LLCP without the mutation, and the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence) that promotes the preferential pairing of the HCP1 and the LLCP, compared with pairing of the HCP1 and the LLCP without the mutation; and

2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation, or the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation.

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCPl and the LLCP, compared with pairing of the HCPl and the LLCP without the mutation, or the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence) that promotes the preferential pairing of the HCPl and the LLCP, compared with pairing of the HCPl and the LLCP without the mutation; and 2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation, and the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation.

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCPl and the LLCP, compared with pairing of the HCPl and the LLCP without the mutation, and the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence) that promotes the preferential pairing of the HCPl and the LLCP, compared with pairing of the HCPl and the LLCP without the mutation; and

2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation, and the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence) that promotes the preferential pairing of the HCP2 and the KLCP, compared with pairing of the HCP2 and the KLCP without the mutation.

In one embodiment, the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that increases the preferential pairing of the HCPl and the LLCP by at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, or 50 folds, compared with pairing of the HCPl and the LLCP without the mutation. In one embodiment, the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence) that increases the preferential pairing of the HCPl and the LLCP by at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, or 50 folds, compared with pairing of the HCPl and the LLCP without the mutation.

In one embodiment, the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence) that increases the preferential pairing of the HCP2 and the KLCP by at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, or 50 folds, compared with pairing of the HCP2 and the KLCP without the mutation. In one embodiment, the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence) that increases the preferential pairing of the HCP2 and the KLCP by at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, or 50 folds, compared with pairing of the HCP2 and the KLCP without the mutation.

In certain embodiments of the foregoing aspects, the multispecific antibody molecule comprises:

i)a) the HCPl comprises a first heavy chain constant region sequence (HCCRS) (e.g., a first CHI sequence),

i) b) the LLCP comprises a lambda light chain constant region sequence (LLCCRS), ii) a) the HCP2 comprises a second heavy chain constant region sequence (HCCRS) (e.g., a second CHI sequence), and

ii)b) the KLCP comprises a kappa light chain constant region sequence (KLCCRS), wherein:

1) the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), or the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence); and

2) the multispecific antibody molecule does not comprise a mutation in the second

HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), or the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence).

In one aspect, disclosed herein is a multispecific antibody comprising:

i) a first antigen-binding domain that binds to a first antigen, wherein the first antigen- binding domain comprises:

a) a first heavy chain polypeptide (HCP1) comprising: a first heavy chain variable region sequence (HCVRS) sufficient that, when paired with i)b) allows the first antigen- binding domain to bind to the first antigen; and a first heavy chain constant region sequence (HCCRS) (e.g., a first CHI sequence), and

b) a lambda light chain polypeptide (LLCP) comprising: a lambda light chain variable region sequence (LLCVRS) sufficient that, when paired with i)a) allows the first antigen-binding domain to bind to the first antigen; and a lambda light chain constant region sequence (LLCCRS), and

ii) a second antigen-binding domain that binds to a second antigen, wherein the second antigen-binding domain comprises:

a) a second heavy chain polypeptide (HCP2) comprising: a second heavy chain variable region sequence (HCVRS) sufficient that, when paired with ii)b) allows the second antigen-binding domain to bind to the second antigen; and a second heavy chain constant region sequence (HCCRS) (e.g., a second CHI sequence) and

b) a kappa light chain polypeptide (KLCP) comprising: a kappa light chain variable region sequence (KLCVRS) sufficient that, when paired with ii)a) allows the second antigen-binding domain to bind to the second antigen; and a kappa light chain constant region sequence (KLCCRS), wherein:

1) the multispecific antibody molecule does not comprise a mutation in the first

HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), or the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence); and

2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), or the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence).

In one embodiment, the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), and the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence).

In one embodiment, the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), and the multispecific antibody molecule does not comprise a mutation in the

KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence).

In one embodiment, the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence), and the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence).

In one embodiment, the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence), and the multispecific antibody molecule does not comprise a mutation in the

KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence).

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), and the multispecific antibody molecule does not comprise a mutation in the

LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence); and 2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), or the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence).

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), or the multispecific antibody molecule does not comprise a mutation in the LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence); and 2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), and the multispecific antibody molecule does not comprise a mutation in the KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence).

In one embodiment, 1) the multispecific antibody molecule does not comprise a mutation in the first HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), and the multispecific antibody molecule does not comprise a mutation in the

LLCCRS (e.g., a mutation relative to a naturally existing lambda light chain constant region sequence); and 2) the multispecific antibody molecule does not comprise a mutation in the second HCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence), and the multispecific antibody molecule does not comprise a mutation in the

KLCCRS (e.g., a mutation relative to a naturally existing kappa light chain constant region sequence).

In one embodiment, the multispecific antibody molecule does not comprise a mutation in any of the following: the first HCCRS, the LLCCRS, the second HCCRS, and the KLCCRS (e.g., a mutation relative to a naturally existing heavy chain constant region sequence, a naturally existing lambda light chain constant region sequence, or a naturally existing kappa light chain constant region sequence).

In one embodiment, the multispecific antibody molecule does not comprise a mutation disclosed in WO2017059551.

In certain embodiments of the foregoing aspects, the multispecific antibody molecule comprises:

i)a) the HCP1 comprises a first heavy chain constant region sequence (HCCRS) (e.g., a first CHI sequence),

i) b) the LLCP comprises a lambda light chain constant region sequence (LLCCRS), ii) a) the HCP2 comprises a second heavy chain constant region sequence (HCCRS) (e.g., a second CHI sequence) and

ii)b) the KLCP comprises a kappa light chain constant region sequence (KLCCRS), wherein: 1) the first HCCRS comprises a naturally existing heavy chain constant region sequence, or the LLCCRS comprises a naturally existing lambda light chain constant region sequence; and

2) the second HCCRS comprises a naturally existing heavy chain constant region

5 sequence, or the KLCCRS comprises a naturally existing kappa light chain constant region

sequence.

In one aspect, disclosed herein is a multispecific antibody molecule comprising:

i) a first antigen-binding domain that binds to a first antigen, wherein the first antigenic) binding domain comprises:

a) a first heavy chain polypeptide (HCP1) comprising: a first heavy chain variable region sequence (HCVRS) sufficient that, when paired with i)b) allows the first antigen- binding domain to bind to the first antigen; and a first heavy chain constant region sequence (HCCRS) (e.g., a first CHI sequence), and

15 b) a lambda light chain polypeptide (LLCP) comprising: a lambda light chain variable region sequence (LLCVRS) sufficient that, when paired with i)a) allows the first antigen-binding domain to bind to the first antigen; and a lambda light chain constant region sequence (LLCCRS), and

ii) a second antigen-binding domain that binds to a second antigen, wherein the second 20 antigen-binding domain comprises:

a) a second heavy chain polypeptide (HCP2) comprising: a second heavy chain variable region sequence (HCVRS) sufficient that, when paired with ii)b) allows the second antigen-binding domain to bind to the second antigen; and a second heavy chain constant region sequence (HCCRS) (e.g., a second CHI sequence) and

25 b) a kappa light chain polypeptide (KLCP) comprising: a kappa light chain variable region sequence (KLCVRS) sufficient that, when paired with ii)a) allows the second antigen-binding domain to bind to the second antigen; and a kappa light chain constant region sequence (KLCCRS), wherein:

1) the first HCCRS comprises a naturally existing heavy chain constant region

30 sequence, or the LLCCRS comprises a naturally existing lambda light chain constant region sequence; and 2) the second HCCRS comprises a naturally existing heavy chain constant region sequence, or the KLCCRS comprises a naturally existing kappa light chain constant region sequence.

In one embodiment, 1) the first HCCRS comprises a naturally existing heavy chain constant region sequence; and 2) the second HCCRS comprises a naturally existing heavy chain constant region sequence. In one embodiment, 1) the first HCCRS comprises a naturally existing heavy chain constant region sequence; and 2) the KLCCRS comprises a naturally existing kappa light chain constant region sequence. In one embodiment, 1) the LLCCRS comprises a naturally existing lambda light chain constant region sequence; and 2) the second HCCRS comprises a naturally existing heavy chain constant region sequence. In one embodiment, 1) the LLCCRS comprises a naturally existing lambda light chain constant region sequence; and 2) the KLCCRS comprises a naturally existing kappa light chain constant region sequence. In one embodiment, 1) the first HCCRS comprises a naturally existing heavy chain constant region sequence, and the LLCCRS comprises a naturally existing lambda light chain constant region sequence; and 2) the second HCCRS comprises a naturally existing heavy chain constant region sequence, or the KLCCRS comprises a naturally existing kappa light chain constant region sequence. In one embodiment, 1) the first HCCRS comprises a naturally existing heavy chain constant region sequence, or the LLCCRS comprises a naturally existing lambda light chain constant region sequence; and 2) the second HCCRS comprises a naturally existing heavy chain constant region sequence, and the KLCCRS comprises a naturally existing kappa light chain constant region sequence.

In one embodiment, i) the first HCCRS comprises a naturally existing heavy chain constant region sequence, ii) the LLCCRS comprises a naturally existing lambda light chain constant region sequence, iii) the second HCCRS comprises a naturally existing heavy chain constant region sequence, and iv) the KLCCRS comprises a naturally existing kappa light chain constant region sequence.

In certain embodiments of the foregoing aspects, the HCP1 preferentially binds to the LLCP over the KLCP. In certain embodiments of the foregoing aspects, the LLCP preferentially binds to the HCP1 over the HCP2. In certain embodiments of the foregoing aspects, the HCP2 preferentially binds to the KLCP over the LLCP. In certain embodiments of the foregoing aspects, the KLCP preferentially binds to the HCP2 over the HCPl. In one embodiment, the HCPl has a higher affinity, e.g., a substantially higher affinity, for the LLCP than for the KLCP (e.g., the KD for the binding between the HCPl and the LLCP is no more than 50%, 40%, 30%, 20%, 10%, 1%, 0.1%, or 0.01% of the KD for the binding between the HCPl and the KLCP). In one embodiment, the LLCP has a higher affinity, e.g., a substantially higher affinity, for the HCPl than for the HCP2 (e.g., the KD for the binding between the LLCP and the HCPl is no more than 50%, 40%, 30%, 20%, 10%, 1%, 0.1%, or 0.01% of the KD for the binding between the LLCP and the first HCP2). In one embodiment, the HCP2 has a higher affinity, e.g., a substantially higher affinity, for the KLCP than for the LLCP (e.g., the KD for the binding between the HCP2 and the KLCP is no more than 50%, 40%, 30%, 20%, 10%, 1%, 0.1%, or 0.01% of the KD for the binding between the HCP2 and the LLCP). In one embodiment, the KLCP has a higher affinity, e.g., a substantially higher affinity, for the HCP2 than for the HCPl (e.g., the KD for the binding between the KLCP and the HCP2 is no more than 50%, 40%, 30%, 20%, 10%, 1%, 0.1%, or 0.01% of the KD for the binding between the KLCP and the HCPl).

In one embodiment, the percent binding between the HCPl and the LLCP in the presence of the KLCP is at least 75, 80, 90, 95, 98, 99, or 99.5%. In one embodiment, when the HCPl, LLCP, and KLCP are present at 1: 1: 1, the percent binding between the HCPl and the LLCP in the presence of the KLCP is at least 75, 80, 90, 95, 98, 99, or 99.5% (setting the binding between the HCPl and the LLCP in the absence of any competing peptide to 100%, and the binding between the HCPl and the LLCP in the presence of LLCP to 50%). In one embodiment, the percent binding was measured by an assay described herein, e.g., the NanoBiT assay described in WO2018/057955.

In one embodiment, the percent binding between the HCPl and the LLCP in the presence of the HCP2 is at least 75, 80, 90, 95, 98, 99, or 99.5%. In one embodiment, when HCPl, LLCP, and HCP2 are present at 1: 1: 1, the percent binding between the HCP 1 and the LLCP in the presence of the HCP2 is at least 75, 80, 90, 95, 98, 99, or 99.5% (setting the binding between the HCPl and the LLCP in the absence of any competing peptide to 100%, and the binding between the HCPl and the LLCP in the presence of HCPl to 50%). In one embodiment, the percent binding was measured by an assay described herein, e.g., the NanoBiT assay described in WO2018/057955. In one embodiment, the percent binding between the HCP2 and the KLCP in the presence of the LLCP is at least 75, 80, 90, 95, 98, 99, or 99.5%. In one embodiment, when HCP2, KLCP, and LLCP are present at 1: 1: 1, the percent binding between the HCP2 and the KLCP in the presence of the LLCP is at least 75, 80, 90, 95, 98, 99, or 99.5% (setting the binding between the HCP2 and the KLCP in the absence of any competing peptide to 100%, and the binding between the HCP2 and the KLCP in the presence of KLCP to 50%). In one embodiment, the percent binding was measured by an assay described herein, e.g., the NanoBiT assay described in WO2018/057955.

In one embodiment, the percent binding between the HCP2 and the KLCP in the presence of the HCP1 is at least 75, 80, 90, 95, 98, 99, or 99.5%. In one embodiment, when HCP2,

KLCP, and HCP1 are present at 1: 1: 1, the percent binding between the HCP2 and the KLCP in the presence of the HCP1 is at least 75, 80, 90, 95, 98, 99, or 99.5% (setting the binding between the HCP2 and the KLCP in the absence of any competing peptide to 100%, and the binding between the HCP2 and the KLCP in the presence of HCP2 to 50%). In one embodiment, the percent binding was measured by an assay described herein, e.g., the NanoBiT assay described in WO2018/057955.

In one embodiment, when the HCP1, LLCP, HCP2, and KLCP are present under preselected conditions, e.g., in aqueous buffer, e.g., at pH 7, in saline, e.g., at pH 7, or under physiological conditions: at least 70, 75, 80, 90, 95, 98, 99, 99.5, or 99.9 % of the HCP1 is complexed, or interfaced with, the LLCP. In one embodiment, when the HCP1, LLCP, HCP2, and KLCP are present under preselected conditions, e.g., in aqueous buffer, e.g., at pH 7, in saline, e.g., at pH 7, or under physiological conditions: at least 70, 75, 80, 90, 95, 98, 99, 99.5, or 99.9 % of the LLCP is complexed, or interfaced with, the HCP1. In one embodiment, when the HCP1, LLCP, HCP2, and KLCP are present under preselected conditions, e.g., in aqueous buffer, e.g., at pH 7, in saline, e.g., at pH 7, or under physiological conditions: at least 70, 75, 80, 90, 95, 98, 99, 99.5, or 99.9 % of the HCP2 is complexed, or interfaced with, the KLCP. In one embodiment, when the HCP1, LLCP, HCP2, and KLCP are present under preselected conditions, e.g., in aqueous buffer, e.g., at pH 7, in saline, e.g., at pH 7, or under physiological conditions: at least 70, 75, 80, 90, 95, 98, 99, 99.5, or 99.9 % of the KLCP is complexed, or interfaced with, the HCP2. In certain embodiments of the foregoing aspects, the multispecific antibody molecule comprises:

1) a) the HCPl comprises a first heavy chain constant region sequence (HCCRS) (e.g., a first CHI sequence),

i)b) the LLCP comprises a lambda light chain constant region sequence (LLCCRS), ii)a) the HCP2 comprises a second heavy chain constant region sequence (HCCRS) (e.g., a second CHI sequence) and

ii)b) the KLCP comprises a kappa light chain constant region sequence (KLCCRS), wherein:

1) the first HCCRS is complexed, or interfaced with, LLCCRS, and

2) the second HCCRS is complexed, or interfaced with, KLCCRS.

In certain embodiments of the foregoing aspects, the HCPl is complexed, or interfaced with, the HCP2. In one embodiment, the HCPl has a greater affinity, e.g., a substantially greater affinity, for HCP2, than for a second molecule of HCPl. In one embodiment, the HCP2 has a greater affinity, e.g., a substantially greater affinity, for HCPl, than for a second molecule of HCP2. In one embodiment, the HCPl comprises a sequence element that increases the ratio of HCP1-HCP2: HCP1-HCP1 pairings, compared to the ratio that would be seen in the absence of the sequence element, e.g., where a naturally occurring sequence replaces the sequence element. In one embodiment, the HCP2 comprises a sequence element that increases the ratio of HCP1- HCP2: HCP2-HCP2 pairings, compared to the ratio that would be seen in the absence of the sequence element, e.g., where a naturally occurring sequence replaces the sequence element. In one embodiment, the sequence element is not a naturally occurring constant region sequence. In one embodiment, the sequence element is disposed in CH3. In one embodiment, one or both of HCPl and HCP2 were selected to minimize self-dimerization (e.g., HCP1-HCP1) as opposed to heterodimerization (e.g., HCP2-HCP2). In one embodiment, HCPl and HCP2 are members of a paired protuberance/cavity, e.g., knob and hole pair. In one embodiment, HCP1-HCP2 paring is promoted by an electrostatic interaction. In one embodiment, HCP1-HCP2 paring is promoted by strand exchange. In one embodiment, HCPl and HCP2 are not members of a paired protuberance/cavity, e.g., knob and hole pair. In one embodiment, the HCPl comprises a first heavy chain constant region sequence (HCCRS), wherein the first HCCRS does not comprise a mutation (e.g., a mutation relative to a naturally existing heavy chain constant region sequence). In one embodiment, the HCP2 comprises a second heavy chain constant region sequence (HCCRS), wherein the second HCCRS does not comprise a mutation (e.g., a mutation relative to a naturally existing heavy chain constant region sequence). In one embodiment, i) the HCP1 comprises a first heavy chain constant region sequence (HCCRS), wherein the first HCCRS does not comprise a mutation (e.g., a mutation relative to a naturally existing heavy chain constant region sequence); and ii) the HCP2 comprises a second heavy chain constant region sequence (HCCRS), wherein the second HCCRS does not comprise a mutation (e.g., a mutation relative to a naturally existing heavy chain constant region sequence). In one embodiment, the HCP1 comprises a first CH2 domain sequence and a first CH3 domain sequence, wherein the first CH2 domain sequence and the first CH3 domain sequence do not comprise a mutation (e.g., a mutation relative to a naturally existing CH2 domain sequence or a naturally existing CH3 domain sequence). In one embodiment, the HCP2 comprises a second CH2 domain sequence and a second CH3 domain sequence, wherein the second CH2 domain sequence and the second CH3 domain sequence do not comprise a mutation (e.g., a mutation relative to a naturally existing CH2 domain sequence or a naturally existing CH3 domain sequence). In one embodiment, i) the HCP1 comprises a first CH2 domain sequence and a first CH3 domain sequence, wherein the first CH2 domain sequence and the first CH3 domain sequence do not comprise a mutation (e.g., a mutation relative to a naturally existing CH2 domain sequence or a naturally existing CH3 domain sequence); and ii) the HCP2 comprises a second CH2 domain sequence and a second CH3 domain sequence, wherein the second CH2 domain sequence and the second CH3 domain sequence do not comprise a mutation (e.g., a mutation relative to a naturally existing CH2 domain sequence or a naturally existing CH3 domain sequence). In certain embodiments of the foregoing aspects, the HCP1 is derived from an antibody arising, either in vivo or in vitro, as a lambda antibody. In certain embodiments of the foregoing aspects, the HCP2 is derived from an antibody arising, either in vivo or in vitro, as a kappa antibody.

In one embodiment, the HCP1 and LLCP comprise amino acid sequences selected from Table 8 (e.g., as paired in Table 8), or functional variant or fragment thereof (e.g., HCP1 comprises VH, CHI, and/or CH2 from an amino acid sequence selected from Table 8, and LLCP comprises VL, and/or CL from an amino acid sequence selected from Table 8). In one embodiment, the HCP2 and KLCP comprise amino acid sequences selected from Table 8 (e.g., as paired in Table 8), or functional variant or fragment thereof (e.g., HCP2 comprises VH, CHI, and/or CH2 from an amino acid sequence selected from Table 8, and KLCP comprises VL, and/or CL from an amino acid sequence selected from Table 8). In one embodiment, the HCP1, LLCP, HCP2, and KLCP comprise amino acid sequences selected from Table 8 (e.g., a single row of Table 8), or functional variant or fragment thereof (e.g., HCP1 and HCP2 comprise VH, CHI, and/or CH2 from amino acid sequences selected from Table 8, and LLCP and KLCP comprise VL, and/or CL from amino acid sequences selected from Table 8).

In one embodiment, the first or second antigen is a tumor antigen, e.g., a pancreatic, lung, or colorectal tumor antigen. In one embodiment, the first or second antigen is chosen from: PD- Ll, HER3, TROP2, mesothelin, IGF-1R, or CA19-9. In one embodiment, the first or second antigen is chosen from: PD-L1, HER3, TROP2, VEGF-A, EGFR, MUC1, DLL4, or HGF. In one embodiment, the first or second antigen is chosen from: PD-L1, HER3, TROP2, VEGF-A, EGFR, MUC1, MAGE- A3, gpA33, NY-ESO-1, ANG2, RSP03, HER2, CEACAM5, or CEA. In one embodiment, the first or second antigen is an antigen of an immune effector cell, e.g., a T cell, an NK cell, or a myeloid cell. In one embodiment, the first or second antigen is chosen from: CD3, PD-1, LAG- 3, TIM-3, CTLA-4, VISTA, TIGIT, PD-L1, B7-H3, 4-1BB, or ICOS. In one embodiment, the first antigen is a tumor antigen, e.g., mesothelin, and the second antigen is an antigen chosen from NKP30, PD-L1, CD3, NKG2D, CD47, 4-1BB, or NKP46; or the second antigen is a tumor antigen, e.g., mesothelin, and the first antigen is an antigen chosen from NKP30, PD-L1, CD3, NKG2D, CD47, 4-1BB, or NKP46. In one embodiment, the first antigen is IGF1R and the second antigen is HER3, or the second antigen is IGF1R and the first antigen is HER3. In one embodiment, the first antigen is mesothelin and the second antigen is PD-L1, or the second antigen is mesothelin and the first antigen is PD-L1. In one embodiment, the first antigen is CTLA4 and the second antigen is IL12P, or the second antigen is CTLA4 and the first antigen is IL12p. In one embodiment, the first antigen is CTLA4 and the second antigen is TRAILR2, or the second antigen is CTLA4 and the first antigen is TRAILR2. In one embodiment, the first antigen is CTLA4 and the second antigen is CD221, or the second antigen is CTLA4 and the first antigen is CD221. In one embodiment, the first antigen is PD1 and the second antigen is TRAILR2, or the second antigen is PDl and the first antigen is TRAILR2. In one embodiment, the first antigen is PDl and the second antigen is PDLl, or the second antigen is PDl and the first antigen is PDLl. In one embodiment, the first antigen is PDl and the second antigen is PDLl, or the second antigen is PDl and the first antigen is PDLl . In one

embodiment, the multispecific antibody molecule further comprises an IL-2 molecule. In one embodiment, the multispecific antibody molecule further comprises a CD40 agonist, e.g., a CD40L polypeptide or an agonistic anti-CD40 antibody molecule.

Table 8. Sequences used to construct multispecific molecules.

Column 1: Column 2: heavy Column 3: lambda Column 4: heavy Column 5: kappa Construct chain polypeptide light chain chain polypeptide light chain

1 (HCP1) polypeptide 2 (HCP2) polypeptide

(LLCP) (KLCP)

Multispecific SEQ ID NO: 378 SEQ ID NO: 345 SEQ ID NO: 379 SEQ ID NO: 318 molecule 1

Multispecific SEQ ID NO: 366 SEQ ID NO: 367 SEQ ID NO: 364 SEQ ID NO: 365 molecule 2

Multispecific SEQ ID NO: 370 SEQ ID NO: 363 SEQ ID NO: 368 SEQ ID NO: 306 molecule 3

Multispecific SEQ ID NO: 377 SEQ ID NO: 348 SEQ ID NO: 368 SEQ ID NO: 306 molecule 4

Multispecific SEQ ID NO: 380 SEQ ID NO: 336 SEQ ID NO: 368 SEQ ID NO: 306 molecule 5

Multispecific SEQ ID NO: 377 SEQ ID NO: 348 SEQ ID NO: 381 SEQ ID NO: 382 molecule 6

Multispecific SEQ ID NO: 366 SEQ ID NO: 367 SEQ ID NO: 381 SEQ ID NO: 382 molecule 7

Multispecific SEQ ID NO: 372 SEQ ID NO: 373 SEQ ID NO: 371 SEQ ID NO: 306 molecule 8

Multispecific SEQ ID NO: 370 SEQ ID NO: 373 SEQ ID NO: 368 SEQ ID NO: 306 molecule 9

Multispecific SEQ ID NO: 375 SEQ ID NO: 373 SEQ ID NO: 371 SEQ ID NO: 306 molecule 10

Multispecific SEQ ID NO: 374 SEQ ID NO: 373 SEQ ID NO: 368 SEQ ID NO: 306 molecule 11

Multispecific SEQ ID NO: 377 SEQ ID NO: 348 SEQ ID NO: 369 SEQ ID NO: 376 molecule 12

Table 9. Corresponding germline sequences of multispecific molecules.

Column 1: Column 2: heavy Column 3: lambda Column 4: heavy Column 5: kappa Construct chain polypeptide 1 light chain chain polypeptide 2 light chain (HCP1) polypeptide (LLCP) (HCP2) polypeptide (KLCP) corresponding corresponding corresponding corresponding germline sequence germline sequence germline sequence germline sequence

Multispecific VH3-9*01 (SEQ ID V13-19*01 (SEQ ID VH3-23*01 (SEQ Vkl-27*01 (SEQ molecule 1 NO: 196) NO: 211) ID NO: 191) ID NO: 200)

Multispecific VH3-66*01 (SEQ V12- 14*01 (SEQ ID VH4-31*01 (SEQ Vkl-39*01 (SEQ molecule 2 ID NO: 194) NO: 210) ID NO: 213) ID NO: 201)

Multispecific VH3-33*01 (SEQ Vll-44*01 (SEQ ID VH3-30*01 (SEQ Vk3-20*01 (SEQ molecule 3 ID NO: 193) NO: 209) ID NO: 192) ID NO: 205)

Multispecific Vk3-20*01 (SEQ V13-19*01 (SEQ ID VH3-30*01 (SEQ Vk3-20*01 (SEQ molecule 4 ID NO: 205) NO: 211) ID NO: 192) ID NO: 205)

Multispecific VH1-69*01 (SEQ V13-19*01 (SEQ ID VH3-30*01 (SEQ Vk3-20*01 (SEQ molecule 5 ID NO: 187) NO: 211) ID NO: 192) ID NO: 205)

Multispecific Vk3-20*01 (SEQ V13-19*01 (SEQ ID VH3-33*01 (SEQ Vk3-l l*01 (SEQ molecule 6 ID NO: 205) NO: 211) ID NO: 193) ID NO: 204)

Multispecific VH3-66*01 (SEQ V12- 14*01 (SEQ ID VH3-33*01 (SEQ Vk3-l l*01 (SEQ molecule 7 ID NO: 194) NO: 210) ID NO: 193) ID NO: 204)

Multispecific VH3-33*01 (SEQ Vll-44*01 (SEQ ID VH3-30*01 (SEQ Vk3-20*01 (SEQ molecule 8 ID NO: 193) NO: 209) ID NO: 192) ID NO: 205)

Multispecific VH3-33*01 (SEQ Vll-44*01 (SEQ ID VH3-30*01 (SEQ Vk3-20*01 (SEQ molecule 9 ID NO: 193) NO: 209) ID NO: 192) ID NO: 205)

Multispecific VH3-33*01 (SEQ Vll-44*01 (SEQ ID VH3-30*01 (SEQ Vk3-20*01 (SEQ molecule 10 ID NO: 193) NO: 209) ID NO: 192) ID NO: 205)

Multispecific VH3-33*01 (SEQ Vll-44*01 (SEQ ID VH3-30*01 (SEQ Vk3-20*01 (SEQ molecule 11 ID NO: 193) NO: 209) ID NO: 192) ID NO: 205)

Multispecific Vk3-20*01 (SEQ V13-19*01 (SEQ ID VH3-30*01 (SEQ Vk3-20*01 (SEQ molecule 12 ID NO: 205) NO: 211) ID NO: 192) ID NO: 205)

Table 10. Amino acid sequences used to construct multispecific constructs.

SEQ Amino Acid Sequence Description Germline ID NO

SEQ QVQLQESGPGLVKPSQTLSLTCTVSGGSINNNNYYWTWIRQ a-mesothelin VH4- ID NO: HPGKGLEWIGYIYYSGSTFYNPSLKSRVTISVDTSKTQFSLKL AB237 heavy 31*01 364 SSVTAADTAVYYCAREDTMTGLDVWGQGTTVTVSSASTKG (SEQ ID

PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT hCHIg_Knob NO: 213)

SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP _Cys

SNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK

DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK

TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLV

KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT

VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ DIQMTQSPSSLSASVGDRVTITCRASQSINNYLNWYQQKPG a-mesothelin Vkl- ID NO: KAPTLLIYAASSLQSGVPSRFSGSRSGTDFTLTISSLQPEDFA AB237 light - 39*01

365 AYFCQQTYSNPTFGQGTKVEVKRTVAAPSVFIFPPSDEQLKS hCLIg_vk (SEQ ID

GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD NO: 201)

SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC

SEQ EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAP a-PDLl VH3- ID NO: GKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQM heavy - 66*01

366 NSLR AEDT A V Y YC ARIKLGTV IT V DYWGQGTLVTVSS AST hCHIg_Hole (SEQ ID

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG _Cys NO: 194)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN

HKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP

KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLS

CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLV

SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHP a-PDLl light V12- ID NO: GKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAED - hCLIg_vl 14*01

367 EADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSS (SEQ ID

EELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETT NO: 210)

KPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVE

KTVAPTECS

SEQ QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQA a-CTLA4 VH3- ID NO: PGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYL heavy - 30*01

368 QMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSAST hCHIg_Knob (SEQ ID

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG _Cys NO: 192)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN

HKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP

KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSL

WCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL

YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

K

SEQ QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQA a-CTLA4 VH3- ID NO: PGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYL heavy - 30*01

369 QMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSAST hCHIg_Knob (SEQ ID

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG _Cys - NO: 192)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN GH_scFv

HKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP

KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSL

WCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL

YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

KGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLRLSCAA

SGFTFSPYSVFWVRQAPGKGLEWVSSINTDSTYKYYADSVK

GRFTISRDNAENSIFLQMNSLRAEDTAVYYCARDRSYYAFSS

GSLSDYYYGLDVWGQGTLVTVSSGGGGSGGGGSGGGGSG

GGGSDIVMTQSPLSLSVTPGEPASISCRSSQSLLHTNLYNYLD

WYVQKPGQSPQLLIYLASNRASGVPDRFSGSGSGTDFTLKIS

RVETEDVGVYYCMQALQIPRTFGQGTKLEIK

SEQ QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQA a-IL12 VH3- ID NO: PGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYL heavy - 33*01 370 QMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSSASTKG hCHIg_Hole (SEQ ID

PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT _Cys NO: 193)

SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP

SNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK

DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK

TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLSCAVK

GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTV

DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQA (X-CTLA4 VH3- ID NO: PGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYL heavy - 30*01 371 QMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSAST hCHIg (SEQ ID

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG NO: 192)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN

HKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP

KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS

KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQA α-Π.12β VH3- ID NO: PGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYL heavy - 33*01

372 QMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSSASTKG hCHIg (SEQ ID

PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT NO: 193)

SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP

SNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK

DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK

TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK

GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPG α-Π.12β light Vll- ID NO: TAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDE - hCLIg_vl - 44*01

373 ADYYCQSYDRYTHPALLFGTGTKVTVLGQPKANPTVTLFPP IL2 (SEQ ID

SSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVET NO: 209)

TKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTV

EKTVAPTECSGGGGSGGGGSGGGGSAPTSSSTKKTQLQLEH

LLLDLQMILNGINNYKNPKLTRMLTAKFAMPKKATELKHL

QCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGS

ETTFMCEYADETATIVEFLNRWITFCQSIISTLT

SEQ QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQA α-Π.12β VH3- ID NO: PGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYL heavy - 33*01 374 QMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSSASTKG hCHIg_Hole (SEQ ID

PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT _Cys NO: 193)

SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP

SNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK

DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK

TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQVSLSCAVK

GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGS

GGGGSGGGGSAPTSSSTKKTQLQLEHLLLDLQMILNGINNY

KNPKLTRMLTAKFAMPKKATELKHLQCLEEELKPLEEVLNL

AQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIV

EFLNRWITFCQSIISTLT

SEQ QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQA α-Π.12β VH3- ID NO: PGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYL heavy - 33*01

375 QMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSSASTKG hCHIg (SEQ ID

PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT NO: 193)

SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP

SNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK

DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK

TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK

GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGS

GGGGSGGGGSAPTSSSTKKTQLQLEHLLLDLQMILNGINNY

KNPKLTRMLTAKFAMPKKATELKHLQCLEEELKPLEEVLNL

AQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIV

EFLNRWITFCQSIISTLT

SEQ EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPG (X-CTLA4 Vk3- ID NO: QAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFA light - 20*01

376 VYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK hCLIg_vk - (SEQ ID

SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ IL2 NO: 205)

DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK

SFNRGECGGGGSGGGGSGGGGSAPTSSSTKKTQLQLEHLLL

DLQMILNGINNYKNPKLTRMLTAKFAMPKKATELKHLQCL

EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETT

FMCEYADETATIVEFLNRWITFCQSIISTLT

SEQ EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQA a-TNFR10 Vk3- ID NO: PGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLY heavy - 20*01

377 LQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTV hCHIg_Hole (SEQ ID

SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS _Cys NO: 205)

WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI

CNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK

CKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQ

VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS

FFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL

SPGK

SEQ QVQLVQSGGGLVQPGGSLRLSCAASGFTFDDYAMHWVRQ a-HER3 VH3- ID NO: APGKGLEWVAGISWDSGSTGYADSVKGRFTISRDNAKNSL heavy - 9*01

378 YLQMNSLRAEDTALYYCARDLGAYQWVEGFDYWGQGTL mFc_Knob_ (SEQ ID

VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV Cys NO: 196)

TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ

TYICNVNHKPSNTKVDKRVEPKSCTIKPCPPCKCPAPNLLGG

PSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVN

NVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFK

CKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPCEEEMTKK QVTLWCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSD

GSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSF SRTPGK

SEQ EVQLLQSGGGLVQPGGSLRLSCAASGFMFSRYPMHWVRQA a-IGFlR VH3- ID NO: PGKGLEWVGSISGSGGATPYADSVKGRFTISRDNSKNTLYL heavy - 23*01

379 QMNSLRAEDTAVYYCAKDFYQILTGNAFDYWGQGTTVTVS mFc_Hole_C (SEQ ID

SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW ys NO: 191)

NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC

NVNHKPSNTKVDKRVEPKSCTIKPCPPCKCPAPNLLGGPSVF

IFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEV

HTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVN

NKDLPAPIERTISKPKGSVRAPQVCVLPPPEEEMTKKQVTLS

CAVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFM

VSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPG

K

SEQ EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAP a-CD221 VH1- ID NO: GQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYME heavy - 69*01 380 LSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWG hCHIg_Hole (SEQ ID

KGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF _Cys NO: 187)

PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS

LGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF

NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL

NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRE

EMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV

LDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYT

QKSLSLSPGK

SEQ QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQA a-PDl heavy VH3- ID NO: PGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLF 33*01

381 LQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPS hCHIg_Knob (SEQ ID

VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS _Cys NO: 193)

GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS

NTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD

TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT

KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP

APIEKTISKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVK

GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQ α-PDl light - Vk3- ID NO: APRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAV hCLIg_vk 11*01

382 YYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKS (SEQ ID

GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD NO: 204)

SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF

NRGEC

SEQ EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPG a-CTLA4 Vk3- ID NO: QAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFA light 20*01 306 VYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLK (SEQ ID

SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ NO: 205)

DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK

SFNRGEC SEQ DIQMTQSPSSLSASLGDRVTITCRASQGISSYLAWYQQKPGK a-IGFlR Vkl- ID NO: APKLLIYAKSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSAT light 27*01

318 YYCQQYWTFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKS (SEQ ID

GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD NO: 200)

SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF

NRGEC

SEQ SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQ a-CD221 V13- ID NO: APILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEAD light 19*01

336 YYCKSRDGSGQHLVFGGGTKLTVLGQPKANPTVTLFPPSSE (SEQ ID

ELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTK NO: 211)

PSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEK

TVAPTECS

SEQ SYELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPG a-HER3 light V13- ID NO: QAPVLVIYGKNNRPSGIPDRFSGSTSGNSASLTITGAQAEDE 19*01 345 ADYYCNSRDSPGNQWVFGGGTKVTVLGGQPKANPTVTLFP (SEQ ID

PSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVE NO: 211)

TTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGST

VEKTVAPTECS

SEQ SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQ a-TRAILR2 V13- ID NO: APVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEA light 19*01

348 DYYCNSRDSSGNHVVFGGGTKLTVLGQPKANPTVTLFPPSS (SEQ ID

EELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETT NO: 211)

KPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVE

KTVAPTECS

SEQ QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPG α-Π.12β light Vll- ID NO: TAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDE 44*01

363 ADYYCQSYDRYTHPALLFGTGTKVTVLGQPKANPTVTLFPP (SEQ ID

SSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVET NO: 209)

TKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTV

EKTVAPTECS

Table 11. Germline sequences

204 Vk3- EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASN 11*01 RATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC

205 Vk3- EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAS 20*01 SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC

209 Vll- QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNN 44*01 QRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYC

210 V12- QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYE 14*01 VSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYC

211 V13- SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKN 19*01 NRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYC

213 VH4- QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGY 31*01 IYYSGSTYYNPSLKSLVTISVDTSKNQFSLKLSSVTAADTAVYYCAR

Tumor Specific Targeting Moieties

The present disclosure provides, inter alia, multispecific (e.g., bi-, tri-, tetra- specific) molecules, that include, e.g., are engineered to contain, one or more tumor specific targeting moieties that direct the molecule to a tumor cell.

Tumor-targeting moieties

In certain embodiments, the multispecific molecules disclosed herein include a tumor- targeting moiety. The tumor targeting moiety can be chosen from an antibody molecule (e.g., an antigen binding domain as described herein), a receptor or a receptor fragment, or a ligand or a ligand fragment, or a combination thereof. In some embodiments, the tumor targeting moiety associates with, e.g., binds to, a tumor cell (e.g., a molecule, e.g., antigen, present on the surface of the tumor cell). In certain embodiments, the tumor targeting moiety targets, e.g., directs the multispecific molecules disclosed herein to a cancer (e.g., a cancer or tumor cells). In some embodiments, the cancer is chosen from a hematological cancer, a solid cancer, a metastatic cancer, or a combination thereof.

In some embodiments, the multispecific molecule, e.g., the tumor-targeting moiety, binds to a solid tumor antigen or a stromal antigen. The solid tumor antigen or stromal antigen can be present on a solid tumor, or a metastatic lesion thereof. In some embodiments, the solid tumor is chosen from one or more of pancreatic (e.g., pancreatic adenocarcinoma), breast, colorectal, lung (e.g., small or non-small cell lung cancer), skin, ovarian, or liver cancer. In one embodiment, the solid tumor is a fibrotic or desmoplastic solid tumor. For example, the solid tumor antigen or stromal antigen can be present on a tumor, e.g., a tumor of a class typified by having one or more of: limited tumor perfusion, compressed blood vessels, or fibrotic tumor interstitium. In certain embodiments, the solid tumor antigen is chosen from one or more of: PDL1, mesothelin, CD47, gangloside 2 (GD2), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron Kinase, c-Met, Immature laminin receptor, TAG-72, BING-4, Calcium-activated chloride channel 2, Cyclin-B l, 9D7, Ep-CAM, EphA3, Her2/neu, Telomerase, SAP-1, Survivin, NY- ESO-l/LAGE-1, PRAME, SSX-2, Melan- A/MART- 1 , Gpl00/pmell7, Tyrosinase, TRP-1/-2, MC1R, β-catenin, BRCAl/2, CDK4, CML66, Fibronectin, p53, Ras, TGF-B receptor, AFP, ETA, MAGE, MUC-1, CA-125, BAGE, GAGE, NY-ESO-1, β-catenin, CDK4, CDC27, CD47, a actinin-4, TRPl/gp75, TRP2, gplOO, Melan- A/MART 1 , gangliosides, WT1, EphA3,

Epidermal growth factor receptor (EGFR), CD20, MART-2, MART-1, MUCl, MUC2, MUMl, MUM2, MUM3, NA88-1, NPM, OA1, OGT, RCC, RUI1, RUI2, SAGE, TRG, TRP1, TSTA, Folate receptor alpha, Ll-CAM, CAIX, EGFRvIII, gpA33, GD3, GM2, VEGFR, Intergrins (Integrin alphaVbeta3, Integrin alpha5Betal), Carbohydrates (Le), IGF1R, EPHA3, TRAILR1, TRAILR2, or RANKL. In some embodiments, the solid tumor antigen is chosen from:

Mesothelin, PDL1, GD2, PMSA, PSCA, CEA, Ron Kinase, or c-Met. In one embodiment, the tumor-targeting moiety is chosen from an antibody molecule to a cancer antigen chosen from mesothelin, PDL1, HER3, IGF1R, FAP, CD47 or CD123. In one embodiment, the tumor- targeting moiety includes an antibody molecule (e.g., Fab or scFv) that binds to mesothelin. In other embodiments, the multispecific molecule, e.g., the tumor-targeting moiety, binds to a stromal antigen. In embodiments, the stromal antigen is chosen from one or more of: fibroblast activating protease (FAP), TGF-beta, hyaluronic acid, collagen, e.g., collagen IV, tenascin C, or tenascin W.

In other embodiments, the multispecific molecule, e.g., the tumor-targeting moiety, binds to a molecule, e.g., antigen, present on the surface of a hematological cancer, e.g., a leukemia or a lymphoma. In some embodiments, the hematological cancer is a B-cell or T cell malignancy. In some embodiments, the hematological cancer is chosen from one or more of a Hodgkin's lymphoma, Non-Hodgkin's lymphoma (e.g., B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B- cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia), acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome (MDS), multiple myeloma, or acute lymphocytic leukemia. In embodiments, the cancer is other than acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). In embodiments, the hematological antigen is chosen from CD19, CD33, CD47, CD123, CD20, CD99, CD30, BCMA, CD38, CD22, SLAMF7, or NY-ESOl.

Cytokine Molecules

Cytokines are proteinaceous signaling compounds that are mediators of the immune response. They control many different cellular functions including proliferation, differentiation and cell survival/apoptosis; cytokines are also involved in several pathophysiological processes including viral infections and autoimmune diseases. Cytokines are synthesized under various stimuli by a variety of cells of both the innate (monocytes, macrophages, dendritic cells) and adaptive (T- and B-cells) immune systems. Cytokines can be classified into two groups: pro- and anti-inflammatory. Pro-inflammatory cytokines, including e.g., IFNgamma, IL-1, IL-6 and TNF- alpha, are predominantly derived from the innate immune cells and Thl cells. Anti-inflammatory cytokines, including e.g., IL-10, IL-4, IL-13 and IL-5, are synthesized from Th2 immune cells.

The present disclosure provides, inter alia, multi- specific (e.g., bi-, tri-, quad- specific) proteins, that include, e.g., are engineered to contain, one or more cytokine molecules, e.g., immunomodulatory (e.g., proinflammatory) cytokines and variants, e.g., functional variants, thereof. Accordingly, in some embodiments, the cytokine molecule is an interleukin or a variant, e.g., a functional variant thereof. In embodiments, the cytokine molecule includes a full length, a fragment or a variant of a cytokine; a cytokine receptor domain, e.g., a cytokine receptor dimerizing domain; or an agonist of a cytokine receptor, e.g., an antibody molecule (e.g., an agonistic antibody) to a cytokine receptor.

In some embodiments the cytokine molecule is chosen from IL-2, IL-7, IL-12, IL-15, IL- 18, IL-21, or interferon gamma, or a fragment or variant thereof, or a combination of any of the aforesaid cytokines. The cytokine molecule can be a monomer or a dimer. In embodiments, the cytokine molecule can further include a cytokine receptor dimerizing domain. In other embodiments, the cytokine molecule is an agonist of a cytokine receptor, e.g., an antibody molecule (e.g., an agonistic antibody) to a cytokine receptor chosen from an IL-15Ra or IL-21R.

In one embodiment, the cytokine molecule is IL-15, e.g., human IL-15 (e.g., comprising the amino acid sequence:

NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIH DTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS (SEQ ID NO: 5), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g. , substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 5.

In some embodiments, the cytokine molecule comprises a receptor dimerizing domain, e.g., an IL15Ralpha dimerizing domain. In one embodiment, the IL15Ralpha dimerizing domain comprises the amino acid sequence:

M APRRARGCRTLGLP ALLLLLLLRPP ATRGITCPPPMS VEH ADIW VKS YS LYS RERYICN S GFKRKAGTS S LTEC VL (SEQ ID NO: 6), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 6. In some embodiments, the cytokine molecule (e.g., IL- 15) and the receptor dimerizing domain (e.g., an IL15Ralpha dimerizing domain) of the multispecific molecule are covalently linked, e.g., via a linker (e.g., a Gly-Ser linker, e.g., a linker comprising the amino acid sequence SGGSGGGGSGGGSGGGGSLQ (SEQ ID NO: 7). In other embodiments, the cytokine molecule (e.g., IL- 15) and the receptor dimerizing domain (e.g., an IL15Ralpha dimerizing domain) of the multispecific molecule are not covalently linked, e.g., are non-covalently associated.

In other embodiments, the cytokine molecule is IL-2, e.g., human IL-2 (e.g., comprising the amino acid sequence:

APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN R WITFCQSIISTLT (SEQ ID NO: 8), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g. , substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 8).

In other embodiments, the cytokine molecule is IL- 18, e.g., human IL- 18 (e.g., comprising the amino acid sequence:

YFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRTIFIISMYKDSQPRGM AVTISVKCEKISTLSCENKIISFKEMNPPDNIKDTKSDIIFFQRSVPGHDNKMQFESSSY EGYFLACEKERDLFKLILKKEDELGDRSIMFTVQNED (SEQ ID NO: 9), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g. , substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 9).

In other embodiments, the cytokine molecule is IL-21, e.g., human IL-21 (e.g., comprising the amino acid sequence:

QGQDRHMIRMRQLIDIVDQLKN Y VNDLVPEFLP APED VETNCE WS AFS CFQKAQLKS A NTGNNERIIN VS IKKLKRKPPS TN AGRRQKHRLTCPS CDS YEKKPPKEFLERFKS LLQKMI HQHLSSRTHGSEDS (SEQ ID NO: 10), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g. , substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 10).

In yet other embodiments, the cytokine molecule is interferon gamma, e.g., human interferon gamma (e.g., comprising the amino acid sequence:

QDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFK NFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVM AELSPAAKTGKRKRSQMLFRG (SEQ ID NO: 11), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or having at least one amino acid alteration, but not more than five, ten or fifteen alterations (e.g. , substitutions, deletions, or insertions, e.g., conservative substitutions) to the amino acid sequence of SEQ ID NO: 11). Immune Cell Engagers

The immune cell engagers of the multispecific molecules disclosed herein can mediate binding to, and/or activation of, an immune cell, e.g., an immune effector cell. In some embodiments, the immune cell is chosen from an NK cell, a B cell, a dendritic cell, or a macrophage cell engager, or a combination thereof. In some embodiments, the immune cell engager is chosen from one, two, three, or all of an NK cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager, or a combination thereof. The immune cell engager can be an agonist of the immune system. In some embodiments, the immune cell engager can be an antibody molecule, a ligand molecule (e.g., a ligand that further comprises an

immunoglobulin constant region, e.g., an Fc region), a small molecule, a nucleotide molecule. T Cell Engagers

The present disclosure provides, inter alia, multispecific (e.g., bi-, tri-, quad- specific) or multifunctional molecules, that are engineered to contain one or more T cell engagers that mediate binding to and/or activation of a T cell. Accordingly, in some embodiments, the T cell engager is selected from an antigen binding domain or ligand that binds to (e.g., and in some embodiments activates) one or more of CD3, TCRa, TCRp, TCRy, TCRC, ICOS, CD28, CD27, HVEM, LIGHT, CD40, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, or CD226. In other embodiments, the T cell engager is selected from an antigen binding domain or ligand that binds to and does not activate one or more of CD3, TCRa, TCRp, TCRy, TCRC, ICOS, CD28, CD27, HVEM, LIGHT, CD40, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, or CD226. In some embodiments, the T cell engager binds to CD3.

Natural Killer Cell Engagers

Natural Killer (NK) cells recognize and destroy tumors and virus-infected cells in an antibody-independent manner. The regulation of NK cells is mediated by activating and inhibiting receptors on the NK cell surface. One family of activating receptors is the natural cytotoxicity receptors (NCRs) which include NKp30, NKp44 and NKp46. The NCRs initiate tumor targeting by recognition of heparan sulfate on cancer cells. NKG2D is a receptor that provides both stimulatory and costimulatory innate immune responses on activated killer (NK) cells, leading to cytotoxic activity. DNAM1 is a receptor involved in intercellular adhesion, lymphocyte signaling, cytotoxicity and lymphokine secretion mediated by cytotoxic T- lymphocyte (CTL) and NK cell. DAP10 (also known as HCST) is a transmembrane adapter protein which associates with KLRKl to form an activation receptor KLRKl-HCST in lymphoid and myeloid cells; this receptor plays a major role in triggering cytotoxicity against target cells expressing cell surface ligands such as MHC class I chain-related MICA and MICB, and U(optionally Ll)6-binding proteins (ULBPs); it KLRKl-HCST receptor plays a role in immune surveillance against tumors and is required for cytolysis of tumors cells; indeed, melanoma cells that do not express KLRK1 ligands escape from immune surveillance mediated by NK cells. CD 16 is a receptor for the Fc region of IgG, which binds complexed or aggregated IgG and also monomeric IgG and thereby mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.

In some embodiments, the NK cell engager is a viral hemagglutinin (HA), HA is a glycoprotein found on the surface of influenza viruses. It is responsible for binding the virus to cells with sialic acid on the membranes, such as cells in the upper respiratory tract or

erythrocytes. HA has at least 18 different antigens. These subtypes are named HI through HI 8. NCRs can recognize viral proteins. NKp46 has been shown to be able to interact with the HA of influenza and the HA-NA of Paramyxovirus, including Sendai virus and Newcastle disease virus. Besides NKp46, NKp44 can also functionally interact with HA of different influenza subtypes.

The present disclosure provides, inter alia, multi- specific (e.g., bi-, tri-, quad- specific) proteins, that are engineered to contain one or more NK cell engager that mediate binding to and/or activation of an NK cell. Accordingly, in some embodiments, the NK cell engager is selected from an antigen binding domain or ligand that binds to (e.g., activates): NKp30, NKp40, NKp44, NKp46, NKG2D, DNAM1, DAP10, CD16 (e.g., CD16a, CD16b, or both), CRTAM, CD27, PSGL1, CD96, CD 100 (SEMA4D), NKp80, CD244 (also known as SLAMF4 or 2B4), SLAMF6, SLAMF7, KIR2DS2, KIR2DS4, KIR3DS 1, KIR2DS3, KIR2DS5, KIR2DS 1, CD94, NKG2C, NKG2E, or CD 160.

In other embodiments, the NK cell engager is a ligand of NKp44 or NKp46, which is a viral HA. Viral hemagglutinins (HA) are glyco proteins which are on the surface of viruses. HA proteins allow viruses to bind to the membrane of cells via sialic acid sugar moieties which contributes to the fusion of viral membranes with the cell membranes (see e.g., Eur J Immunol. 2001 Sep;31(9):2680-9 "Recognition of viral hemagglutinins by NKp44 but not by NKp30"; and Nature. 2001 Feb 22;409(6823): 1055-60 "Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells" the contents of each of which are incorporated by reference herein).

In yet other embodiments, the NK cell engager is a ligand of DAP10, which is an adapter for NKG2D (see e.g., Proc Natl Acad Sci U S A. 2005 May 24; 102(21): 7641-7646; and Blood, 15 September 2011 Volume 118, Number 11, the full contents of each of which is incorporated by reference herein). In other embodiments, the NK cell engager is a ligand of CD 16, which is a CD16a/b ligand, e.g., a CD16a/b ligand further comprising an antibody Fc region (see e.g., Front

Immunol. 2013; 4: 76 discusses how antibodies use the Fc to trigger NK cells through CD16,the full contents of which are incorporated herein).

B Cell, Macrophage & Dendritic Cell Engagers

Broadly, B cells, also known as B lymphocytes, are a type of white blood cell of the lymphocyte subtype. They function in the humoral immunity component of the adaptive immune system by secreting antibodies. Additionally, B cells present antigen (they are also classified as professional antigen-presenting cells (APCs)) and secrete cytokines. Macrophages are a type of white blood cell that engulfs and digests cellular debris, foreign substances, microbes, cancer cells via phagocytosis. Besides phagocytosis, they play important roles in nonspecific defense (innate immunity) and also help initiate specific defense mechanisms (adaptive immunity) by recruiting other immune cells such as lymphocytes. For example, they are important as antigen presenters to T cells. Beyond increasing inflammation and stimulating the immune system, macrophages also play an important anti-inflammatory role and can decrease immune reactions through the release of cytokines. Dendritic cells (DCs) are antigen-presenting cells that function in processing antigen material and present it on the cell surface to the T cells of the immune system.

The present disclosure provides, inter alia, multi- specific (e.g., bi-, tri-, quad- specific) proteins, that include, e.g., are engineered to contain, one or more B cell, macrophage, and/or dendritic cell engager that mediate binding to and/ or activation of a B cell, macrophage, and/or dendritic cell.

Accordingly, in some embodiments, the immune cell engager comprises a B cell, macrophage, and/or dendritic cell engager chosen from one or more of CD40 ligand (CD40L) or a CD70 ligand; an antibody molecule that binds to CD40 or CD70; an antibody molecule to OX40; an OX40 ligand (OX40L); an agonist of a Toll-like receptor (e.g., as described herein, e.g., a TLR4, e.g., a constitutively active TLR4 (caTLR4), or a TLR9 agonists); a 41BB; a CD2; a CD47; or a STING agonist, or a combination thereof.

In some embodiments, the B cell engager is a CD40L, an OX40L, or a CD70 ligand, or an antibody molecule that binds to OX40, CD40 or CD70. In some embodiments, the macrophage engager is a CD2 agonist. In some embodiments, the macrophage engager is an antigen binding domain that binds to: CD40L or antigen binding domain or ligand that binds CD40, a Toll like receptor (TLR) agonist (e.g., as described herein), e.g., a TLR9 or TLR4 (e.g., caTLR4 (constitutively active TLR4), CD47, or a STING agonist. In some embodiments, the STING agonist is a cyclic dinucleotide, e.g., cyclic di-GMP (cdGMP) or cyclic di-AMP (cdAMP). In some embodiments, the STING agonist is biotinylated.

In some embodiments, the dendritic cell engager is a CD2 agonist. In some embodiments, the dendritic cell engager is a ligand, a receptor agonist, or an antibody molecule that binds to one or more of: OX40L, 41BB, a TLR agonist (e.g., as described herein) (e.g., TLR9 agonist, TLR4 (e.g., caTLR4 (constitutively active TLR4)), CD47, or and a STING agonist. In some embodiments, the STING agonist is a cyclic dinucleotide, e.g., cyclic di-GMP (cdGMP) or cyclic di-AMP (cdAMP). In some embodiments, the STING agonist is biotinylated.

In other embodiments, the immune cell engager mediates binding to, or activation of, one or more of a B cell, a macrophage, and/or a dendritic cell. Exemplary B cell, macrophage, and/or dendritic cell engagers can be chosen from one or more of CD40 ligand (CD40L) or a

CD70 ligand; an antibody molecule that binds to CD40 or CD70; an antibody molecule to OX40; an OX40 ligand (OX40L); a Toll-like receptor agonist (e.g., a TLR4, e.g., a constitutively active TLR4 (caTLR4) or a TLR9 agonist); a 41BB agonist; a CD2; a CD47; or a STING agonist, or a combination thereof.

In some embodiments, the B cell engager is chosen from one or more of a CD40L, an

OX40L, or a CD70 ligand, or an antibody molecule that binds to OX40, CD40 or CD70.

In other embodiments, the macrophage cell engager is chosen from one or more of a CD2 agonist; a CD40L; an OX40L; an antibody molecule that binds to OX40, CD40 or CD70; a Tolllike receptor agonist or a fragment thereof (e.g., a TLR4, e.g., a constitutively active TLR4 (caTLR4)); a CD47 agonist; or a STING agonist.

In other embodiments, the dendritic cell engager is chosen from one or more of a CD2 agonist, an OX40 antibody, an OX40L, 4 IBB agonist, a Toll-like receptor agonist or a fragment thereof (e.g., a TLR4, e.g., a constitutively active TLR4 (caTLR4)), CD47 agonist, or a STING agonist. Toll-Like Receptors

Toll-Like Receptors (TLRs) are evolutionary conserved receptors are homologues of the Drosophila Toll protein, and recognize highly conserved structural motifs known as pathogen- associated microbial patterns (PAMPs), which are exclusively expressed by microbial pathogens, or danger-associated molecular patterns (DAMPs) that are endogenous molecules released from necrotic or dying cells. PAMPs include various bacterial cell wall components such as lipopolysaccharide (LPS), peptidoglycan (PGN) and lipopeptides, as well as flagellin, bacterial DNA and viral double- stranded RNA. DAMPs include intracellular proteins such as heat shock proteins as well as protein fragments from the extracellular matrix. Stimulation of TLRs by the corresponding PAMPs or DAMPs initiates signaling cascades leading to the activation of transcription factors, such as AP-1, NF-κΒ and interferon regulatory factors (IRFs). Signaling by TLRs results in a variety of cellular responses, including the production of interferons (IFNs), pro-inflammatory cytokines and effector cytokines that direct the adaptive immune response. TLRs are implicated in a number of inflammatory and immune disorders and play a role in cancer (Rakoff-Nahoum S. & Medzhitov R., 2009. Toll-like receptors and cancer. Nat Revs Cancer 9:57- 63.)

TLR3, TLR7, TLR8 and TLR9 recognize viral nucleic acids and induce type I IFNs. The signaling mechanisms leading to the induction of type I IFNs differ depending on the TLR activated. They involve the interferon regulatory factors, IRFs, a family of transcription factors known to play a critical role in antiviral defense, cell growth and immune regulation. Three IRFs (IRF3, IRF5 and IRF7) function as direct transducers of virus -mediated TLR signaling. TLR3 and TLR4 activate IRF3 and IRF7, while TLR7 and TLR8 activate IRF5 and IRF7 (Doyle S. et al., 2002. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 17(3):251- 63). Furthermore, type I IFN production stimulated by TLR9 ligand CpG-A has been shown to be mediated by PI(3)K and mTOR (Costa-Mattioli M. & Sonenberg N. 2008. RAPping production of type I interferon in pDCs through mTOR. Nature Immunol. 9: 1097-1099).

TLR Agonists

A TLR agonist can agonize one or more TLR, e.g., one or more of human TLR- 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, an adjunctive agent described herein is a TLR agonist. In some embodiments, the TLR agonist specifically agonizes human TLR-9. In some embodiments, the TLR-9 agonist is a CpG moiety. As used herein, a CpG moiety, is a linear dinucleotide having the sequence: 5'— C— phosphate— G— 3', that is, cytosine and guanine separated by only one phosphate.

In some embodiments, the CpG moiety comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more CpG

dinucleotides. In some embodiments, the CpG moiety consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 CpG dinucleotides. In some embodiments, the CpG moiety has 1-5, 1-10, 1-20, 1-30, 1-40, 1-50, 5-10, 5-20, 5-30, 10- 20, 10-30, 10-40, or 10-50 CpG dinucleotides.

In some embodiments, the TLR-9 agonist is a synthetic ODN (oligodeoxynucleotides).

CpG ODNs are short synthetic single- stranded DNA molecules containing unmethylated CpG dinucleotides in particular sequence contexts (CpG motifs). CpG ODNs possess a partially or completely phosphorothioated (PS) backbone, as opposed to the natural phosphodiester (PO) backbone found in genomic bacterial DNA. There are three major classes of CpG ODNs: classes A, B and C, which differ in their immuno stimulatory activities. CpG-A ODNs are characterized by a PO central CpG-containing palindromic motif and a PS -modified 3' poly-G string. They induce high IFN-a production from pDCs but are weak stimulators of TLR9-dependent NF-KB signaling and pro -inflammatory cytokine (e.g. IL-6) production. CpG-B ODNs contain a full PS backbone with one or more CpG dinucleotides. They strongly activate B cells and TLR9- dependent NF-κΒ signaling but weakly stimulate IFN-a secretion. CpG-C ODNs combine features of both classes A and B. They contain a complete PS backbone and a CpG-containing palindromic motif. C-Class CpG ODNs induce strong IFN-a production from pDC as well as B cell stimulation. Exemplary Multispecific Molecules

Described below are exemplary multispecific molecules of the present disclosure illustrated through specific embodiments.

In some embodiments the multispecific molecule comprises

(a) a first polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a first antigen binding moiety (ABM) (e.g., wherein the first ABM comprises a VH-CH1 of a first Fab molecule, that binds to, e.g., a cancer antigen, connected, optionally via a linker to, a first subunit of a heterodimerization domain (e.g., an

immunoglobulin CH2 connected to a TCRa constant domain);

(b) a second polypeptide chain having the following configuration from N-terminus to C- terminus: a first portion of a second ABM (e.g., wherein the second ABM comprises a VH-CH1 of a second Fab molecule, that binds to, e.g., a cancer antigen, connected, optionally via a linker to, a second subunit of a heterodimerization domain (e.g., an immunoglobulin CH2 connected to a TCRP constant domain);

(c) a third polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the first ABM (e.g., a VL-CL of the first Fab, where the VL is of kappa subtype and binds to, e.g., a cancer antigen (e.g., the same cancer antigen bound by the VH-CH1 of the first Fab molecule);

(d) a fourth polypeptide having the following configuration from N-terminus to C- terminus: a second portion of the second antigen domain (e.g. a VL-CL of the second Fab, where the VL is of lambda subtype and binds to, e.g., a cancer antigen, (e.g., the same cancer antigen bound by the VH-CH1 of the second Fab molecule).

In one embodiment, the molecule is comprised of a heterodimeric, human

immunoglobulin IgGl Fc-TCR domain with one heavy chain with variable domain from ipilimumab wherein the protein sequence from the N-terminus to the C-terminus of one of the heavy chains is comprised of an Ig kappa signal peptide (underlined), the ipilimumab heavy chain containing the CH2-TCRa core:

METDTLLLWVLLLWVPGSTGQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQA PGKG LEWVTFI SYDGNNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAI YYCARTGWLGPFDYW GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFP AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPA PELL GGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTI SKAKPDIQNPDPAVYQLRDSKSSDKSV CLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACANAFNNS I IPEDT FFPSPE (SEQ ID NO: 12), while the other heavy chain from the N-terminus to the C-terminus is comprised of an Ig kappa signal peptide (underlined), and the briakinumab heavy chain sequence containing the CH2-TCRP core:

METDTLLLWVLLLWVPGSTGQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQA PGKG LEWVAFIRYDGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQG TMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEL LGGP SVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKTI SKAKEDLNKVFPPEVALFEPSEAEI SHTQK ATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATF WQDP RNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD (SEQ ID NO: 13). One of the light chains has the protein sequence from the N-terminus to the C-terminus is comprised of an Ig kappa signal peptide (underlined) , and the ipilimumab light chain sequence (kappa):

METDTLLLWVLLLWVPGSTGEIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQK PGQA PRLLI YGAFSRATGIPDRFSGSGSGTDFTLTI SRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDS TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 14), while the other light chain from the N-terminus to the C-terminus is comprised of an Ig kappa signal peptide (underlined), and the briakinumab light chain sequence (lambda):

METDTLLLWVLLLWVPGSTGQSVLTQPPSVSGAPGQRVTI SCSGSRSNIGSNTVKWYQQLPGTA PKLLI YYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKV TVLGQPKANPTVTLFPPSSEELQANKATLVCLI SDFYPGAVTVAWKADGSPVKAGVETTKPSKQ SNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 15).

Nucleic Acids

The invention also features nucleic acids comprising nucleotide sequences that encode heavy and light chain variable regions and CDRs or hypervariable loops of the antibody molecules, as described herein. For example, the invention features a first and second nucleic acid encoding heavy and light chain variable regions, respectively, of an antibody molecule chosen from one or more of the antibody molecules disclosed herein. The nucleic acid can comprise a nucleotide sequence as set forth in the tables herein, or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, or which differs by no more than 3, 6, 15, 30, or 45 nucleotides from the sequences shown in the tables herein. In certain embodiments, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g. , a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one or more substitutions, e.g. , conserved substitutions). In other embodiments, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g. , a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one or more substitutions, e.g. , conserved substitutions). In yet another embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs or hypervariable loops from heavy and light chain variable regions having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g. , a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one or more substitutions, e.g. , conserved substitutions).

In certain embodiments, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having the nucleotide sequence as set forth in the tables herein, a sequence substantially homologous thereto (e.g. , a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). In another

embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having the nucleotide sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g. , a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). In yet another embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs or hypervariable loops from heavy and light chain variable regions having the nucleotide sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g. , a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). In another aspect, the application features host cells and vectors containing the nucleic acids described herein. The nucleic acids may be present in a single vector or separate vectors present in the same host cell or separate host cell, as described in more detail herein below. Vectors

Further provided herein are vectors comprising the nucleotide sequences encoding an antibody molecule described herein. In one embodiment, the vectors comprise nucleotides encoding an antibody molecule described herein. In one embodiment, the vectors comprise the nucleotide sequences described herein. The vectors include, but are not limited to, a virus, plasmid, cosmid, lambda phage or a yeast artificial chromosome (YAC).

Numerous vector systems can be employed. For example, one class of vectors utilizes DNA elements which are derived from animal viruses such as, for example, bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (Rous Sarcoma Virus, MMTV or MOMLV) or SV40 virus. Another class of vectors utilizes RNA elements derived from RNA viruses such as Semliki Forest virus, Eastern Equine Encephalitis virus and

Flaviviruses.

Additionally, cells which have stably integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow for the selection of transfected host cells. The marker may provide, for example, prototropy to an auxotrophic host, biocide resistance (e.g., antibiotics), or resistance to heavy metals such as copper, or the like. The selectable marker gene can be either directly linked to the DNA sequences to be expressed, or introduced into the same cell by cotransformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as

transcriptional promoters, enhancers, and termination signals.

Once the expression vector or DNA sequence containing the constructs has been prepared for expression, the expression vectors may be transfected or introduced into an appropriate host cell. Various techniques may be employed to achieve this, such as, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, lipid based transfection or other conventional techniques. In the case of protoplast fusion, the cells are grown in media and screened for the appropriate activity.

Methods and conditions for culturing the resulting transfected cells and for recovering the antibody molecule produced are known to those skilled in the art, and may be varied or optimized depending upon the specific expression vector and mammalian host cell employed, based upon the present description. Cells

In another aspect, the application features host cells and vectors containing the nucleic acids described herein. The nucleic acids may be present in a single vector or separate vectors present in the same host cell or separate host cell. The host cell can be a eukaryotic cell, e.g., a mammalian cell, an insect cell, a yeast cell, or a prokaryotic cell, e.g., E. coli. For example, the mammalian cell can be a cultured cell or a cell line. Exemplary mammalian cells include lymphocytic cell lines (e.g., NSO), Chinese hamster ovary cells (CHO), COS cells, oocyte cells, and cells from a transgenic animal, e.g., mammary epithelial cell.

The invention also provides host cells comprising a nucleic acid encoding an antibody molecule as described herein.

In one embodiment, the host cells are genetically engineered to comprise nucleic acids encoding the antibody molecule.

In one embodiment, the host cells are genetically engineered by using an expression cassette. The phrase "expression cassette," refers to nucleotide sequences, which are capable of affecting expression of a gene in hosts compatible with such sequences. Such cassettes may include a promoter, an open reading frame with or without introns, and a termination signal. Additional factors necessary or helpful in effecting expression may also be used, such as, for example, an inducible promoter.

The invention also provides host cells comprising the vectors described herein.

The cell can be, but is not limited to, a eukaryotic cell, a bacterial cell, an insect cell, or a human cell. Suitable eukaryotic cells include, but are not limited to, Vero cells, HeLa cells, COS cells, CHO cells, HEK293 cells, BHK cells and MDCKII cells. Suitable insect cells include, but are not limited to, Sf9 cells.

Methods of Manufacturing Multispecific Molecules

Provided herein are, inter alia, methods of producing the multispecific molecules (e.g., multispecific (e.g., bispecific) antibody molecules) described herein. Accordingly, provided herein are methods of generating multispecific (e.g., bispecific) molecules comprising a non- immunoglobulin dimerization domain (e.g., a naturally occurring dimerization domain, e.g., a T cell receptor (TCR) constant domain) (e.g., as described herein).

In some embodiments, the multispecific (e.g., bispecific) molecules are produced in a single cell.

In some embodiments, disclosed herein are methods of making, e.g., producing, the multispecific molecule (e.g., multispecific antibody molecule) comprising an immunoglobulin CH2 domain and a TCR constant domain, comprising (a) generating a first antibody (e.g., a human antibody) comprising (i) a first heavy chain comprising a CH2 domain connected (optionally via a linker) to a first non-immunoglobulin dimerization domain (e.g., a naturally occurring dimerization domain, e.g., a TCRa constant domain) and (ii) a first light chain (e.g., a kappa light chain); (b) generating a second antibody (e.g., a human antibody) comprising a second heavy chain comprising a CH2 domain connected (optionally via a linker) to a second non-immunoglobulin dimerization domain (e.g., a naturally occurring dimerization domain, e.g., a TCRP constant domain) and (ii) a second light chain (e.g., a lambda light chain), wherein the first and the second non-immunoglobulin dimerization domains are not the same; (c) transfecting a cell (or cells) with a nucleic acid encoding the amino acid sequence of the first antibody and the second antibody; (d) culturing the cell (or cells) under suitable conditions, e.g., conditions suitable for gene expression; (d) purifying the antibody (e.g., using Protein A); and (e) optionally determining the presence of the first and second heavy chain (e.g. via gel

electrophoresis under reducing conditions); and (f) optionally determining the presence of correctly paired first and second heavy chains with the first and the second light chains, respectively (e.g., via mass spectrometry). Uses and Combination Therapies

Methods described herein include treating a cancer in a subject by using a multispecific molecule described herein, e.g., using a pharmaceutical composition described herein. Also provided are methods for reducing or ameliorating a symptom of a cancer in a subject, as well as methods for inhibiting the growth of a cancer and/or killing one or more cancer cells. In embodiments, the methods described herein decrease the size of a tumor and/or decrease the number of cancer cells in a subject administered with a described herein or a pharmaceutical composition described herein.

In embodiments, the cancer is a hematological cancer. In embodiments, the

hematological cancer is a leukemia or a lymphoma. As used herein, a "hematologic cancer" refers to a tumor of the hematopoietic or lymphoid tissues, e.g., a tumor that affects blood, bone marrow, or lymph nodes. Exemplary hematologic malignancies include, but are not limited to, leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, acute monocytic leukemia (AMoL), chronic myelomonocytic leukemia (CMML), juvenile

myelomonocytic leukemia (JMML), or large granular lymphocytic leukemia), lymphoma (e.g., AIDS-related lymphoma, cutaneous T-cell lymphoma, Hodgkin lymphoma (e.g., classical Hodgkin lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma), mycosis fungoides, non-Hodgkin lymphoma (e.g., B-cell non-Hodgkin lymphoma (e.g., Burkitt lymphoma, small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B -lymphoblastic lymphoma, or mantle cell lymphoma) or T-cell non-Hodgkin lymphoma (mycosis fungoides, anaplastic large cell lymphoma, or precursor T-lymphoblastic lymphoma)), primary central nervous system lymphoma, Sezary syndrome, Waldenstrom macroglobulinemia), chronic myeloproliferative neoplasm, Langerhans cell histiocytosis, multiple myeloma/plasma cell neoplasm,

myelodysplastic syndrome, or myelodysplastic/myeloproliferative neoplasm.

In embodiments, the cancer is a solid cancer. Exemplary solid cancers include, but are not limited to, ovarian cancer, rectal cancer, stomach cancer, testicular cancer, cancer of the anal region, uterine cancer, colon cancer, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine, cancer of the esophagus, melanoma, Kaposi's sarcoma, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, brain stem glioma, pituitary adenoma, epidermoid cancer, carcinoma of the cervix squamous cell cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the vagina, sarcoma of soft tissue, cancer of the urethra, carcinoma of the vulva, cancer of the penis, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, spinal axis tumor, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, metastatic lesions of said cancers, or combinations thereof.

In embodiments, the multispecific molecules (or pharmaceutical composition) are administered in a manner appropriate to the disease to be treated or prevented. The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease. Appropriate dosages may be determined by clinical trials. For example, when "an effective amount" or "a therapeutic amount" is indicated, the precise amount of the pharmaceutical composition (or multispecific molecules) to be administered can be determined by a physician with consideration of individual differences in tumor size, extent of infection or metastasis, age, weight, and condition of the subject. In embodiments, the pharmaceutical composition described herein can be administered at a dosage of 10 ⁴ to 10 ⁹ cells/kg body weight, e.g., 10 ⁵ to 10 ⁶ cells/kg body weight, including all integer values within those ranges. In embodiments, the pharmaceutical composition described herein can be administered multiple times at these dosages. In embodiments, the pharmaceutical composition described herein can be administered using infusion techniques described in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988).

In embodiments, the multispecific molecules or pharmaceutical composition is administered to the subject parenterally. In embodiments, the cells are administered to the subject intravenously, subcutaneously, intratumorally, intranodally, intramuscularly,

intradermally, or intraperitoneally. In embodiments, the cells are administered, e.g., injected, directly into a tumor or lymph node. In embodiments, the cells are administered as an infusion (e.g., as described in Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988) or an intravenous push. In embodiments, the cells are administered as an injectable depot formulation.

In embodiments, the subject is a mammal. In embodiments, the subject is a human, monkey, pig, dog, cat, cow, sheep, goat, rabbit, rat, or mouse. In embodimnets, the subject is a human. In embodiments, the subject is a pediatric subject, e.g. , less than 18 years of age, e.g., less than 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or less years of age. In embodiments, the subject is an adult, e.g. , at least 18 years of age, e.g., at least 19, 20, 21, 22, 23, 24, 25, 25-30, 30-35, 35- 40, 40-50, 50-60, 60-70, 70-80, or 80-90 years of age. Combination Therapies

The multispecific molecules disclosed herein can be used in combination with a second therapeutic agent or procedure.

In embodiments, the multispecific molecule and the second therapeutic agent or procedure are administered/performed after a subject has been diagnosed with a cancer, e.g., before the cancer has been eliminated from the subject. In embodiments, the multispecific molecule and the second therapeutic agent or procedure are administered/performed

simultaneously or concurrently. For example, the delivery of one treatment is still occurring when the delivery of the second commences, e.g., there is an overlap in administration of the treatments. In other embodiments, the multispecific molecule and the second therapeutic agent or procedure are administered/performed sequentially. For example, the delivery of one treatment ceases before the delivery of the other treatment begins.

In embodiments, combination therapy can lead to more effective treatment than monotherapy with either agent alone. In embodiments, the combination of the first and second treatment is more effective (e.g., leads to a greater reduction in symptoms and/or cancer cells) than the first or second treatment alone. In embodiments, the combination therapy permits use of a lower dose of the first or the second treatment compared to the dose of the first or second treatment normally required to achieve similar effects when administered as a monotherapy. In embodiments, the combination therapy has a partially additive effect, wholly additive effect, or greater than additive effect.

In one embodiment, the multispecific molecule is administered in combination with a therapy, e.g., a cancer therapy {e.g., one or more of anti-cancer agents, immunotherapy, photodynamic therapy (PDT), surgery and/or radiation). The terms "chemotherapeutic,"

"chemotherapeutic agent," and "anti-cancer agent" are used interchangeably herein. The administration of the multispecific molecule and the therapy, e.g., the cancer therapy, can be sequential (with or without overlap) or simultaneous. Administration of the multispecific molecule can be continuous or intermittent during the course of therapy {e.g., cancer therapy). Certain therapies described herein can be used to treat cancers and non-cancerous diseases. For example, PDT efficacy can be enhanced in cancerous and non-cancerous conditions {e.g., tuberculosis) using the methods and compositions described herein (reviewed in, e.g., Agostinis, P. et al. (2011) CA Cancer J. Clin. 61:250-281). Anti-cancer therapies

In other embodiments, the multispecific molecule is administered in combination with a low or small molecular weight chemotherapeutic agent. Exemplary low or small molecular weight chemotherapeutic agents include, but not limited to, 13-cis-retinoic acid (isotretinoin, ACCUTANE®), 2-CdA (2-chlorodeoxyadenosine, cladribine, LEUSTATIN™), 5-azacitidine (azacitidine, VIDAZA®), 5-fluorouracil (5-FU, fluorouracil, ADRUCIL®), 6-mercaptopurine (6-MP, mercaptopurine, PURINETHOL®), 6-TG (6-thioguanine, thioguanine, THIOGUANINE TABLOID®), abraxane (paclitaxel protein-bound), actinomycin-D (dactinomycin,

COSMEGEN®), alitretinoin (PANRETIN®), all-transretinoic acid (ATRA, tretinoin,

VESANOID®), altretamine (hexamethylmelamine, HMM, HEXALEN®), amethopterin (methotrexate, methotrexate sodium, MTX, TREXALL™, RHEUMATREX®), amifostine (ETHYOL®), arabinosylcytosine (Ara-C, cytarabine, CYTOSAR-U®), arsenic trioxide (TRISENOX®), asparaginase (Erwinia L-asparaginase, L-asparaginase, ELSPAR®,

KIDROLASE®), BCNU (carmustine, BiCNU®), bendamustine (TREANDA®), bexarotene (TARGRETIN®), bleomycin (BLENOXANE®), busulfan (BUSULFEX®, MYLERAN®), calcium leucovorin (Citrovorum Factor, folinic acid, leucovorin), camptothecin-11 (CPT-11, irinotecan, CAMPTOSAR®), capecitabine (XELODA®), carboplatin (PARAPLATIN®), carmustine wafer (prolifeprospan 20 with carmustine implant, GLIADEL® wafer), CCI-779 (temsirolimus, TORISEL®), CCNU (lomustine, CeeNU), CDDP (cisplatin, PLATINOL®, PLATINOL-AQ®), chlorambucil (leukeran), cyclophosphamide (CYTOXAN®, NEOSAR®), dacarbazine (DIC, DTIC, imidazole carboxamide, DTIC-DOME®), daunomycin (daunorubicin, daunorubicin hydrochloride, rubidomycin hydrochloride, CERUBIDINE®), decitabine

(DACOGEN®), dexrazoxane (ZINECARD®), DHAD (mitoxantrone, NOVANTRONE®), docetaxel (TAXOTERE®), doxorubicin (ADRIAMYCIN®, RUBEX®), epirubicin

(ELLENCE™), estramustine (EMCYT®), etoposide (VP-16, etoposide phosphate,

TOPOSAR®, VEPESID®, ETOPOPHOS®), floxuridine (FUDR®), fludarabine

(FLUDARA®), fluorouracil (cream) (CARAC™, EFUDEX®, FLUOROPLEX®), gemcitabine (GEMZAR®), hydroxyurea (HYDREA®, DROXIA™, MYLOCEL™), idarubicin

(IDAMYCIN®), ifosfamide (IFEX®), ixabepilone (IXEMPRA™), LCR (leurocristine, vincristine, VCR, ONCOVIN®, VINCASAR PFS®), L-PAM (L-sarcolysin, melphalan, phenylalanine mustard, ALKERAN®), mechlorethamine (mechlorethamine hydrochloride, mustine, nitrogen mustard, MUSTARGEN®), mesna (MESNEX™), mitomycin (mitomycin-C, MTC, MUTAMYCIN®), nelarabine (ARRANON®), oxaliplatin (ELOXATIN™), paclitaxel (TAXOL®, ONXAL™), pegaspargase (PEG-L-asparaginase, ONCOSPAR®), PEMETREXED (ALIMTA®), pentostatin (NIPENT®), procarbazine (MATULANE®), streptozocin

(ZANOSAR®), temozolomide (TEMODAR®), teniposide (VM-26, VUMON®), TESPA (thiophosphoamide, thiotepa, TSPA, THIOPLEX®), topotecan (HYC AMTIN® ) , vinblastine (vinblastine sulfate, vincaleukoblastine, VLB, ALKABAN-AQ®, VELBAN®), vinorelbine (vinorelbine tartrate, NAVELBINE®), and vorinostat (ZOLINZA®).

In another embodiment, the multispecific molecule is administered in conjunction with a biologic. Biologies useful in the treatment of cancers are known in the art and a binding molecule of the invention may be administered, for example, in conjunction with such known biologies. For example, the FDA has approved the following biologies for the treatment of breast cancer: HERCEPTIN® (trastuzumab, Genentech Inc., South San Francisco, Calif.; a humanized monoclonal antibody that has anti-tumor activity in HER2-positive breast cancer); FASLODEX® (fulvestrant, AstraZeneca Pharmaceuticals, LP, Wilmington, Del.; an estrogen- receptor antagonist used to treat breast cancer); ARIMIDEX® (anastrozole, AstraZeneca Pharmaceuticals, LP; a nonsteroidal aromatase inhibitor which blocks aromatase, an enzyme needed to make estrogen); Aromasin® (exemestane, Pfizer Inc., New York, N.Y.; an

irreversible, steroidal aromatase inactivator used in the treatment of breast cancer); FEMARA® (letrozole, Novartis Pharmaceuticals, East Hanover, N.J.; a nonsteroidal aromatase inhibitor approved by the FDA to treat breast cancer); and NOLVADEX® (tamoxifen, AstraZeneca Pharmaceuticals, LP; a nonsteroidal antiestrogen approved by the FDA to treat breast cancer). Other biologies with which the binding molecules of the invention may be combined include: AVASTIN® (bevacizumab, Genentech Inc.; the first FDA-approved therapy designed to inhibit angiogenesis); and ZEVALIN® (ibritumomab tiuxetan, Biogen Idee, Cambridge, Mass.; a radiolabeled monoclonal antibody currently approved for the treatment of B-cell lymphomas).

In addition, the FDA has approved the following biologies for the treatment of colorectal cancer: AVASTIN®; ERBITUX® (cetuximab, ImClone Systems Inc., New York, N.Y., and Bristol-Myers Squibb, New York, N.Y.; is a monoclonal antibody directed against the epidermal growth factor receptor (EGFR)); GLEEVEC® (imatinib mesylate; a protein kinase inhibitor); and ERGAMISOL® (levamisole hydrochloride, Janssen Pharmaceutica Products, LP, Titusville, N.J.; an immunomodulator approved by the FDA in 1990 as an adjuvant treatment in

combination with 5-f uorouracil after surgical resection in patients with Dukes' Stage C colon cancer).

For the treatment of lung cancer, exemplary biologies include TARCEVA® (erlotinib

HCL, OSI Pharmaceuticals Inc., Melville, N.Y.; a small molecule designed to target the human epidermal growth factor receptor 1 (HER1) pathway).

For the treatment of multiple myeloma, exemplary biologies include VELCADE® Velcade (bortezomib, Millennium Pharmaceuticals, Cambridge Mass.; a proteasome inhibitor). Additional biologies include THALIDOMID® (thalidomide, Clegene Corporation, Warren, N.J.; an immunomodulatory agent and appears to have multiple actions, including the ability to inhibit the growth and survival of myeloma cells and anti-angiogenesis).

Additional exemplary cancer therapeutic antibodies include, but are not limited to, 3F8, abagovomab, adecatumumab, afutuzumab, alacizumab pegol, alemtuzumab (CAMPATH®, MABCAMPATH®), altumomab pentetate (HYBRI-CEAKER®), anatumomab mafenatox, anrukinzumab (IMA-638), apolizumab, arcitumomab (CEA-SCAN®), bavituximab,

bectumomab (LYMPHOSCAN®), belimumab (BENLYSTA®, LYMPHOSTAT-B®), besilesomab (SCINTIMUN®), bevacizumab (AVASTIN®), bivatuzumab mertansine, blinatumomab, brentuximab vedotin, cantuzumab mertansine, capromab pendetide

(PROSTASCINT®), catumaxomab (REMOVAB®), CC49, cetuximab (C225, ERBITUX®), citatuzumab bogatox, cixutumumab, clivatuzumab tetraxetan, conatumumab, dacetuzumab, denosumab (PROLIA®), detumomab, ecromeximab, edrecolomab (PANOREX®), elotuzumab, epitumomab cituxetan, epratuzumab, ertumaxomab (REXOMUN®), etaracizumab,

farletuzumab, figitumumab, fresolimumab, galiximab, gemtuzumab ozogamicin

(MYLOTARG®), girentuximab, glembatumumab vedotin, ibritumomab (ibritumomab tiuxetan, ZEVALIN®), igovomab (INDIMACIS-125®), intetumumab, inotuzumab ozogamicin, ipilimumab, iratumumab, labetuzumab (CEA-CIDE®), lexatumumab, lintuzumab,

lucatumumab, lumiliximab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, nacolomab tafenatox, naptumomab estafenatox, necitumumab, nimotuzumab (THERACIM®, THERALOC®), nofetumomab merpentan (VERLUMA®), ofatumumab

(ARZERRA®), olaratumab, oportuzumab monatox, oregovomab (OVAREX®), panitumumab (VECTIBIX®), pemtumomab (THERAGYN® ) , pertuzumab (OMNITARG®), pintumomab, pritumumab, ramucirumab, ranibizumab (LUCENTIS®), rilotumumab, rituximab

(MABTHERA®, RITUXAN®), robatumumab, satumomab pendetide, sibrotuzumab, siltuximab, sontuzumab, tacatuzumab tetraxetan (AFP-CIDE®), taplitumomab paptox, tenatumomab, TGN1412, ticilimumab (tremelimumab), tigatuzumab, TNX-650, tositumomab (BEXXAR®), trastuzumab (HERCEPTIN®), tremelimumab, tucotuzumab celmoleukin, veltuzumab, volociximab, votumumab (HUMASPECT®), zalutumumab (HUMAX-EGFR®), and zanolimumab (HUMAX-CD4® ) .

In other embodiments, the multispecific molecule is administered in combination with a viral cancer therapeutic agent. Exemplary viral cancer therapeutic agents include, but not limited to, vaccinia virus (vvDD-CDSR), carcinoembryonic antigen-expressing measles virus, recombinant vaccinia virus (TK-deletion plus GM-CSF), Seneca Valley virus-001, Newcastle virus, coxsackie virus A21, GL-ONC1, EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine, carcinoembryonic antigen-expressing measles virus, G207 oncolytic virus, modified vaccinia virus Ankara vaccine expressing p53, OncoVEX GM-CSF modified herpes-simplex 1 virus, fowlpox virus vaccine vector, recombinant vaccinia prostate-specific antigen vaccine, human papillomavirus 16/18 LI virus-like particle/AS04 vaccine, MVA-EBNA1/LMP2 Inj. vaccine, quadrivalent HPV vaccine, quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (GARDASIL®), recombinant fowlpox- CEA(6D)/TRICOM vaccine; recombinant vaccinia-CEA(6D)-TRICOM vaccine, recombinant modified vaccinia Ankara-5T4 vaccine, recombinant fowlpox-TRICOM vaccine, oncolytic herpes virus NV1020, HPV LI VLP vaccine V504, human papillomavirus bivalent (types 16 and 18) vaccine (CERVARIX®), herpes simplex virus HF10, Ad5CMV-p53 gene, recombinant vaccinia DF3/MUC1 vaccine, recombinant vaccinia- MUC-1 vaccine, recombinant vaccinia- TRICOM vaccine, ALVAC MART-1 vaccine, replication-defective herpes simplex virus type I (HSV-1) vector expressing human Preproenkephalin (NP2), wild-type reovirus, reovirus type 3 Dearing (REOLYSIN®), oncolytic virus HSV1716, recombinant modified vaccinia Ankara (MVA)-based vaccine encoding Epstein-Barr virus target antigens, recombinant fowlpox- prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, rAd-p53 gene, Ad5-delta24RGD, HPV vaccine 580299, JX- 594 (thymidine kinase-deleted vaccinia virus plus GM-CSF), HPV-16/18 L1/AS04, fowlpox virus vaccine vector, vaccinia-tyrosinase vaccine, MEDI-517 HPV-16/18 VLP AS04 vaccine, adenoviral vector containing the thymidine kinase of herpes simplex virus TK99UN, HspE7, FP253/Fludarabine, ALVAC(2) melanoma multi-antigen therapeutic vaccine, ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine, Ad-REIC/Dkk-3, rAd-IFN SCH 721015, TIL-Ad-INFg, Ad-ISF35, and coxsackievirus A21 (CVA21, CAVATAK®).

In other embodiments, the multispecific molecule is administered in combination with a nanopharmaceutical. Exemplary cancer nanopharmaceuticals include, but not limited to, ABRAXANE® (paclitaxel bound albumin nanoparticles), CRLXlOl (CPT conjugated to a linear cyclodextrin-based polymer), CRLX288 (conjugating docetaxel to the biodegradable polymer poly (lactic-co-glycolic acid)), cytarabine liposomal (liposomal Ara-C, DEPOCYT™), daunorubicin liposomal (DAUNOXOME®), doxorubicin liposomal (DOXIL®, CAELYX®), encapsulated-daunorubicin citrate liposome (DAUNOXOME®), and PEG anti-VEGF aptamer (MACUGEN®).

In some embodiments, the multispecific molecule is administered in combination with paclitaxel or a paclitaxel formulation, e.g., TAXOL®, protein-bound paclitaxel (e.g.,

ABRAXANE®). Exemplary paclitaxel formulations include, but are not limited to, nanoparticle albumin-bound paclitaxel (ABRAXANE®, marketed by Abraxis Bioscience), docosahexaenoic acid bound-paclitaxel (DHA-paclitaxel, Taxoprexin, marketed by Protarga), polyglutamate bound-paclitaxel (PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX, marketed by Cell Therapeutic), the tumor-activated prodrug (TAP), ANG105 (Angiopep-2 bound to three molecules of paclitaxel, marketed by ImmunoGen), paclitaxel-EC-1 (paclitaxel bound to the erbB2-recognizing peptide EC-1; see Li et al., Biopolymers (2007) 87:225-230), and glucose- conjugated paclitaxel (e.g., 2'-paclitaxel methyl 2-glucopyranosyl succinate, see Liu et al., Bioorganic & Medicinal Chemistry Letters (2007) 17:617-620).

Exemplary RNAi and antisense RNA agents for treating cancer include, but not limited to, CALAA-01, siG12D LODER (Local Drug EluteR), and ALN-VSP02.

Other cancer therapeutic agents include, but not limited to, cytokines (e.g., aldesleukin (IL-2, Interleukin-2, PROLEUKIN®), alpha Interferon (IFN-alpha, Interferon alfa, INTRON® A (Interferon alfa-2b), ROFERON-A® (Interferon alfa-2a)), Epoetin alfa (PROCRIT®), filgrastim (G-CSF, Granulocyte - Colony Stimulating Factor, NEUPOGEN®), GM-CSF (Granulocyte Macrophage Colony Stimulating Factor, sargramostim, LEUKINE™), IL- 11 (Interleukin-11, oprelvekin, NEUMEGA®), Interferon alfa-2b (PEG conjugate) (PEG interferon, PEG- INTRON™), and pegfilgrastim (NEULASTA™)), hormone therapy agents (e.g.,

aminoglutethimide (CYTADREN®), anastrozole (ARIMIDEX®), bicalutamide (CASODEX®), exemestane (AROMASIN®), fluoxymesterone (HALOTESTIN®), flutamide (EULEXIN®), fulvestrant (FASLODEX®), goserelin (ZOLADEX®), letrozole (FEMARA®), leuprolide (ELIGARD™, LUPRON®, LUPRON DEPOT®, VIADUR™), megestrol (megestrol acetate, MEGACE®), nilutamide (ANANDRON®, NILANDRON®), octreotide (octreotide acetate, SANDOSTATIN®, SANDOSTATIN LAR®), raloxifene (EVISTA®), romiplostim

(NPLATE®), tamoxifen (NOVALDEX®), and toremifene (FARESTON®)), phospholipase A2 inhibitors (e.g., anagrelide (AGRYLIN®)), biologic response modifiers (e.g., BCG

(THERACYS®, TICE®), and Darbepoetin alfa (ARANESP®)), target therapy agents (e.g., bortezomib (VELCADE®), dasatinib (SPRYCEL™), denileukin diftitox (ONTAK®), erlotinib (TARCEVA®), everolimus (AFINITOR®), gefitinib (IRESSA®), imatinib mesylate (STI-571, GLEEVEC™), lapatinib (TYKERB®), sorafenib (NEXAVAR®), and SU11248 (sunitinib, SUTENT®)), immunomodulatory and antiangiogenic agents (e.g., CC-5013 (lenalidomide, REVLIMID®), and thalidomide (THALOMID®)), glucocorticosteroids (e.g., cortisone

(hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, ALA- CORT®, HYDROCORT ACETATE®, hydrocortone phosphate LANACORT®, SOLU- CORTEF®), decadron (dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®), methylprednisolone (6- methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, DURALONE®, MEDRALONE®, MEDROL®, M-PREDNISOL®, SOLU-MEDROL®), prednisolone (DELTA-CORTEF®, ORAPRED®, PEDIAPRED®, PRELONE®), and prednisone (DELTASONE®, LIQUID PRED®, METICORTEN®, ORASONE®)), and bisphosphonates (e.g., pamidronate (AREDIA®), and zoledronic acid (ZOMETA®))

In some embodiments, the multispecific molecule is used in combination with a tyrosine kinase inhibitor (e.g., a receptor tyrosine kinase (RTK) inhibitor). Exemplary tyrosine kinase inhibitor include, but are not limited to, an epidermal growth factor (EGF) pathway inhibitor (e.g., an epidermal growth factor receptor (EGFR) inhibitor), a vascular endothelial growth factor (VEGF) pathway inhibitor (e.g., an antibody against VEGF, a VEGF trap, a vascular endothelial growth factor receptor (VEGFR) inhibitor (e.g., a VEGFR-1 inhibitor, a VEGFR-2 inhibitor, a VEGFR-3 inhibitor)), a platelet derived growth factor (PDGF) pathway inhibitor (e.g., a platelet derived growth factor receptor (PDGFR) inhibitor (e.g., a PDGFR-β inhibitor)), a RAF-1 inhibitor, a KIT inhibitor and a RET inhibitor. In some embodiments, the anti-cancer agent used in combination with the AHCM agent is selected from the group consisting of:

axitinib (AG013736), bosutinib (SKI-606), cediranib (RECENTIN™, AZD2171), dasatinib (SPRYCEL®, BMS-354825), erlotinib (TARCEVA®), gefitinib (IRESSA®), imatinib

(Gleevec®, CGP57148B, STI-571), lapatinib (TYKERB®, TYVERB®), lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib (TASIGNA®), semaxanib (semaxinib, SU5416), sunitinib

(SUTENT®, SU11248), toceranib (PALLADIA®), vandetanib (ZACTIMA®, ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab (HERCEPTIN®), bevacizumab (AVASTIN®), rituximab (RITUXAN®), cetuximab (ERBITUX®), panitumumab (VECTIBIX®), ranibizumab (Lucentis®), nilotinib (TASIGNA®), sorafenib (NEXAVAR®), alemtuzumab (CAMPATH®), gemtuzumab ozogamicin (MYLOTARG®), ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK™), SGX523, PF-04217903, PF-02341066, PF- 299804, BMS-777607, ABT-869, MP470, BIBF 1 120 ( VARGATEF® ) , AP24534, JNJ-

26483327, MGCD265, DCC-2036, BMS-690154, CEP- 11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, XL228, AEE788, AG-490, AST-6, BMS-599626, CUDC-101, PD153035, pelitinib (EKB-569), vandetanib (zactima), WZ3146, WZ4002, WZ8040, ABT-869 (linifanib), AEE788, AP24534 (ponatinib), AV-951(tivozanib), axitinib, BAY 73-4506

(regorafenib), brivanib alaninate (BMS-582664), brivanib (BMS-540215), cediranib (AZD2171), CHIR-258 (dovitinib), CP 673451, CYC116, E7080, ΚΪ8751, masitinib (AB 1010), MGCD-265, motesanib diphosphate (AMG-706), MP-470, OSI-930, Pazopanib Hydrochloride,

PD173074,nSorafenib Tosylate(Bay 43-9006), SU 5402, TSU-68(SU6668), vatalanib, XL880 (GSK1363089, EXEL-2880). Selected tyrosine kinase inhibitors are chosen from sunitinib, erlotinib, gefitinib, or sorafenib. In one embodiment, the tyrosine kinase inhibitor is sunitinib.

In one embodiment, the multispecific molecule is administered in combination with one of more of: an anti-angiogenic agent, or a vascular targeting agent or a vascular disrupting agent. Exemplary anti-angiogenic agents include, but are not limited to, VEGF inhibitors (e.g., anti- VEGF antibodies (e.g., bevacizumab); VEGF receptor inhibitors (e.g., itraconazole); inhibitors of cell proliferatin and/or migration of endothelial cells (e.g., carboxyamidotriazole, TNP-470); inhibitors of angiogenesis stimulators (e.g., suramin), among others. A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis (reviewed in, e.g., Thorpe, P.E. (2004) Clin. Cancer Res. Vol. 10:415-427). VTAs can be small-molecule. Exemplary small-molecule VTAs include, but are not limited to, microtubule destabilizing drugs (e.g., combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503); and vadimezan (ASA404).

Immune checkpoint inhibitors

In other embodiments, methods described herein comprise use of an immune checkpoint inhibitor in combination with the multispecific molecule. The methods can be used in a therapeutic protocol in vivo.

In embodiments, an immune checkpoint inhibitor inhibits a checkpoint molecule.

Exemplary checkpoint molecules include but are not limited to CTLA4, PD1, PD-Ll, PD-L2, TIM3, LAG3, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM

(TNFRSF14 or CD270), BTLA, KIR, MHC class I, MHC class II, GAL9, VISTA, BTLA, TIGIT, LAIR1, and A2aR. See, e.g., Pardoll. Nat. Rev. Cancer 12.4(2012):252-64, incorporated herein by reference.

In embodiments, the immune checkpoint inhibitor is a PD-1 inhibitor, e.g., an anti-PD-1 antibody such as Nivolumab, Pembrolizumab or Pidilizumab. Nivolumab (also called MDX- 1106, MDX- 1106-04, ONO-4538, or BMS-936558) is a fully human IgG4 monoclonal antibody that specifically inhibits PD1. See, e.g., US 8,008,449 and WO2006/121168. Pembrolizumab (also called Lambrolizumab, MK-3475, MK03475, SCH-900475 or KEYTRUDA®; Merck) is a humanized IgG4 monoclonal antibody that binds to PD-1. See, e.g., Hamid, O. et al. (2013) New England Journal of Medicine 369 (2): 134-44, US 8,354,509 and WO2009/114335. Pidilizumab (also called CT-011 or Cure Tech) is a humanized IgGlk monoclonal antibody that binds to PD1. See, e.g., WO2009/101611. In one embodiment, the inhibitor of PD-1 is an antibody molecule having a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence of Nivolumab, Pembrolizumab or

Pidilizumab. Additional anti-PDl antibodies, e.g., AMP 514 (Amplimmune), are described, e.g., in US 8,609,089, US 2010028330, and/or US 20120114649.

In some embodiments, the PD-1 inhibitor is an immunoadhesin, e.g., an immunoadhesin comprising an extracellular/PD- 1 binding portion of a PD-1 ligand (e.g., PD-Ll or PD-L2) that is fused to a constant region (e.g. , an Fc region of an immunoglobulin). In embodiments, the PD- 1 inhibitor is AMP-224 (B7-DCIg, e.g., described in WO2011/066342and WO2010/027827), a PD-L2 Fc fusion soluble receptor that blocks the interaction between B7-H1 and PD- 1.

In embodiments, the immune checkpoint inhibitor is a PD-Ll inhibitor, e.g., an antibody molecule. In some embodiments, the PD-Ll inhibitor is YW243.55.S70, MPDL3280A, MEDI- 4736, MSB-0010718C, or MDX-1105. In some embodiments, the anti-PD-Ll antibody is MSB0010718C (also called A09-246-2; Merck Serono), which is a monoclonal antibody that binds to PD-Ll . Exemplary humanized anti-PD-Ll antibodies are described, e.g., in

WO2013/079174. In one embodiment, the PD-Ll inhibitor is an anti-PD-Ll antibody, e.g., YW243.55.S70. The YW243.55.S70 antibody is described, e.g., in WO 2010/077634. In one embodiment, the PD-Ll inhibitor is MDX- 1105 (also called BMS-936559), which is described, e.g., in WO2007/005874. In one embodiment, the PD-Ll inhibitor is MDPL3280A (Genentech / Roche), which is a human Fc-optimized IgGl monoclonal antibody against PD-Ll . See, e.g., U.S. Patent No.: 7,943,743 and U.S Publication No.: 20120039906. In one embodiment, the inhibitor of PD-Ll is an antibody molecule having a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to the sequence of

YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX- 1105.

In embodiments, the immune checkpoint inhibitor is a PD-L2 inhibitor, e.g., AMP-224 (which is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD 1 and B7- HI . See, e.g., WO2010/027827 and WO2011/066342.

In one embodiment, the immune checkpoint inhibitor is a LAG-3 inhibitor, e.g., an anti- LAG-3 antibody molecule. In embodiments, the anti-LAG-3 antibody is BMS-986016 (also called BMS986016; Bristol-Myers Squibb). BMS-986016 and other humanized anti-LAG-3 antibodies are described, e.g., in US 2011/0150892, WO2010/019570, and WO2014/008218.

In embodiments, the immune checkpoint inhibitor is a TIM-3 inhibitor, e.g., anti-TIM3 antibody molecule, e.g., described in U.S. Patent No.: 8,552,156, WO 2011/155607, EP 2581113 and U.S Publication No.: 2014/044728.

In embodiments, the immune checkpoint inhibitor is a CTLA-4 inhibitor, e.g., anti- CTLA-4 antibody molecule. Exemplary anti-CTLA4 antibodies include Tremelimumab (IgG2 monoclonal antibody from Pfizer, formerly known as ticilimumab, CP-675,206); and Ipilimumab (also called MDX-010, CAS No. 477202-00-9). Other exemplary anti-CTLA-4 antibodies are described, e.g., in U.S. Pat. No. 5,811,097.

EXAMPLES

The following examples are intended to be illustrative, and are not meant in any way to be limiting.

Example 1

1. Construction of the plasmids.

The DNA encoding the protein sequences was optimized for expression in Cricetulus griseus, synthesized, and cloned into the pcDNA3.4-TOPO (Life Technologies A14697) using Gateway cloning. All constructs contained an Ig Kappa leader sequence. The nucleic acid sequences used are shown in Table 1.

Table 1. Nucleic acid sequences.

CAATACCGTGAAGTGGTATCAGCAGCTGCCCGGCACAGCTCCCAAA

CTGCTGATCTACTACAACGACCAGCGGCCTTCTGGCGTGCCCGATA GATTCTCTGGCTCCAAGTCTGGCACCTCTGCCAGCCTGGCTATTAC CGGACTGCAGGCTGAGGACGAGGCCGACTACTACTGCCAGTCTTAC GACCGGTACACCCATCCTGCTCTGCTGTTTGGCACCGGCACCAAAG TGACAGTGCTG

SEQ ID hCL (kappa) CGGACAGTGGCCGCTCCTTCCGTGTTCATCTTCCCACCTTCCGACG NO: 20 AGCAGCTGAAGTCCGGCACAGCTTCTGTCGTGTGCCTGCTGAACAA

CTTCTACCCTCGGGAAGCCAAGGTGCAGTGGAAGGTGGACAATGCC CTGCAGTCCGGCAACTCCCAAGAGTCTGTGACCGAGCAGGACTCCA AGGACAGCACCTACAGCCTGTCCTCCACACTGACCCTGTCCAAGGC CGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCATCAG GGCCTGTCTAGCCCTGTGACCAAGTCTTTCAACCGGGGCGAGTGC

SEQ ID hCL (lambda) GGCCAGCCTAAGGCCAATCCTACCGTGACACTGTTCCCTCCATCCT NO: 21 CCGAAGAACTGCAGGCCAACAAGGCTACCCTCGTGTGCCTGATCTC

CGACTTTTACCCTGGCGCTGTGACCGTGGCCTGGAAGGCTGATGGA TCTCCTGTGAAGGCTGGCGTGGAAACCACCAAGCCTTCCAAGCAGT CCAACAACAAATACGCCGCCTCCTCCTACCTGTCTCTGACCCCTGA ACAGTGGAAGTCCCACCGGTCCTACAGCTGCCAAGTGACCCATGAG GGCTCCACCGTGGAAAAGACCGTGGCTCCTACCGAGTGCTCC

SEQ ID hCHl GCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGCA NO: 22 AGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGA

CTACTTTCCTGAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTG ACATCCGGCGTGCACACCTTTCCAGCTGTGCTGCAATCCTCCGGCC TGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCTCTGGG CACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACC AAGGTGGACAAGAGAGTGGAACCCAAGTCCTGC

SEQ ID hCH2 GATAAGACCCACACCTGTCCACCATGTCCTGCTCCAGAACTGCTCG NO: 23 GCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCT

GATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTG TCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCG TGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAA CTCCACCTACAGAGTGGTGTCCGTGCTGACCGTGCTGCACCAGGAT TGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCC TGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAA

SEQ ID hTCRa CCTGACATTCAGAACCCCGATCCTGCCGTGTACCAGCTGAGAGACT NO: 24 CCAAGTCCTCCGATAAGTCTGTGTGCCTGTTCACCGACTTCGACTC

CCAGACCAACGTGTCCCAGTCCAAGGACTCCGACGTGTACATCACC GATAAGTGCGTGCTGGACATGCGGAGCATGGACTTCAAGTCTAACT CCGCCGTGGCCTGGTCTAACAAGTCCGATTTCGCCTGCGCCAACGC CTTCAACAACAGCATTATCCCCGAGGACACATTCTTCCCATCACCT GAG

SEQ ID hTCRp GAGGACCTGAACAAGGTTTTCCCACCTGAGGTGGCCCTGTTCGAGC NO: 25 CTTCTGAGGCTGAGATCTCTCACACCCAGAAAGCTACCCTCGTGTG

TCTGGCCACCGGCTTCTACCCTGATCACGTGGAACTGTCTTGGTGG GTCAACGGAAAAGAGGTGCACTCCGGCGTCTGCACCGATCCTCAGC CTCTGAAAGAACAGCCCGCTCTGAACGACTCCAGATACGCCCTGTC CTCTCGGCTGAGAGTGTCTGCCACCTTCTGGCAGGACCCTCGGAAC CACTTTAGATGCCAGGTGCAGTTCTACGGCCTGTCCGAGGCTGATG AGTGGACCCAGGCTAGAGCCAAGCCAGTGACACAGATCGTGTCTGC CGAAGCCTGGGGCAGAGCCGAT SEQID G GGT NO: 26

SEQID GG GGTGGC NO: 27

SEQID GGG GGTGGCGGA NO: 28

SEQID GGGG GGTGGCGGAGGA NO: 29

SEQID GGGGS GGTGGCGGAGGAAGC NO: 30

SEQID GGGGSG GGTGGCGGAGGAAGCGGT NO: 31

SEQID GGGGS GG GGTGGCGGAGGAAGCGGTGGC NO: 32

SEQID GGGGS GGG GGTGGCGGAGGAAGCGGTGGCGGC NO: 33

SEQID GGGGS GGGG GGTGGCGGAGGAAGCGGTGGCGGCGGA NO: 34

SEQID GGGGS GGGGS GGTGGCGGAGGAAGCGGTGGCGGCGGATCT NO: 35

SEQID mCH2 ACCATCAAGCCTTGTCCTCCATGCAAGTGCCCCGCTCCTAATC NO: 36 TGCTCGGAGGCCCTTCCGTGTTCATCTTCCCACCTAAGATCAA

GGACGTGCTGATGATCTCCCTGTCTCCTATCGTGACCTGCGTG GTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGTT GGTTCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGAC ACACAGAGAGGACTACAACAGCACCCTGAGAGTGGTGTCTGCC CTGCCTATCCAGCACCAGGATTGGATGTCCGGCAAAGAATTCA AGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAGCG GACCATCTCCAAGCCT

SEQID mTCRa AAGCCTAACATCCAGAATCCTGAGCCTGCCGTGTACCAGCTGA NO: 37 AGGACCCTAGATCTCAGGACTCTACCCTGTGCCTGTTCACCGA

CTTCGACTCCCAGATCAACGTGCCCAAGACCATGGAATCCGGC ACCTTCATCACCGATAAGTGCGTGCTGGACATGAAGGCCATGG ACTCCAAGTCCAACGGCGCTATCGCCTGGTCCAACCAGACCAG CTTCACATGCCAGGACATCTTCAAAGAGACAAACGCCACCTAT CCTTCCAGCGACGTGCCCTGTGATGCTACCCTGACCGAGAAGT CCTTCGAGACAGACATGAACCTGAACTTCCAGAACCTGTCCTG ATGA

SEQID mTCRp GTGGTGGAAGATCTGCGGAACGTGACCCCTCCTAAGGTGTCCC NO: 38 TGTTCGAGCCTTCCAAGGCCGAGATCGCCAACAAGCAGAAAGC

TACCCTCGTGTGCCTGGCCAGAGGCTTCTTTCCTGACCACGTG GAACTGTCTTGGTGGGTCAACGGCAAAGAGGTGCACTCCGGCG TCTGTACCGATCCTCAGGCCTACAAAGAGTCCAACTACTCCTA CAGCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCTTCTGGCAC AACCCTCGGAACCACTTCAGATGCCAGGTGCAGTTTCACGGCC TGTCCGAAGAGGACAAGTGGCCTGAGGGATCCCCTAAGCCTGT GACACAGAACATCTCTGCCGAGGCCTGGGGTAGAGCTGATGGT

GGC

SEQ ID mIL2 F56A Y59A CTGGAACAGCTGCTGATGGACCTGCAAGAGCTGCTGTCCCGGA NO: 39 TGGAAAACTACCGGAACCTGAAGCTGCCCCGGATGCTGACCGC

TAAGT TCGCTCTGCCTAAGCAGGCCACCGAGCTGAAGGATCTG CAGTGCCTGGAAGATGAGCTGGGCCCTCTGAGACACGTGCTGG ATCTGACCCAGTCCAAGTCCT T TCAGCTCGAGGACGCCGAGAA CT TCATCTCCAACATCAGAGTGACCGTGGTCAAGCTGAAGGGC TCCGACAACACCT TCGAGTGCCAGT TCGACGATGAGTCCGCTA CAGTGGTGGACT TCCTGCGGAGATGGATCGCCT TCTGCCAGTC CATCATCTCCACCTCTCCACAGTGATGA

SEQ ID GGGGS GGGGS G GGAGGATCTGGCGGAGGTGGAAGCGGCGGAGGCGGATCT TCTC NO: 40 GGGS AT

SEQ ID hCH3_Knob GGCCAGCCTAGGGAACCCCAGGT T TACACCCTGCCTCCATGCC NO: 41 GGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGCCTGGT

TAAGGGCT TCTACCCCTCCGATATCGCCGTGGAATGGGAGTCT AATGGCCAGCCTGAGAACAACTACAAGACAACCCCTCCTGTGC TGGACTCCGACGGCTCAT TCT TCCTGTACTCCAAGCTGACAGT GGACAAGTCCAGATGGCAGCAGGGCAACGTGT TCTCCTGCTCC GTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGTCCC TGTCTCTGAGCCCCGGCAAG

SEQ ID hCH3_hole GCCAGCCTCGGGAACCTCAAGTCTGTACCCTGCCTCCTAGCCG NO: 42 GGAAGAGATGACCAAGAACCAGGTGTCCCTGTCCTGCGCTGTG

AAGGGCT TCTACCCT TCCGATATCGCCGTGGAATGGGAGAGCA ATGGCCAGCCTGAGAACAACTACAAGACCACACCTCCTGTGCT GGACTCCGACGGCTCAT TCT TCCTGGTGTCCAAGCTGACAGTG GACAAGTCCAGATGGCAGCAGGGCAACGTGT TCTCCTGCTCCG TGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGTCCCT GTCTCTGAGCCCCGGCAAG

Table 2. Sequences used to construct ORFs.

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 49 NO: 16 NO: 22 NO: 23 NO: 31 NO: 24

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 50 NO: 16 NO: 22 NO: 23 NO: 32 NO: 24

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 51 NO: 16 NO: 22 NO: 23 NO: 33 NO: 24

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 52 NO: 16 NO: 22 NO: 23 NO: 34 NO: 24

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 53 NO: 16 NO: 22 NO: 23 NO: 35 NO: 24

SEQ ID SEQID SEQID NO: 54 NO: 17 NO: 20

SEQ ID SEQID SEQID SEQID SEQID NO: 55 NO: 18 NO: 22 NO: 23 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 56 NO: 18 NO: 22 NO: 23 NO: 26 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 57 NO: 18 NO: 22 NO: 23 NO: 27 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 58 NO: 18 NO: 22 NO: 23 NO: 28 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 59 NO: 18 NO: 22 NO: 23 NO: 29 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 60 NO: 18 NO: 22 NO: 23 NO: 30 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 61 NO: 18 NO: 22 NO: 23 NO: 31 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 62 NO: 18 NO: 22 NO: 23 NO: 32 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 63 NO: 18 NO: 22 NO: 23 NO: 33 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 64 NO: 18 NO: 22 NO: 23 NO: 34 NO: 25

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 65 NO: 18 NO: 22 NO: 23 NO: 35 NO: 25

SEQ ID SEQID SEQID NO: 66 NO: 19 NO: 21

SEQ ID SEQID SEQID NO: 67 NO: 36 NO: 37

SEQ ID SEQID SEQID SEQID NO: 68 NO: 36 NO: 26 NO: 37

SEQ ID SEQID SEQID SEQID NO: 69 NO: 36 NO: 27 NO: 22

SEQ ID SEQID SEQID SEQID NO: 70 NO: 36 NO: 28 NO: 37

SEQ ID SEQID SEQID SEQID NO: 71 NO: 36 NO: 29 NO: 37 SEQ ID SEQID SEQID SEQID

NO: 72 NO: 36 NO: 30 NO: 37

SEQ ID SEQID SEQID SEQID NO: 73 NO: 36 NO: 31 NO: 37

SEQ ID SEQID SEQID SEQID NO: 74 NO: 36 NO: 32 NO: 37

SEQ ID SEQID SEQID SEQID NO: 75 NO: 36 NO: 33 NO: 37

SEQ ID SEQID SEQID SEQID NO: 76 NO: 36 NO: 34 NO: 37

SEQ ID SEQID SEQID SEQID NO: 77 NO: 36 NO: 35 NO: 37

SEQ ID SEQID SEQID SEQID SEQID NO: 78 NO: 36 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 79 NO: 36 NO: 26 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 80 NO: 36 NO: 27 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 81 NO: 36 NO: 28 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 82 NO: 36 NO: 29 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 83 NO: 36 NO: 30 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 84 NO: 36 NO: 31 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 85 NO: 36 NO: 32 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 86 NO: 36 NO: 33 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 87 NO: 36 NO: 34 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQID SEQID SEQID NO: 88 NO: 36 NO: 35 NO: 38 NO: 40 NO: 39

SEQ ID SEQID SEQID SEQ ID SEQID NO: 89 NO: 16 NO: 22 NO: 23 NO: 41

SEQ ID SEQID SEQID SEQ ID SEQID NO: 90 NO: 18 NO: 22 NO: 23 NO: 42

Table 3. Sequences used to construct ORFs.

AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAACCT GACATTCAGAACCCCGATCCTGCCGTGTACCAGCTGAGAGACTCCAAGTCCTCCGAT AAGTCTGTGTGCCTGTTCACCGACTTCGACTCCCAGACCAACGTGTCCCAGTCCAAG GACTCCGACGTGTACATCACCGATAAGTGCGTGCTGGACATGCGGAGCATGGACTTC AAGTCTAACTCCGCCGTGGCCTGGTCTAACAAGTCCGATTTCGCCTGCGCCAACGCC TTCAACAACAGCATTATCCCCGAGGACACATTCTTCCCATCACCTGAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 44 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT CCTGACATTCAGAACCCCGATCCTGCCGTGTACCAGCTGAGAGACTCCAAGTCCTCC GATAAGTCTGTGTGCCTGTTCACCGACTTCGACTCCCAGACCAACGTGTCCCAGTCC AAGGACTCCGACGTGTACATCACCGATAAGTGCGTGCTGGACATGCGGAGCATGGAC TTCAAGTCTAACTCCGCCGTGGCCTGGTCTAACAAGTCCGATTTCGCCTGCGCCAAC GCCTTCAACAACAGCATTATCCCCGAGGACACATTCTTCCCATCACCTGAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 45 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT GGCCCTGACATTCAGAACCCCGATCCTGCCGTGTACCAGCTGAGAGACTCCAAGTCC TCCGATAAGTCTGTGTGCCTGTTCACCGACTTCGACTCCCAGACCAACGTGTCCCAG TCCAAGGACTCCGACGTGTACATCACCGATAAGTGCGTGCTGGACATGCGGAGCATG GACTTCAAGTCTAACTCCGCCGTGGCCTGGTCTAACAAGTCCGATTTCGCCTGCGCC AACGCCTTCAACAACAGCATTATCCCCGAGGACACATTCTTCCCATCACCTGAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 46 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT GGCGGACCTGACATTCAGAACCCCGATCCTGCCGTGTACCAGCTGAGAGACTCCAAG TCCTCCGATAAGTCTGTGTGCCTGTTCACCGACTTCGACTCCCAGACCAACGTGTCC CAGTCCAAGGACTCCGACGTGTACATCACCGATAAGTGCGTGCTGGACATGCGGAGC ATGGACTTCAAGTCTAACTCCGCCGTGGCCTGGTCTAACAAGTCCGATTTCGCCTGC GCCAACGCCTTCAACAACAGCATTATCCCCGAGGACACATTCTTCCCATCACCTGAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 47 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT GGCGGAGGACCTGACATTCAGAACCCCGATCCTGCCGTGTACCAGCTGAGAGACTCC AAGTCCTCCGATAAGTCTGTGTGCCTGTTCACCGACTTCGACTCCCAGACCAACGTG TCCCAGTCCAAGGACTCCGACGTGTACATCACCGATAAGTGCGTGCTGGACATGCGG AGCATGGACTTCAAGTCTAACTCCGCCGTGGCCTGGTCTAACAAGTCCGATTTCGCC TGCGCCAACGCCTTCAACAACAGCATTATCCCCGAGGACACATTCTTCCCATCACCT GAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 48 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT GGCGGAGGAAGCCCTGACATTCAGAACCCCGATCCTGCCGTGTACCAGCTGAGAGAC TCCAAGTCCTCCGATAAGTCTGTGTGCCTGTTCACCGACTTCGACTCCCAGACCAAC GTGTCCCAGTCCAAGGACTCCGACGTGTACATCACCGATAAGTGCGTGCTGGACATG CGGAGCATGGACTTCAAGTCTAACTCCGCCGTGGCCTGGTCTAACAAGTCCGATTTC GCCTGCGCCAACGCCTTCAACAACAGCATTATCCCCGAGGACACATTCTTCCCATCA CCTGAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 49 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT GGCGGAGGAAGCGGTCCTGACATTCAGAACCCCGATCCTGCCGTGTACCAGCTGAGA GACTCCAAGTCCTCCGATAAGTCTGTGTGCCTGTTCACCGACTTCGACTCCCAGACC AACGTGTCCCAGTCCAAGGACTCCGACGTGTACATCACCGATAAGTGCGTGCTGGAC ATGCGGAGCATGGACTTCAAGTCTAACTCCGCCGTGGCCTGGTCTAACAAGTCCGAT TTCGCCTGCGCCAACGCCTTCAACAACAGCATTATCCCCGAGGACACATTCTTCCCA TCACCTGAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 50 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT GGCGGAGGAAGCGGTGGCCCTGACATTCAGAACCCCGATCCTGCCGTGTACCAGCTG AGAGACTCCAAGTCCTCCGATAAGTCTGTGTGCCTGTTCACCGACTTCGACTCCCAG ACCAACGTGTCCCAGTCCAAGGACTCCGACGTGTACATCACCGATAAGTGCGTGCTG GACATGCGGAGCATGGACTTCAAGTCTAACTCCGCCGTGGCCTGGTCTAACAAGTCC GATTTCGCCTGCGCCAACGCCTTCAACAACAGCATTATCCCCGAGGACACATTCTTC CCATCACCTGAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 51 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT GGCGGAGGAAGCGGTGGCGGCCCTGACATTCAGAACCCCGATCCTGCCGTGTACCAG CTGAGAGACTCCAAGTCCTCCGATAAGTCTGTGTGCCTGTTCACCGACTTCGACTCC CAGACCAACGTGTCCCAGTCCAAGGACTCCGACGTGTACATCACCGATAAGTGCGTG CTGGACATGCGGAGCATGGACTTCAAGTCTAACTCCGCCGTGGCCTGGTCTAACAAG TCCGATTTCGCCTGCGCCAACGCCTTCAACAACAGCATTATCCCCGAGGACACATTC TTCCCATCACCTGAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 52 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT GGCGGAGGAAGCGGTGGCGGCGGACCTGACATTCAGAACCCCGATCCTGCCGTGTAC CAGCTGAGAGACTCCAAGTCCTCCGATAAGTCTGTGTGCCTGTTCACCGACTTCGAC TCCCAGACCAACGTGTCCCAGTCCAAGGACTCCGACGTGTACATCACCGATAAGTGC GTGCTGGACATGCGGAGCATGGACTTCAAGTCTAACTCCGCCGTGGCCTGGTCTAAC AAGTCCGATTTCGCCTGCGCCAACGCCTTCAACAACAGCATTATCCCCGAGGACACA TTCTTCCCATCACCTGAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 53 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCAGCTACACCATGCACTGGGTCCGA CAGGCCCCTGGCAAAGGATTGGAGTGGGTCACCTTCATCTCTTACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCTTTGATTATTGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCT GAGCCTGTGACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTT CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGT GGCGGAGGAAGCGGTGGCGGCGGATCTCCTGACATTCAGAACCCCGATCCTGCCGTG TACCAGCTGAGAGACTCCAAGTCCTCCGATAAGTCTGTGTGCCTGTTCACCGACTTC GACTCCCAGACCAACGTGTCCCAGTCCAAGGACTCCGACGTGTACATCACCGATAAG TGCGTGCTGGACATGCGGAGCATGGACTTCAAGTCTAACTCCGCCGTGGCCTGGTCT AACAAGTCCGATTTCGCCTGCGCCAACGCCTTCAACAACAGCATTATCCCCGAGGAC ACATTCTTCCCATCACCTGAG

SEQ ID GAGATCGTGCTGACCCAGTCTCCTGGCACACTGTCACTGTCTCCAGGCGAGAGAGCT NO: 54 ACCCTGTCCTGTAGAGCCTCTCAGTCCGTGGGCTCCTCTTACCTGGCTTGGTATCAG

CAGAAGCCCGGCCAGGCTCCTAGACTGTTGATCTACGGCGCCTTCTCCAGAGCCACA GGCATCCCTGATAGATTCTCCGGCTCTGGCTCTGGCACCGACTTCACCCTGACCATC TCCAGACTGGAACCCGAGGACTTCGCCGTGTACTACTGTCAGCAGTACGGCTCCTCT CCTTGGACCTTTGGCCAGGGCACCAAGGTGGAAATCAAGCGGACAGTGGCCGCTCCT TCCGTGTTCATCTTCCCACCTTCCGACGAGCAGCTGAAGTCCGGCACAGCTTCTGTC GTGTGCCTGCTGAACAACTTCTACCCTCGGGAAGCCAAGGTGCAGTGGAAGGTGGAC AATGCCCTGCAGTCCGGCAACTCCCAAGAGTCTGTGACCGAGCAGGACTCCAAGGAC AGCACCTACAGCCTGTCCTCCACACTGACCCTGTCCAAGGCCGACTACGAGAAGCAC AAGGTGTACGCCTGCGAAGTGACCCATCAGGGCCTGTCTAGCCCTGTGACCAAGTCT TTCAACCGGGGCGAGTGC

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 55 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCTCTTACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCGCCTTCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAATTGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTG ACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTTCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGAGGACCTGAAC AAGGTTTTCCCACCTGAGGTGGCCCTGTTCGAGCCTTCTGAGGCTGAGATCTCTCAC ACCCAGAAAGCTACCCTCGTGTGTCTGGCCACCGGCTTCTACCCTGATCACGTGGAA CTGTCTTGGTGGGTCAACGGAAAAGAGGTGCACTCCGGCGTCTGCACCGATCCTCAG CCTCTGAAAGAACAGCCCGCTCTGAACGACTCCAGATACGCCCTGTCCTCTCGGCTG AGAGTGTCTGCCACCTTCTGGCAGGACCCTCGGAACCACTTTAGATGCCAGGTGCAG TTCTACGGCCTGTCCGAGGCTGATGAGTGGACCCAGGCTAGAGCCAAGCCAGTGACA CAGATCGTGTCTGCCGAAGCCTGGGGCAGAGCCGAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 56 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCTCTTACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCGCCTTCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAATTGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTG ACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTTCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGAGGACCTG AACAAGGTTTTCCCACCTGAGGTGGCCCTGTTCGAGCCTTCTGAGGCTGAGATCTCT CACACCCAGAAAGCTACCCTCGTGTGTCTGGCCACCGGCTTCTACCCTGATCACGTG GAACTGTCTTGGTGGGTCAACGGAAAAGAGGTGCACTCCGGCGTCTGCACCGATCCT CAGCCTCTGAAAGAACAGCCCGCTCTGAACGACTCCAGATACGCCCTGTCCTCTCGG CTGAGAGTGTCTGCCACCTTCTGGCAGGACCCTCGGAACCACTTTAGATGCCAGGTG CAGTTCTACGGCCTGTCCGAGGCTGATGAGTGGACCCAGGCTAGAGCCAAGCCAGTG ACACAGATCGTGTCTGCCGAAGCCTGGGGCAGAGCCGAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 57 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCTCTTACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCGCCTTCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAATTGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTG ACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTTCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGGCGAGGAC CTGAACAAGGTTTTCCCACCTGAGGTGGCCCTGTTCGAGCCTTCTGAGGCTGAGATC TCTCACACCCAGAAAGCTACCCTCGTGTGTCTGGCCACCGGCTTCTACCCTGATCAC GTGGAACTGTCTTGGTGGGTCAACGGAAAAGAGGTGCACTCCGGCGTCTGCACCGAT CCTCAGCCTCTGAAAGAACAGCCCGCTCTGAACGACTCCAGATACGCCCTGTCCTCT CGGCTGAGAGTGTCTGCCACCTTCTGGCAGGACCCTCGGAACCACTTTAGATGCCAG GTGCAGTTCTACGGCCTGTCCGAGGCTGATGAGTGGACCCAGGCTAGAGCCAAGCCA GTGACACAGATCGTGTCTGCCGAAGCCTGGGGCAGAGCCGAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 58 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCTCTTACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCGCCTTCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAATTGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTG ACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTTCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGGCGGAGAG GACCTGAACAAGGTTTTCCCACCTGAGGTGGCCCTGTTCGAGCCTTCTGAGGCTGAG ATCTCTCACACCCAGAAAGCTACCCTCGTGTGTCTGGCCACCGGCTTCTACCCTGAT CACGTGGAACTGTCTTGGTGGGTCAACGGAAAAGAGGTGCACTCCGGCGTCTGCACC GATCCTCAGCCTCTGAAAGAACAGCCCGCTCTGAACGACTCCAGATACGCCCTGTCC TCTCGGCTGAGAGTGTCTGCCACCTTCTGGCAGGACCCTCGGAACCACTTTAGATGC CAGGTGCAGTTCTACGGCCTGTCCGAGGCTGATGAGTGGACCCAGGCTAGAGCCAAG CCAGTGACACAGATCGTGTCTGCCGAAGCCTGGGGCAGAGCCGAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 59 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCTCTTACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCGCCTTCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAATTGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTG ACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTTCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGGCGGAGGA GAGGACCTGAACAAGGTTTTCCCACCTGAGGTGGCCCTGTTCGAGCCTTCTGAGGCT GAGATCTCTCACACCCAGAAAGCTACCCTCGTGTGTCTGGCCACCGGCTTCTACCCT GATCACGTGGAACTGTCTTGGTGGGTCAACGGAAAAGAGGTGCACTCCGGCGTCTGC ACCGATCCTCAGCCTCTGAAAGAACAGCCCGCTCTGAACGACTCCAGATACGCCCTG TCCTCTCGGCTGAGAGTGTCTGCCACCTTCTGGCAGGACCCTCGGAACCACTTTAGA TGCCAGGTGCAGTTCTACGGCCTGTCCGAGGCTGATGAGTGGACCCAGGCTAGAGCC AAGCCAGTGACACAGATCGTGTCTGCCGAAGCCTGGGGCAGAGCCGAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 60 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCTCTTACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCGCCTTCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAATTGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTG ACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTTCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGGCGGAGGA AGCGAGGACCTGAACAAGGTTTTCCCACCTGAGGTGGCCCTGTTCGAGCCTTCTGAG GCTGAGATCTCTCACACCCAGAAAGCTACCCTCGTGTGTCTGGCCACCGGCTTCTAC CCTGATCACGTGGAACTGTCTTGGTGGGTCAACGGAAAAGAGGTGCACTCCGGCGTC TGCACCGATCCTCAGCCTCTGAAAGAACAGCCCGCTCTGAACGACTCCAGATACGCC CTGTCCTCTCGGCTGAGAGTGTCTGCCACCTTCTGGCAGGACCCTCGGAACCACTTT AGATGCCAGGTGCAGTTCTACGGCCTGTCCGAGGCTGATGAGTGGACCCAGGCTAGA GCCAAGCCAGTGACACAGATCGTGTCTGCCGAAGCCTGGGGCAGAGCCGAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 61 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCTCTTACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCGCCTTCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAAT TGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCT TCCACCAAGGGACCCTCTGTGT TCCCTCTGGCTCCT TCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACT T TCCTGAGCCTGTG ACCGTGTCT TGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCT T TCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCT TCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCT TCCGTGT TCCTGT T TCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGT TCAAT TGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGAT TGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGGCGGAGGA AGCGGTGAGGACCTGAACAAGGT T T TCCCACCTGAGGTGGCCCTGT TCGAGCCT TCT GAGGCTGAGATCTCTCACACCCAGAAAGCTACCCTCGTGTGTCTGGCCACCGGCT TC TACCCTGATCACGTGGAACTGTCT TGGTGGGTCAACGGAAAAGAGGTGCACTCCGGC GTCTGCACCGATCCTCAGCCTCTGAAAGAACAGCCCGCTCTGAACGACTCCAGATAC GCCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TCTGGCAGGACCCTCGGAACCAC T T TAGATGCCAGGTGCAGT TCTACGGCCTGTCCGAGGCTGATGAGTGGACCCAGGCT AGAGCCAAGCCAGTGACACAGATCGTGTCTGCCGAAGCCTGGGGCAGAGCCGAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGT TGTGCAGCCTGGCAGATCCCTGAGA NO: 62 CTGTCT TGTGCCGCCTCCGGCT TCACCT TCTCCTCT TACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGAT TGGAGTGGGTCGCCT TCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGAT TCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAAT TGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCT TCCACCAAGGGACCCTCTGTGT TCCCTCTGGCTCCT TCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACT T TCCTGAGCCTGTG ACCGTGTCT TGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCT T TCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCT TCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCT TCCGTGT TCCTGT T TCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGT TCAAT TGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGAT TGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGGCGGAGGA AGCGGTGGCGAGGACCTGAACAAGGT T T TCCCACCTGAGGTGGCCCTGT TCGAGCCT TCTGAGGCTGAGATCTCTCACACCCAGAAAGCTACCCTCGTGTGTCTGGCCACCGGC T TCTACCCTGATCACGTGGAACTGTCT TGGTGGGTCAACGGAAAAGAGGTGCACTCC GGCGTCTGCACCGATCCTCAGCCTCTGAAAGAACAGCCCGCTCTGAACGACTCCAGA TACGCCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TCTGGCAGGACCCTCGGAAC CACT T TAGATGCCAGGTGCAGT TCTACGGCCTGTCCGAGGCTGATGAGTGGACCCAG GCTAGAGCCAAGCCAGTGACACAGATCGTGTCTGCCGAAGCCTGGGGCAGAGCCGAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGT TGTGCAGCCTGGCAGATCCCTGAGA NO: 63 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCTCTTACGGAATGCACTGGGTCCGA CAGGCCCCTGGCAAAGGATTGGAGTGGGTCGCCTTCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAATTGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTG ACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTTCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGGCGGAGGA AGCGGTGGCGGCGAGGACCTGAACAAGGTTTTCCCACCTGAGGTGGCCCTGTTCGAG CCTTCTGAGGCTGAGATCTCTCACACCCAGAAAGCTACCCTCGTGTGTCTGGCCACC GGCTTCTACCCTGATCACGTGGAACTGTCTTGGTGGGTCAACGGAAAAGAGGTGCAC TCCGGCGTCTGCACCGATCCTCAGCCTCTGAAAGAACAGCCCGCTCTGAACGACTCC AGATACGCCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCTTCTGGCAGGACCCTCGG AACCACTTTAGATGCCAGGTGCAGTTCTACGGCCTGTCCGAGGCTGATGAGTGGACC CAGGCTAGAGCCAAGCCAGTGACACAGATCGTGTCTGCCGAAGCCTGGGGCAGAGCC GAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGA NO: 64 CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCCTCTTACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGATTGGAGTGGGTCGCCTTCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGATTCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAATTGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCTTCCACCAAGGGACCCTCTGTGTTCCCTCTGGCTCCTTCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACTTTCCTGAGCCTGTG ACCGTGTCTTGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCTTTCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCTTCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCTTCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCTTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGGCGGAGGA AGCGGTGGCGGCGGAGAGGACCTGAACAAGGTTTTCCCACCTGAGGTGGCCCTGTTC GAGCCTTCTGAGGCTGAGATCTCTCACACCCAGAAAGCTACCCTCGTGTGTCTGGCC ACCGGCTTCTACCCTGATCACGTGGAACTGTCTTGGTGGGTCAACGGAAAAGAGGTG CACTCCGGCGTCTGCACCGATCCTCAGCCTCTGAAAGAACAGCCCGCTCTGAACGAC TCCAGATACGCCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TCTGGCAGGACCCT CGGAACCACT T TAGATGCCAGGTGCAGT TCTACGGCCTGTCCGAGGCTGATGAGTGG ACCCAGGCTAGAGCCAAGCCAGTGACACAGATCGTGTCTGCCGAAGCCTGGGGCAGA GCCGAT

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGT TGTGCAGCCTGGCAGATCCCTGAGA NO: 65 CTGTCT TGTGCCGCCTCCGGCT TCACCT TCTCCTCT TACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGAT TGGAGTGGGTCGCCT TCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGAT TCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAAT TGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCT TCCACCAAGGGACCCTCTGTGT TCCCTCTGGCTCCT TCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACT T TCCTGAGCCTGTG ACCGTGTCT TGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCT T TCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCT TCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCT TCCGTGT TCCTGT T TCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGT TCAAT TGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGAT TGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGTGGCGGAGGA AGCGGTGGCGGCGGATCTGAGGACCTGAACAAGGT T T TCCCACCTGAGGTGGCCCTG T TCGAGCCT TCTGAGGCTGAGATCTCTCACACCCAGAAAGCTACCCTCGTGTGTCTG GCCACCGGCT TCTACCCTGATCACGTGGAACTGTCT TGGTGGGTCAACGGAAAAGAG GTGCACTCCGGCGTCTGCACCGATCCTCAGCCTCTGAAAGAACAGCCCGCTCTGAAC GACTCCAGATACGCCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TCTGGCAGGAC CCTCGGAACCACT T TAGATGCCAGGTGCAGT TCTACGGCCTGTCCGAGGCTGATGAG TGGACCCAGGCTAGAGCCAAGCCAGTGACACAGATCGTGTCTGCCGAAGCCTGGGGC AGAGCCGAT

SEQ ID CAGTCCGTGT TGACCCAGCCTCCT TCTGT T TCTGGCGCTCCTGGCCAGAGAGTGACC NO: 66 ATCTCT TGCTCCGGCTCTCGGTCCAACATCGGCTCCAATACCGTGAAGTGGTATCAG

CAGCTGCCCGGCACAGCTCCCAAACTGCTGATCTACTACAACGACCAGCGGCCT TCT GGCGTGCCCGATAGAT TCTCTGGCTCCAAGTCTGGCACCTCTGCCAGCCTGGCTAT T ACCGGACTGCAGGCTGAGGACGAGGCCGACTACTACTGCCAGTCT TACGACCGGTAC ACCCATCCTGCTCTGCTGT T TGGCACCGGCACCAAAGTGACAGTGCTGGGCCAGCCT AAGGCCAATCCTACCGTGACACTGT TCCCTCCATCCTCCGAAGAACTGCAGGCCAAC AAGGCTACCCTCGTGTGCCTGATCTCCGACT T T TACCCTGGCGCTGTGACCGTGGCC TGGAAGGCTGATGGATCTCCTGTGAAGGCTGGCGTGGAAACCACCAAGCCT TCCAAG CAGTCCAACAACAAATACGCCGCCTCCTCCTACCTGTCTCTGACCCCTGAACAGTGG AAGTCCCACCGGTCCTACAGCTGCCAAGTGACCCATGAGGGCTCCACCGTGGAAAAG ACCGTGGCTCCTACCGAGTGCTCC

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 67 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTAAGCCTAACATCCAGAATCCTGAGCCTGCCGTGTACCAG CTGAAGGACCCTAGATCTCAGGACTCTACCCTGTGCCTGT TCACCGACT TCGACTCC CAGATCAACGTGCCCAAGACCATGGAATCCGGCACCT TCATCACCGATAAGTGCGTG CTGGACATGAAGGCCATGGACTCCAAGTCCAACGGCGCTATCGCCTGGTCCAACCAG ACCAGCT TCACATGCCAGGACATCT TCAAAGAGACAAACGCCACCTATCCT TCCAGC GACGTGCCCTGTGATGCTACCCTGACCGAGAAGTCCT TCGAGACAGACATGAACCTG AACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 68 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTAAGCCTAACATCCAGAATCCTGAGCCTGCCGTGTAC CAGCTGAAGGACCCTAGATCTCAGGACTCTACCCTGTGCCTGT TCACCGACT TCGAC TCCCAGATCAACGTGCCCAAGACCATGGAATCCGGCACCT TCATCACCGATAAGTGC GTGCTGGACATGAAGGCCATGGACTCCAAGTCCAACGGCGCTATCGCCTGGTCCAAC CAGACCAGCT TCACATGCCAGGACATCT TCAAAGAGACAAACGCCACCTATCCT TCC AGCGACGTGCCCTGTGATGCTACCCTGACCGAGAAGTCCT TCGAGACAGACATGAAC CTGAACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 69 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGCT TCCACCAAGGGACCCTCTGTGT TCCCTCTG GCTCCT TCCAGCAAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAG GACTACT T TCCTGAGCCTGTGACCGTGTCT TGGAACTCTGGCGCTCTGACATCCGGC GTGCACACCT T TCCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTC GTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCAC AAGCCT TCCAACACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGC

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 70 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAAAGCCTAACATCCAGAATCCTGAGCCTGCC GTGTACCAGCTGAAGGACCCTAGATCTCAGGACTCTACCCTGTGCCTGT TCACCGAC T TCGACTCCCAGATCAACGTGCCCAAGACCATGGAATCCGGCACCT TCATCACCGAT AAGTGCGTGCTGGACATGAAGGCCATGGACTCCAAGTCCAACGGCGCTATCGCCTGG TCCAACCAGACCAGCT TCACATGCCAGGACATCT TCAAAGAGACAAACGCCACCTAT CCT TCCAGCGACGTGCCCTGTGATGCTACCCTGACCGAGAAGTCCT TCGAGACAGAC ATGAACCTGAACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 71 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAAGCCTAACATCCAGAATCCTGAGCCT GCCGTGTACCAGCTGAAGGACCCTAGATCTCAGGACTCTACCCTGTGCCTGT TCACC GACT TCGACTCCCAGATCAACGTGCCCAAGACCATGGAATCCGGCACCT TCATCACC GATAAGTGCGTGCTGGACATGAAGGCCATGGACTCCAAGTCCAACGGCGCTATCGCC TGGTCCAACCAGACCAGCT TCACATGCCAGGACATCT TCAAAGAGACAAACGCCACC TATCCT TCCAGCGACGTGCCCTGTGATGCTACCCTGACCGAGAAGTCCT TCGAGACA GACATGAACCTGAACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 72 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCAAGCCTAACATCCAGAATCCTGAG CCTGCCGTGTACCAGCTGAAGGACCCTAGATCTCAGGACTCTACCCTGTGCCTGT TC ACCGACT TCGACTCCCAGATCAACGTGCCCAAGACCATGGAATCCGGCACCT TCATC ACCGATAAGTGCGTGCTGGACATGAAGGCCATGGACTCCAAGTCCAACGGCGCTATC GCCTGGTCCAACCAGACCAGCT TCACATGCCAGGACATCT TCAAAGAGACAAACGCC ACCTATCCT TCCAGCGACGTGCCCTGTGATGCTACCCTGACCGAGAAGTCCT TCGAG ACAGACATGAACCTGAACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 73 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTAAGCCTAACATCCAGAATCCT GAGCCTGCCGTGTACCAGCTGAAGGACCCTAGATCTCAGGACTCTACCCTGTGCCTG T TCACCGACT TCGACTCCCAGATCAACGTGCCCAAGACCATGGAATCCGGCACCT TC ATCACCGATAAGTGCGTGCTGGACATGAAGGCCATGGACTCCAAGTCCAACGGCGCT ATCGCCTGGTCCAACCAGACCAGCT TCACATGCCAGGACATCT TCAAAGAGACAAAC GCCACCTATCCT TCCAGCGACGTGCCCTGTGATGCTACCCTGACCGAGAAGTCCT TC GAGACAGACATGAACCTGAACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 74 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTGGCAAGCCTAACATCCAGAAT CCTGAGCCTGCCGTGTACCAGCTGAAGGACCCTAGATCTCAGGACTCTACCCTGTGC CTGT TCACCGACT TCGACTCCCAGATCAACGTGCCCAAGACCATGGAATCCGGCACC T TCATCACCGATAAGTGCGTGCTGGACATGAAGGCCATGGACTCCAAGTCCAACGGC GCTATCGCCTGGTCCAACCAGACCAGCT TCACATGCCAGGACATCT TCAAAGAGACA AACGCCACCTATCCT TCCAGCGACGTGCCCTGTGATGCTACCCTGACCGAGAAGTCC T TCGAGACAGACATGAACCTGAACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 75 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTGGCGGCAAGCCTAACATCCAG AATCCTGAGCCTGCCGTGTACCAGCTGAAGGACCCTAGATCTCAGGACTCTACCCTG TGCCTGT TCACCGACT TCGACTCCCAGATCAACGTGCCCAAGACCATGGAATCCGGC ACCT TCATCACCGATAAGTGCGTGCTGGACATGAAGGCCATGGACTCCAAGTCCAAC GGCGCTATCGCCTGGTCCAACCAGACCAGCT TCACATGCCAGGACATCT TCAAAGAG ACAAACGCCACCTATCCT TCCAGCGACGTGCCCTGTGATGCTACCCTGACCGAGAAG TCCT TCGAGACAGACATGAACCTGAACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 76 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTGGCGGCGGAAAGCCTAACATC CAGAATCCTGAGCCTGCCGTGTACCAGCTGAAGGACCCTAGATCTCAGGACTCTACC CTGTGCCTGT TCACCGACT TCGACTCCCAGATCAACGTGCCCAAGACCATGGAATCC GGCACCT TCATCACCGATAAGTGCGTGCTGGACATGAAGGCCATGGACTCCAAGTCC AACGGCGCTATCGCCTGGTCCAACCAGACCAGCT TCACATGCCAGGACATCT TCAAA GAGACAAACGCCACCTATCCT TCCAGCGACGTGCCCTGTGATGCTACCCTGACCGAG AAGTCCT TCGAGACAGACATGAACCTGAACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 77 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTGGCGGCGGATCTAAGCCTAAC ATCCAGAATCCTGAGCCTGCCGTGTACCAGCTGAAGGACCCTAGATCTCAGGACTCT ACCCTGTGCCTGT TCACCGACT TCGACTCCCAGATCAACGTGCCCAAGACCATGGAA TCCGGCACCT TCATCACCGATAAGTGCGTGCTGGACATGAAGGCCATGGACTCCAAG TCCAACGGCGCTATCGCCTGGTCCAACCAGACCAGCT TCACATGCCAGGACATCT TC AAAGAGACAAACGCCACCTATCCT TCCAGCGACGTGCCCTGTGATGCTACCCTGACC GAGAAGTCCT TCGAGACAGACATGAACCTGAACT TCCAGAACCTGTCCTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 78 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGTGGTGGAAGATCTGCGGAACGTGACCCCTCCTAAGGTG TCCCTGT TCGAGCCT TCCAAGGCCGAGATCGCCAACAAGCAGAAAGCTACCCTCGTG TGCCTGGCCAGAGGCT TCT T TCCTGACCACGTGGAACTGTCT TGGTGGGTCAACGGC AAAGAGGTGCACTCCGGCGTCTGTACCGATCCTCAGGCCTACAAAGAGTCCAACTAC TCCTACAGCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TCTGGCACAACCCTCGG AACCACT TCAGATGCCAGGTGCAGT T TCACGGCCTGTCCGAAGAGGACAAGTGGCCT GAGGGATCCCCTAAGCCTGTGACACAGAACATCTCTGCCGAGGCCTGGGGTAGAGCT GATGGTGGCGGAGGATCTGGCGGAGGTGGAAGCGGCGGAGGCGGATCT TCTCATCTG GAACAGCTGCTGATGGACCTGCAAGAGCTGCTGTCCCGGATGGAAAACTACCGGAAC CTGAAGCTGCCCCGGATGCTGACCGCTAAGT TCGCTCTGCCTAAGCAGGCCACCGAG CTGAAGGATCTGCAGTGCCTGGAAGATGAGCTGGGCCCTCTGAGACACGTGCTGGAT CTGACCCAGTCCAAGTCCT T TCAGCTCGAGGACGCCGAGAACT TCATCTCCAACATC AGAGTGACCGTGGTCAAGCTGAAGGGCTCCGACAACACCT TCGAGTGCCAGT TCGAC GATGAGTCCGCTACAGTGGTGGACT TCCTGCGGAGATGGATCGCCT TCTGCCAGTCC ATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 79 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGTGGTGGAAGATCTGCGGAACGTGACCCCTCCTAAG GTGTCCCTGT TCGAGCCT TCCAAGGCCGAGATCGCCAACAAGCAGAAAGCTACCCTC GTGTGCCTGGCCAGAGGCT TCT T TCCTGACCACGTGGAACTGTCT TGGTGGGTCAAC GGCAAAGAGGTGCACTCCGGCGTCTGTACCGATCCTCAGGCCTACAAAGAGTCCAAC TACTCCTACAGCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TCTGGCACAACCCT CGGAACCACT TCAGATGCCAGGTGCAGT T TCACGGCCTGTCCGAAGAGGACAAGTGG CCTGAGGGATCCCCTAAGCCTGTGACACAGAACATCTCTGCCGAGGCCTGGGGTAGA GCTGATGGTGGCGGAGGATCTGGCGGAGGTGGAAGCGGCGGAGGCGGATCT TCTCAT CTGGAACAGCTGCTGATGGACCTGCAAGAGCTGCTGTCCCGGATGGAAAACTACCGG AACCTGAAGCTGCCCCGGATGCTGACCGCTAAGT TCGCTCTGCCTAAGCAGGCCACC GAGCTGAAGGATCTGCAGTGCCTGGAAGATGAGCTGGGCCCTCTGAGACACGTGCTG GATCTGACCCAGTCCAAGTCCT T TCAGCTCGAGGACGCCGAGAACT TCATCTCCAAC ATCAGAGTGACCGTGGTCAAGCTGAAGGGCTCCGACAACACCT TCGAGTGCCAGT TC GACGATGAGTCCGCTACAGTGGTGGACT TCCTGCGGAGATGGATCGCCT TCTGCCAG TCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 80 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGTGGTGGAAGATCTGCGGAACGTGACCCCTCCT AAGGTGTCCCTGT TCGAGCCT TCCAAGGCCGAGATCGCCAACAAGCAGAAAGCTACC CTCGTGTGCCTGGCCAGAGGCT TCT T TCCTGACCACGTGGAACTGTCT TGGTGGGTC AACGGCAAAGAGGTGCACTCCGGCGTCTGTACCGATCCTCAGGCCTACAAAGAGTCC AACTACTCCTACAGCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TCTGGCACAAC CCTCGGAACCACT TCAGATGCCAGGTGCAGT T TCACGGCCTGTCCGAAGAGGACAAG TGGCCTGAGGGATCCCCTAAGCCTGTGACACAGAACATCTCTGCCGAGGCCTGGGGT AGAGCTGATGGTGGCGGAGGATCTGGCGGAGGTGGAAGCGGCGGAGGCGGATCT TCT CATCTGGAACAGCTGCTGATGGACCTGCAAGAGCTGCTGTCCCGGATGGAAAACTAC CGGAACCTGAAGCTGCCCCGGATGCTGACCGCTAAGT TCGCTCTGCCTAAGCAGGCC ACCGAGCTGAAGGATCTGCAGTGCCTGGAAGATGAGCTGGGCCCTCTGAGACACGTG CTGGATCTGACCCAGTCCAAGTCCT T TCAGCTCGAGGACGCCGAGAACT TCATCTCC AACATCAGAGTGACCGTGGTCAAGCTGAAGGGCTCCGACAACACCT TCGAGTGCCAG T TCGACGATGAGTCCGCTACAGTGGTGGACT TCCTGCGGAGATGGATCGCCT TCTGC CAGTCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 81 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGTGGTGGAAGATCTGCGGAACGTGACCCCT CCTAAGGTGTCCCTGT TCGAGCCT TCCAAGGCCGAGATCGCCAACAAGCAGAAAGCT ACCCTCGTGTGCCTGGCCAGAGGCT TCT T TCCTGACCACGTGGAACTGTCT TGGTGG GTCAACGGCAAAGAGGTGCACTCCGGCGTCTGTACCGATCCTCAGGCCTACAAAGAG TCCAACTACTCCTACAGCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TCTGGCAC AACCCTCGGAACCACT TCAGATGCCAGGTGCAGT T TCACGGCCTGTCCGAAGAGGAC AAGTGGCCTGAGGGATCCCCTAAGCCTGTGACACAGAACATCTCTGCCGAGGCCTGG GGTAGAGCTGATGGTGGCGGAGGATCTGGCGGAGGTGGAAGCGGCGGAGGCGGATCT TCTCATCTGGAACAGCTGCTGATGGACCTGCAAGAGCTGCTGTCCCGGATGGAAAAC TACCGGAACCTGAAGCTGCCCCGGATGCTGACCGCTAAGT TCGCTCTGCCTAAGCAG GCCACCGAGCTGAAGGATCTGCAGTGCCTGGAAGATGAGCTGGGCCCTCTGAGACAC GTGCTGGATCTGACCCAGTCCAAGTCCT T TCAGCTCGAGGACGCCGAGAACT TCATC TCCAACATCAGAGTGACCGTGGTCAAGCTGAAGGGCTCCGACAACACCT TCGAGTGC CAGT TCGACGATGAGTCCGCTACAGTGGTGGACT TCCTGCGGAGATGGATCGCCT TC TGCCAGTCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 82 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAGTGGTGGAAGATCTGCGGAACGTGACC CCTCCTAAGGTGTCCCTGT TCGAGCCT TCCAAGGCCGAGATCGCCAACAAGCAGAAA GCTACCCTCGTGTGCCTGGCCAGAGGCT TCT T TCCTGACCACGTGGAACTGTCT TGG TGGGTCAACGGCAAAGAGGTGCACTCCGGCGTCTGTACCGATCCTCAGGCCTACAAA GAGTCCAACTACTCCTACAGCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TCTGG CACAACCCTCGGAACCACT TCAGATGCCAGGTGCAGT T TCACGGCCTGTCCGAAGAG GACAAGTGGCCTGAGGGATCCCCTAAGCCTGTGACACAGAACATCTCTGCCGAGGCC TGGGGTAGAGCTGATGGTGGCGGAGGATCTGGCGGAGGTGGAAGCGGCGGAGGCGGA TCT TCTCATCTGGAACAGCTGCTGATGGACCTGCAAGAGCTGCTGTCCCGGATGGAA AACTACCGGAACCTGAAGCTGCCCCGGATGCTGACCGCTAAGT TCGCTCTGCCTAAG CAGGCCACCGAGCTGAAGGATCTGCAGTGCCTGGAAGATGAGCTGGGCCCTCTGAGA CACGTGCTGGATCTGACCCAGTCCAAGTCCT T TCAGCTCGAGGACGCCGAGAACT TC ATCTCCAACATCAGAGTGACCGTGGTCAAGCTGAAGGGCTCCGACAACACCT TCGAG TGCCAGT TCGACGATGAGTCCGCTACAGTGGTGGACT TCCTGCGGAGATGGATCGCC T TCTGCCAGTCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 83 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGTGGTGGAAGATCTGCGGAACGTG ACCCCTCCTAAGGTGTCCCTGT TCGAGCCT TCCAAGGCCGAGATCGCCAACAAGCAG AAAGCTACCCTCGTGTGCCTGGCCAGAGGCT TCT T TCCTGACCACGTGGAACTGTCT TGGTGGGTCAACGGCAAAGAGGTGCACTCCGGCGTCTGTACCGATCCTCAGGCCTAC AAAGAGTCCAACTACTCCTACAGCCTGTCCTCTCGGCTGAGAGTGTCTGCCACCT TC TGGCACAACCCTCGGAACCACT TCAGATGCCAGGTGCAGT T TCACGGCCTGTCCGAA GAGGACAAGTGGCCTGAGGGATCCCCTAAGCCTGTGACACAGAACATCTCTGCCGAG GCCTGGGGTAGAGCTGATGGTGGCGGAGGATCTGGCGGAGGTGGAAGCGGCGGAGGC GGATCT TCTCATCTGGAACAGCTGCTGATGGACCTGCAAGAGCTGCTGTCCCGGATG GAAAACTACCGGAACCTGAAGCTGCCCCGGATGCTGACCGCTAAGT TCGCTCTGCCT AAGCAGGCCACCGAGCTGAAGGATCTGCAGTGCCTGGAAGATGAGCTGGGCCCTCTG AGACACGTGCTGGATCTGACCCAGTCCAAGTCCT T TCAGCTCGAGGACGCCGAGAAC T TCATCTCCAACATCAGAGTGACCGTGGTCAAGCTGAAGGGCTCCGACAACACCT TC GAGTGCCAGT TCGACGATGAGTCCGCTACAGTGGTGGACT TCCTGCGGAGATGGATC GCCT TCTGCCAGTCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 84 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTGTGGTGGAAGATCTGCGGAAC GTGACCCCTCCTAAGGTGTCCCTGT TCGAGCCT TCCAAGGCCGAGATCGCCAACAAG CAGAAAGCTACCCTCGTGTGCCTGGCCAGAGGCT TCT T TCCTGACCACGTGGAACTG TCT TGGTGGGTCAACGGCAAAGAGGTGCACTCCGGCGTCTGTACCGATCCTCAGGCC TACAAAGAGTCCAACTACTCCTACAGCCTGTCCTCTCGGCTGAGAGTGTCTGCCACC T TCTGGCACAACCCTCGGAACCACT TCAGATGCCAGGTGCAGT T TCACGGCCTGTCC GAAGAGGACAAGTGGCCTGAGGGATCCCCTAAGCCTGTGACACAGAACATCTCTGCC GAGGCCTGGGGTAGAGCTGATGGTGGCGGAGGATCTGGCGGAGGTGGAAGCGGCGGA GGCGGATCT TCTCATCTGGAACAGCTGCTGATGGACCTGCAAGAGCTGCTGTCCCGG ATGGAAAACTACCGGAACCTGAAGCTGCCCCGGATGCTGACCGCTAAGT TCGCTCTG CCTAAGCAGGCCACCGAGCTGAAGGATCTGCAGTGCCTGGAAGATGAGCTGGGCCCT CTGAGACACGTGCTGGATCTGACCCAGTCCAAGTCCT T TCAGCTCGAGGACGCCGAG AACT TCATCTCCAACATCAGAGTGACCGTGGTCAAGCTGAAGGGCTCCGACAACACC T TCGAGTGCCAGT TCGACGATGAGTCCGCTACAGTGGTGGACT TCCTGCGGAGATGG ATCGCCT TCTGCCAGTCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 85 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTGGCGTGGTGGAAGATCTGCGG AACGTGACCCCTCCTAAGGTGTCCCTGT TCGAGCCT TCCAAGGCCGAGATCGCCAAC AAGCAGAAAGCTACCCTCGTGTGCCTGGCCAGAGGCT TCT T TCCTGACCACGTGGAA CTGTCT TGGTGGGTCAACGGCAAAGAGGTGCACTCCGGCGTCTGTACCGATCCTCAG GCCTACAAAGAGTCCAACTACTCCTACAGCCTGTCCTCTCGGCTGAGAGTGTCTGCC ACCT TCTGGCACAACCCTCGGAACCACT TCAGATGCCAGGTGCAGT T TCACGGCCTG TCCGAAGAGGACAAGTGGCCTGAGGGATCCCCTAAGCCTGTGACACAGAACATCTCT GCCGAGGCCTGGGGTAGAGCTGATGGTGGCGGAGGATCTGGCGGAGGTGGAAGCGGC GGAGGCGGATCT TCTCATCTGGAACAGCTGCTGATGGACCTGCAAGAGCTGCTGTCC CGGATGGAAAACTACCGGAACCTGAAGCTGCCCCGGATGCTGACCGCTAAGT TCGCT CTGCCTAAGCAGGCCACCGAGCTGAAGGATCTGCAGTGCCTGGAAGATGAGCTGGGC CCTCTGAGACACGTGCTGGATCTGACCCAGTCCAAGTCCT T TCAGCTCGAGGACGCC GAGAACT TCATCTCCAACATCAGAGTGACCGTGGTCAAGCTGAAGGGCTCCGACAAC ACCT TCGAGTGCCAGT TCGACGATGAGTCCGCTACAGTGGTGGACT TCCTGCGGAGA TGGATCGCCT TCTGCCAGTCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 86 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTGGCGGCGTGGTGGAAGATCTG CGGAACGTGACCCCTCCTAAGGTGTCCCTGT TCGAGCCT TCCAAGGCCGAGATCGCC AACAAGCAGAAAGCTACCCTCGTGTGCCTGGCCAGAGGCT TCT T TCCTGACCACGTG GAACTGTCT TGGTGGGTCAACGGCAAAGAGGTGCACTCCGGCGTCTGTACCGATCCT CAGGCCTACAAAGAGTCCAACTACTCCTACAGCCTGTCCTCTCGGCTGAGAGTGTCT GCCACCT TCTGGCACAACCCTCGGAACCACT TCAGATGCCAGGTGCAGT T TCACGGC CTGTCCGAAGAGGACAAGTGGCCTGAGGGATCCCCTAAGCCTGTGACACAGAACATC TCTGCCGAGGCCTGGGGTAGAGCTGATGGTGGCGGAGGATCTGGCGGAGGTGGAAGC GGCGGAGGCGGATCT TCTCATCTGGAACAGCTGCTGATGGACCTGCAAGAGCTGCTG TCCCGGATGGAAAACTACCGGAACCTGAAGCTGCCCCGGATGCTGACCGCTAAGT TC GCTCTGCCTAAGCAGGCCACCGAGCTGAAGGATCTGCAGTGCCTGGAAGATGAGCTG GGCCCTCTGAGACACGTGCTGGATCTGACCCAGTCCAAGTCCT T TCAGCTCGAGGAC GCCGAGAACT TCATCTCCAACATCAGAGTGACCGTGGTCAAGCTGAAGGGCTCCGAC AACACCT TCGAGTGCCAGT TCGACGATGAGTCCGCTACAGTGGTGGACT TCCTGCGG AGATGGATCGCCT TCTGCCAGTCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 87 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTGGCGGCGGAGTGGTGGAAGAT CTGCGGAACGTGACCCCTCCTAAGGTGTCCCTGT TCGAGCCT TCCAAGGCCGAGATC GCCAACAAGCAGAAAGCTACCCTCGTGTGCCTGGCCAGAGGCT TCT T TCCTGACCAC GTGGAACTGTCT TGGTGGGTCAACGGCAAAGAGGTGCACTCCGGCGTCTGTACCGAT CCTCAGGCCTACAAAGAGTCCAACTACTCCTACAGCCTGTCCTCTCGGCTGAGAGTG TCTGCCACCT TCTGGCACAACCCTCGGAACCACT TCAGATGCCAGGTGCAGT T TCAC GGCCTGTCCGAAGAGGACAAGTGGCCTGAGGGATCCCCTAAGCCTGTGACACAGAAC ATCTCTGCCGAGGCCTGGGGTAGAGCTGATGGTGGCGGAGGATCTGGCGGAGGTGGA AGCGGCGGAGGCGGATCT TCTCATCTGGAACAGCTGCTGATGGACCTGCAAGAGCTG CTGTCCCGGATGGAAAACTACCGGAACCTGAAGCTGCCCCGGATGCTGACCGCTAAG T TCGCTCTGCCTAAGCAGGCCACCGAGCTGAAGGATCTGCAGTGCCTGGAAGATGAG CTGGGCCCTCTGAGACACGTGCTGGATCTGACCCAGTCCAAGTCCT T TCAGCTCGAG GACGCCGAGAACT TCATCTCCAACATCAGAGTGACCGTGGTCAAGCTGAAGGGCTCC GACAACACCT TCGAGTGCCAGT TCGACGATGAGTCCGCTACAGTGGTGGACT TCCTG CGGAGATGGATCGCCT TCTGCCAGTCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID ACCATCAAGCCT TGTCCTCCATGCAAGTGCCCCGCTCCTAATCTGCTCGGAGGCCCT NO: 88 TCCGTGT TCATCT TCCCACCTAAGATCAAGGACGTGCTGATGATCTCCCTGTCTCCT

ATCGTGACCTGCGTGGTGGTGGACGTGTCCGAGGATGATCCTGACGTGCAGATCAGT TGGT TCGTGAACAACGTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGAC TACAACAGCACCCTGAGAGTGGTGTCTGCCCTGCCTATCCAGCACCAGGAT TGGATG TCCGGCAAAGAAT TCAAGTGCAAAGTGAACAACAAGGACCTGCCTGCTCCAATCGAG CGGACCATCTCCAAGCCTGGTGGCGGAGGAAGCGGTGGCGGCGGATCTGTGGTGGAA GATCTGCGGAACGTGACCCCTCCTAAGGTGTCCCTGT TCGAGCCT TCCAAGGCCGAG ATCGCCAACAAGCAGAAAGCTACCCTCGTGTGCCTGGCCAGAGGCT TCT T TCCTGAC CACGTGGAACTGTCT TGGTGGGTCAACGGCAAAGAGGTGCACTCCGGCGTCTGTACC GATCCTCAGGCCTACAAAGAGTCCAACTACTCCTACAGCCTGTCCTCTCGGCTGAGA GTGTCTGCCACCT TCTGGCACAACCCTCGGAACCACT TCAGATGCCAGGTGCAGT T T CACGGCCTGTCCGAAGAGGACAAGTGGCCTGAGGGATCCCCTAAGCCTGTGACACAG AACATCTCTGCCGAGGCCTGGGGTAGAGCTGATGGTGGCGGAGGATCTGGCGGAGGT GGAAGCGGCGGAGGCGGATCT TCTCATCTGGAACAGCTGCTGATGGACCTGCAAGAG CTGCTGTCCCGGATGGAAAACTACCGGAACCTGAAGCTGCCCCGGATGCTGACCGCT AAGT TCGCTCTGCCTAAGCAGGCCACCGAGCTGAAGGATCTGCAGTGCCTGGAAGAT GAGCTGGGCCCTCTGAGACACGTGCTGGATCTGACCCAGTCCAAGTCCT T TCAGCTC GAGGACGCCGAGAACT TCATCTCCAACATCAGAGTGACCGTGGTCAAGCTGAAGGGC TCCGACAACACCT TCGAGTGCCAGT TCGACGATGAGTCCGCTACAGTGGTGGACT TC CTGCGGAGATGGATCGCCT TCTGCCAGTCCATCATCTCCACCTCTCCACAGTGATGA

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGT TGTGCAGCCTGGCAGATCCCTGAGA NO: 89 CTGTCT TGTGCCGCCTCCGGCT TCACCT TCTCCAGCTACACCATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGAT TGGAGTGGGTCACCT TCATCTCT TACGACGGCAACAAC AAGTACTACGCCGACTCCGTGAAGGGCAGAT TCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCATCTACTAC TGTGCTAGAACCGGCTGGCTGGGCCCCT T TGAT TAT TGGGGACAGGGCACCCTGGTC ACCGTGTCCTCTGCT TCCACCAAGGGACCCTCTGTGT TCCCTCTGGCTCCT TCCAGC AAGTCTACCTCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACT T TCCT GAGCCTGTGACCGTGTCT TGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCT T T CCAGCTGTGCTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCTCTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCT TCCAAC ACCAAGGTGGACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCA CCATGTCCTGCTCCAGAACTGCTCGGCGGACCT TCCGTGT TCCTGT T TCCTCCAAAG CCTAAGGACACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGAT GTGTCTCACGAGGATCCCGAAGTGAAGT TCAAT TGGTACGTGGACGGCGTGGAAGTG CACAACGCCAAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTG TCCGTGCTGACCGTGCTGCACCAGGAT TGGCTGAACGGCAAAGAGTACAAGTGCAAG GTGTCCAACAAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGGC CAGCCTAGGGAACCCCAGGT T TACACCCTGCCTCCATGCCGGGAAGAGATGACCAAG AACCAGGTGTCCCTGTGGTGCCTGGT TAAGGGCT TCTACCCCTCCGATATCGCCGTG GAATGGGAGTCTAATGGCCAGCCTGAGAACAACTACAAGACAACCCCTCCTGTGCTG GACTCCGACGGCTCAT TCT TCCTGTACTCCAAGCTGACAGTGGACAAGTCCAGATGG CAGCAGGGCAACGTGT TCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC ACCCAGAAGTCCCTGTCTCTGAGCCCCGGCAAG

SEQ ID CAGGTGCAGCTGGTGGAATCTGGTGGCGGAGT TGTGCAGCCTGGCAGATCCCTGAGA NO: 90 CTGTCT TGTGCCGCCTCCGGCT TCACCT TCTCCTCT TACGGAATGCACTGGGTCCGA

CAGGCCCCTGGCAAAGGAT TGGAGTGGGTCGCCT TCATCAGATACGACGGCTCCAAC AAGTACTACGCCGACTCCGTGAAGGGCAGAT TCACCATCTCTCGGGACAACTCCAAG AACACCCTGTACCTGCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTAC TGCAAGACCCACGGCTCTCACGACAAT TGGGGCCAGGGCACAATGGTCACCGTGTCC TCTGCT TCCACCAAGGGACCCTCTGTGT TCCCTCTGGCTCCT TCCAGCAAGTCTACC TCTGGCGGAACAGCTGCTCTGGGCTGCCTGGTCAAGGACTACT T TCCTGAGCCTGTG ACCGTGTCT TGGAACTCTGGCGCTCTGACATCCGGCGTGCACACCT T TCCAGCTGTG CTGCAATCCTCCGGCCTGTACTCTCTGTCCTCCGTCGTGACCGTGCCT TCTAGCTCT CTGGGCACCCAGACCTACATCTGCAATGTGAACCACAAGCCT TCCAACACCAAGGTG GACAAGAGAGTGGAACCCAAGTCCTGCGATAAGACCCACACCTGTCCACCATGTCCT GCTCCAGAACTGCTCGGCGGACCT TCCGTGT TCCTGT T TCCTCCAAAGCCTAAGGAC ACCCTGATGATCTCTCGGACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGTCTCAC GAGGATCCCGAAGTGAAGT TCAAT TGGTACGTGGACGGCGTGGAAGTGCACAACGCC AAGACCAAGCCTAGAGAGGAACAGTACAACTCCACCTACAGAGTGGTGTCCGTGCTG ACCGTGCTGCACCAGGAT TGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAAC AAGGCCCTGCCTGCTCCTATCGAAAAGACCATCTCCAAGGCCAAAGCCAGCCTCGGG AACCTCAAGTCTGTACCCTGCCTCCTAGCCGGGAAGAGATGACCAAGAACCAGGTGT CCCTGTCCTGCGCTGTGAAGGGCT TCTACCCT TCCGATATCGCCGTGGAATGGGAGA GCAATGGCCAGCCTGAGAACAACTACAAGACCACACCTCCTGTGCTGGACTCCGACG GCTCAT TCT TCCTGGTGTCCAAGCTGACAGTGGACAAGTCCAGATGGCAGCAGGGCA ACGTGT TCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGT CCCTGTCTCTGAGCCCCGGCAAG . Expression and Purification.

The plasmids were co-transfected into either Expi293 cells (Life Technologies A14527) or ExpiCHO cells (Life Technologies A29127). Transfections were performed using 1 mg of total DNA for a multispecific construct with a 1: 1 heavy chain ratio and 3:2 light chain to heavy chain ratio. Transfection in Expi293 cells was done using linear 25,000 Da

polyethylenimine (PEI, Poly sciences Inc 23966) in a 3: 1 ratio with the total DNA. The DNA and PEI were each added to 50 mL of OptiMem (Life Technologies 31985088) medium and sterile filtered. The DNA and PEI were combined for 10 minutes and added to the Expi293 cells with a density of 1.8-2.8 x 10 ⁶ cells/mL and a viability of at least 95 %. The ExpiCHO transfection was performed according to the manufacturer's instructions. Expi293 cells were grown in a humidified incubator at 37 °C with 8 % C0 ₂ for 5-7 days after transfection and ExpiCHO cells were grown for 14 days at 32 °C with 5 % C0 ₂ . The cells were pelleted by centrifugation at 4500 x g and the supernatant was filtered through a 0.2 μιη membrane. Protein A resin (GE 17- 1279-03) was added to the filtered supernatant and incubated for 1-3 hours at room temperature. The resin was packed into a column washed with 3 x 10 column volumes of Dulbecco's phosphate-buffered saline (DPBS, Life Technologies 14190-144). The bound protein was eluted from the column with 20 mM citrate, 100 mM NaCl, pH 2.9. The molecule was polished by size exclusion on a Superdex 200 column with a running buffer of DPBS. Fractions containing monomeric compound were pooled.

Table 4. Amino Acid sequences.

NO: 97 TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT

KVDKRVEPKSC

SEQ ID hCH2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDV NO: 98 SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

WLNGKEYKCKVSNKALPAPIEKTISKAK

SEQ ID hTCRa PDIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYIT NO: 99 DKCVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSP

E

SEQ ID hTCRp EDLNKVFPPEVALFEPSEAEISHTQKATLVCLATGFYPDHVELSWW NO: 100 VNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRN

HFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID G G NO: 101

SEQ ID GG GG NO: 102

SEQ ID GGG GGG NO: 103

SEQ ID GGGG GGGG NO: 104

SEQ ID GGGGS GGGGS NO: 105

SEQ ID GGGGSG GGGGSG NO: 106

SEQ ID GGGGS GG GGGGSGG NO: 107

SEQ ID GGGGS GGG GGGGSGGG NO: 108

SEQ ID GGGGS GGGG GGGGSGGGG NO: 109

SEQ ID GGGGS GGGGS GGGGSGGGGS NO: 110

SEQ ID mCH2 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCV NO: 111 VVDVSEDDPDVQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSA

LP IQHQDWMSGKEFKCKVNNKDLPAP IERTI SKP

SEQ ID mTCRa KPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESG NO: 112 TFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATY

PSSDVPCDATLTEKSFETDMNLNFQNLS

SEQ ID mTCRp VVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHV NO: 113 ELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATFWH

NPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRAD

SEQ ID mIL2 F56A Y59A SHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELK NO: 114 DLQCLEDELGPLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKL

KGSDNTFECQFDDESATVVDFLRRWIAFCQS I I STSPQ

SEQ ID GGGGS GGGGSG GGGGSGGGGSGGGGS NO: 115 GGGS

SEQ ID hCH3_Knob GQPREPQVYTLPPCREEMTKNQVSLWCLVKGFYPSDIAVEWES NO: 116 NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS

VMHEALHNHYTQKSLSLSPGK

SEQ ID hCH3_Hole GQPREPQVCTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWES NO: 117 NGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCS

VMHEALHNHYTQKSLSLSPGK

Table 5. Sequences used to construct heavy and light chains.

SEQID SEQID SEQID SEQID SEQID SEQID

NO: 137 NO: 93 NO: 97 NO: 98 NO: 107 NO: 100

SEQID SEQID SEQID SEQID SEQID SEQID NO: 138 NO: 93 NO: 97 NO: 98 NO: 108 NO: 100

SEQID SEQID SEQID SEQID SEQID SEQID NO: 139 NO: 93 NO: 97 NO: 98 NO: 109 NO: 100

SEQID SEQID SEQID SEQID SEQID SEQID NO: 140 NO: 93 NO: 97 NO: 98 NO: 110 NO: 100

SEQID SEQID SEQID NO: 141 NO: 94 NO: 96

SEQID SEQID SEQID NO: 142 NO: 111 NO: 112

SEQID SEQID SEQID SEQID NO: 143 NO: 111 NO: 101 NO: 112

SEQID SEQID SEQID SEQID NO: 144 NO: 111 NO: 102 NO: 112

SEQID SEQID SEQID SEQID NO: 145 NO: 111 NO: 103 NO: 112

SEQID SEQID SEQID SEQID NO: 146 NO: 111 NO: 104 NO: 112

SEQID SEQID SEQID SEQID NO: 147 NO: 111 NO: 105 NO: 112

SEQID SEQID SEQID SEQID NO: 148 NO: 111 NO: 106 NO: 112

SEQID SEQID SEQID SEQID NO: 149 NO: 111 NO: 107 NO: 112

SEQID SEQID SEQID SEQID NO: 150 NO: 111 NO: 108 NO: 112

SEQID SEQID SEQID SEQID NO: 151 NO: 111 NO: 109 NO: 112

SEQID SEQID SEQID SEQID NO: 152 NO: 111 NO: 110 NO: 112

SEQID SEQID SEQID SEQID SEQID NO: 153 NO: 111 NO: 113 NO: 115 NO: 114

SEQID SEQID SEQID SEQID SEQID SEQID NO: 154 NO: 111 NO: 101 NO: 113 NO: 115 NO: 114

SEQID SEQID SEQID SEQID SEQID SEQID NO: 155 NO: 111 NO: 102 NO: 113 NO: 115 NO: 114

SEQID SEQID SEQID SEQID SEQID SEQID NO: 156 NO: 111 NO: 103 NO: 113 NO: 115 NO: 114

SEQID SEQID SEQID SEQID SEQID SEQID NO: 157 NO: 111 NO: 104 NO: 113 NO: 115 NO: 114

SEQID SEQID SEQID SEQID SEQID SEQID NO: 166 NO: 111 NO: 105 NO: 113 NO: 115 NO: 114

SEQID SEQID SEQID SEQID SEQID SEQID NO: 167 NO: 111 NO: 106 NO: 113 NO: 115 NO: 114 SEQID SEQID SEQID SEQID SEQID SEQID NO: 160 NO: 111 NO: 107 NO: 113 NO: 115 NO: 114

SEQID SEQID SEQID SEQID SEQID SEQID NO: 161 NO: 111 NO: 108 NO: 113 NO: 115 NO: 114

SEQID SEQID SEQID SEQID SEQID SEQID NO: 162 NO: 111 NO: 109 NO: 113 NO: 115 NO: 114

SEQID SEQID SEQID SEQID SEQID SEQID NO: 163 NO: 111 NO: 110 NO: 113 NO: 115 NO: 114

SEQ ID SEQID SEQID SEQ ID SEQID NO: 164 NO: 91 NO: 97 NO: 98 NO: 116

SEQ ID SEQID SEQID SEQ ID SEQID NO: 165 NO: 93 NO: 97 NO: 98 NO: 117

Table 6. Sequences used to construct heavy and light chains.

DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAP IEKTI SKAKGGGPDIQNPDPAVYQLRDSKSSDKSVCLFT DFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACANAFNN SIIPEDTFFPSPE

SEQ ID NO: 122 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISY

DGNNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFD YWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAP IEKTI SKAKGGGGPDIQNPDPAVYQLRDSKSSDKSVCLF TDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACANAFN NSIIPEDTFFPSPE

SEQ ID NO: 123 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISY

DGNNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFD YWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAP IEKTI SKAKGGGGSPDIQNPDPAVYQLRDSKSSDKSVCL FTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACANAF NNSIIPEDTFFPSPE

SEQ ID NO: 124 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISY

DGNNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFD YWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAP IEKTI SKAKGGGGSGPDIQNPDPAVYQLRDSKSSDKSVC LFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACANA FNNS I IPEDTFFPSPE

SEQ ID NO: 125 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISY

DGNNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFD YWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAP IEKTI SKAKGGGGSGGPDIQNPDPAVYQLRDSKSSDKSV CLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACAN AFNNS I IPEDTFFPSPE

SEQ ID NO: 126 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISY

DGNNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFD YWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAP IEKTI SKAKGGGGSGGGPDIQNPDPAVYQLRDSKSSDKS VCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACA NAFNNS I IPEDTFFPSPE

SEQ ID NO: 127 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISY

DGNNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFD YWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAP IEKTI SKAKGGGGSGGGGPDIQNPDPAVYQLRDSKSSDK SVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFAC ANAFNNS I IPEDTFFPSPE

SEQ ID NO: 128 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISY

DGNNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFD YWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAP IEKTI SKAKGGGGSGGGGSPDIQNPDPAVYQLRDSKSSD KSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFA CANAFNNS I IPEDTFFPSPE

SEQ ID NO: 129 EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAF

SRATGIPDRFSGSGSGTDFTLTI SRLEPEDFAVYYCQQYGSSPWTFGQGTKVE IK

SEQ ID NO: 130 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKEDLNKVFPPEVALFEPSEAEI SHTQKATLVCLA TGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATF WQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 131 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGEDLNKVFPPEVALFEPSEAEI SHTQKATLVCL ATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSAT FWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 132 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGGEDLNKVFPPEVALFEPSEAEI SHTQKATLVC LATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSA TFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 133 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGGGEDLNKVFPPEVALFEPSEAEI SHTQKATLV CLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVS ATFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 134 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGGGGEDLNKVFPPEVALFEPSEAEI SHTQKATL VCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRV SATFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 135 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGGGGSEDLNKVFPPEVALFEPSEAEI SHTQKAT LVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLR VSATFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 136 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGGGGSGEDLNKVFPPEVALFEPSEAEI SHTQKA TLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRL RVSATFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 137 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGGGGSGGEDLNKVFPPEVALFEPSEAEI SHTQK ATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSR LRVSATFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 138 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGGGGSGGGEDLNKVFPPEVALFEPSEAEI SHTQ KATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSS RLRVSATFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 139 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGGGGSGGGGEDLNKVFPPEVALFEPSEAEI SHT QKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALS SRLRVSATFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRAD

SEQ ID NO: 140 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY

DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGGGGSGGGGSEDLNKVFPPEVALFEPSEAEI SH TQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYAL SSRLRVSATFWQDPRNHFRCQVQFYGLSEADEWTQARAKPVTQIVSAEAWGRA D

SEQ ID NO: 141 QSVLTQPPSVSGAPGQRVTI SCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYND

QRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGT KVTVLGQPKANPTVTLFPPSSEELQANKATLVCLI SDFYPGAVTVAWKADGSP VKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVA PTECS

SEQ ID NO: 142 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKT MESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVP CDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 143 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPK TMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDV PCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 144 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVP KTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSD VPCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 145 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINV PKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSS DVPCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 146 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQIN VPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPS SDVPCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 147 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQI NVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYP SSDVPCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 148 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQ INVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATY PSSDVPCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 149 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGGKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFDS QINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNAT YPSSDVPCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 150 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGGGKPNIQNPEPAVYQLKDPRSQDSTLCLFTDFD SQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNA TYPSSDVPCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 151 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGGGGKPNIQNPEPAVYQLKDPRSQDSTLCLFTDF DSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETN ATYPSSDVPCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 152 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGGGGSKPNIQNPEPAVYQLKDPRSQDSTLCLFTD FDSQINVPKTMESGTFITDKCVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKET NATYPSSDVPCDATLTEKSFETDMNLNFQNLS

SEQ ID NO: 153 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPVVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFF PDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATFWHNPRNHF RCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGGGSGGGGSSH LEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQCLEDELGPL RHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDDESATVVDFL RRWIAFCQSIISTSPQ

SEQ ID NO: 154 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGVVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGF FPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATFWHNPRNH FRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGGGSGGGGSS HLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQCLEDELGP LRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDDESATVVDF LRRWIAFCQSIISTSPQ

SEQ ID NO: 155 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGVVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARG FFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATFWHNPRN HFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGGGSGGGGS SHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQCLEDELG PLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDDESATVVD FLRRWIAFCQSIISTSPQ

SEQ ID NO: 156 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGVVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLAR GFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATFWHNPR NHFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGGGSGGGG SSHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQCLEDEL GPLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDDESATVV DFLRRWIAFCQS I I STSPQ

SEQ ID NO: 157 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGVVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCLA RGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATFWHNP RNHFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGGGSGGG GSSHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQCLEDE LGPLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDDESATV VDFLRRWIAFCQSIISTSPQ

SEQ ID NO: 166 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSVVEDLRNVTPPKVSLFEPSKAEIANKQKATLVCL ARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATFWHN PRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGGGSGG GGSSHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQCLED ELGPLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDDESAT VVDFLRRWIAFCQSIISTSPQ

SEQ ID NO: 167 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGVVEDLRNVTPPKVSLFEPSKAEIANKQKATLVC LARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATFWH NPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGGGSG GGGSSHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQCLE DELGPLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDDESA TVVDFLRRWIAFCQSIISTSPQ

SEQ ID NO: 160 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGGVVEDLRNVTPPKVSLFEPSKAEIANKQKATLV CLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATFW HNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGGGS GGGGSSHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQCL EDELGPLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDDES ATVVDFLRRWIAFCQS I I STSPQ

SEQ ID NO: 161 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGGGVVEDLRNVTPPKVSLFEPSKAEIANKQKATL VCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSATF WHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGGG SGGGGSSHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQC LEDELGPLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDDE SATVVDFLRRWIAFCQSIISTSPQ

SEQ ID NO: 162 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGGGGVVEDLRNVTPPKVSLFEPSKAEIANKQKAT LVCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSAT FWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGGG GSGGGGSSHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDLQ CLEDELGPLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFDD ESATVVDFLRRWIAFCQS I I STSPQ

SEQ ID NO: 163 TIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPD

VQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNN KDLPAP IERTI SKPGGGGSGGGGSVVEDLRNVTPPKVSLFEPSKAEIANKQKA TLVCLARGFFPDHVELSWWVNGKEVHSGVCTDPQAYKESNYSYSLSSRLRVSA TFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNI SAEAWGRADGGGGSGG GGSGGGGSSHLEQLLMDLQELLSRMENYRNLKLPRMLTAKFALPKQATELKDL QCLEDELGPLRHVLDLTQSKSFQLEDAENFI SNIRVTVVKLKGSDNTFECQFD DESATVVDFLRRWIAFCQS I I STSPQ

SEQ ID NO: 164 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISY

DGNNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFD YWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAP IEKTI SKAKGQPREPQVYTLPPCREEMTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO: 165 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRY DGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWG QGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAP IEKTI SKAKGQPREPQVCTLPPSREEMTKNQVSLSCAVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK

Table 7. Sequences used to construct multispecific molecules.

3. Kappa/Lambda select resin analysis of chain pairing.

The kappa and lambda light chain pairing of bispecific constructs was analyzed by incubating 1 mg of protein with 100 μΐ _^ of either KappaSelect (GE 17-5458-01) or

LambdaFabSelect (GE 17-5482-01) resin. After incubating for 1-3 hours, the resin was packed into a column, washed with 3 x 10 column volumes of Dulbecco's phosphate-buffered saline (DPBS, Life Technologies 14190-144). The bound protein was eluted from the column with 100 mM citrate, pH 2.5. The content of the load, flow-through, and elution fractions was analyzed using gels of samples non-reduced and reduced with 200 mM Bond-Breaker TCEP (Thermo Scientific 77720), allowing for the identification of the various chains. For quantitative assessment of the chain pairing, the amount of protein in the load and flow-through fractions was assessed using the absorbance at 280 nm with a NanoDrop.

Example 2

Multispecific molecule 1, represented by FIG. 4A, comprises an anti-CTLA4 targeting arm and an anti-IL12p targeting arm. As illustrated by FIG. 4A, one CH3 domain comprises knob mutations, and the other CH3 domain comprises hole mutations. Multispecific molecule 1 was expressed by co-transfecting cells with SEQ ID: 89, SEQ ID: 54, SEQ ID: 90, and SEQ ID: 66, to produce the four distinct chains: SEQ ID: 164, SEQ ID: 129, SEQ ID: 165, and SEQ ID: 141. A KappaSelect and LambdaFabSelect analysis was performed with multispecific molecule 1. The gel shows no protein in the flow-through of the KappaSelect or LambdaFabSelect columns (FIG. 5). The data suggest that multispecific molecule 1, which has the knob-into-holes IgG configuration shown in FIG. 4A, demonstrates correct heavy chain heterodimer formation and the two Fabs do not swap the kappa and lambda light chains with each other.

Example 3

Multispecific molecule 2, represented by FIG. 4B, comprises an anti-CTLA4 targeting arm and an anti-IL12p targeting arm. As shown in FIG. 4B, one CH2 domain is linked to TCRa constant domain, and the other CH2 domain is linked to TCRP constant domain. Multispecific molecule 2 was expressed by co-transfecting cells with SEQ ID: 43, SEQ ID: 54, SEQ ID: 55, and SEQ ID: 66, to produce the four distinct chains: SEQ ID: 118, SEQ ID: 129, SEQ ID: 130, and SEQ ID: 141. Multispecific molecule 2 was purified and a gel of the final molecule is shown in FIG. 6, displaying the intact protein in the non-reduced sample and all of the chains in the reduced sample. FIG. 6 suggests that multispecific molecule 2 behaves like a proper IgG like molecule. FIG.7 shows the size exclusion chromatogram of multispecific molecule 2, indicating that it runs as heterodimer. A KappaSelect and LambdaFabSelect analysis was performed with multispecific molecule 2, shown in FIG. 8. Similar to multispecific molecule 1 tested in

Example 2, the gel in FIG. 8 shows that there was no protein in the flow-through for either the KappaSelect or LambdaFabSelect columns. The data suggest that the two Fabs in multispecific molecule 2 do not swap light chains and the protein is an intact heterodimer, running at -150 kDa.

Multispecific molecules 1 and 2 share the two Fab targeting arms and differ only in that multispecific molecule 1 comprises knob-into-holes CH3 domains whereas in multispecific molecule 2, the two CH3 domains in heavy chains are replaced by a TCRa constant domain and a TCRP constant domain, respectively (see FIGs. 4A and 4B). The data described in Example 2 and Example 3 demonstrate that both molecules form stable heterodimers. Without wishing to be bound by theory, the TCRa constant domain and TCRP constant domain can replace knob- into-holes CH3 domains to drive heterodimer formation. INCORPORATION BY REFERENCE

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.